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Abstract 
Background and aims: Assisted reproductive technology (ART) has provided great hope for 
millions of infertile couples since the birth of the first in vitro fertilization (IVF) baby in 1978. 
In recent years, frozen-thawed embryo transfer has no longer been merely an add-on to the 
conventional fresh embryo transfer. Transfer of a cryopreserved embryo has contributed to 
nearly half of the embryo transfer cycles in Australia and New Zealand. There has been 
considerable debate about clinical efficacy and safety of fresh versus frozen-thawed embryo 
transfer. The aim of this PhD thesis is to inform infertile patients, clinicians and health 
policymakers regarding the fertility and pregnancy outcomes following fresh versus frozen-
thawed embryo transfer, in terms of maximizing the live birth rate while minimizing the 
adverse perinatal outcomes. 
Materials and methods: The thesis includes four studies using population-based data 
extracted from the Australian and New Zealand Assisted Reproduction Database (ANZARD) 
and the Victorian Assisted Reproductive Treatment Authority (VARTA). The risks of ectopic 
pregnancy, small/large for gestational age birth, and cycle-based live birth following frozen-
thawed embryo transfer were compared with those of fresh embryo transfer. This program of 
research also investigated the cumulative live birth rate from one oocyte retrieval following a 
‘fresh transfer’ strategy versus a ‘freeze-all’ strategy where all embryos were cryopreserved 
for future transfer in subsequent cycles. 
Results: Compared with fresh embryo transfer, frozen-thawed embryo transfer was associated 
with a decreased risk of ectopic pregnancy and small for gestational age birth, but an increased 
risk of large for gestational age birth. The ‘freeze-all’ strategy resulted in a similar cumulative 
live birth rate as the ‘fresh transfer’ strategy among high responders (>15 oocytes retrieved in 
an oocyte retrieval), but did not benefit normal (10–15 oocytes) and suboptimal responders 
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(<10 oocytes). Vitrification was the preferred cryopreservation method for blastocysts where 
vitrified blastocyst transfer resulted in a significantly higher live birth rate with similar 
perinatal outcomes compared with slow frozen blastocyst transfer. 
Conclusion: This PhD thesis provides the population-based evidence of fertility and 
pregnancy outcomes following fresh versus frozen-thawed embryo transfer in ART treatment. 
This PhD thesis suggests that, from a population perspective, the ‘freeze-all’ strategy may 
benefit some subgroups of patients, but should not be offered universally.  
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1.1 BACKGROUND 
Assisted reproductive technology (ART) has provided great hope for millions of infertile 
couples worldwide. Since the world’s first in vitro fertilization (IVF) baby Louise Brown was 
born in 1978, more than 6 million babies have been born following ART treatment (Chambers 
et al., 2017; Dyer et al., 2016; European IVF Monitoring Consortium et al., 2017; Steptoe & 
Edwards, 1978). In Australia, over 35000 women undertook ART treatment in 2015, 
approximating 7 per 1000 women of reproductive age (15–44 years) (Fitzgerald et al., 2017). 
It is estimated that 4.3% of all babies born in Australia in 2015 were the result of ART treatment 
(Australian Institute of Health and Welfare, 2017; Fitzgerald et al., 2017). 
ART treatment refers to all treatments or procedures that involve the in vitro handling of 
both human oocytes and sperm, or embryos to establish a pregnancy (Zegers-Hochschild et al., 
2009). This includes, but is not limited to, IVF, intracytoplasmic sperm injection (ICSI), 
gamete intrafallopian transfer (GIFT), and gamete and embryo cryopreservation (Zegers-
Hochschild et al., 2009). I will refer to these treatments or procedures collectively as ART 
treatment throughout this thesis. ART treatment does not include intrauterine or artificial 
insemination in which only sperm are handled. 
A typical ART treatment cycle involves controlled ovarian stimulation to induce the 
maturation of multiple oocytes, aspiration of matured oocytes from a woman’s ovaries, 
fertilization of the oocytes with sperm and embryo maturation in the laboratory, and then the 
transfer of one or more resulting fresh embryos back into the woman’s uterus in the stimulated 
cycle (fresh embryo transfer) (Fitzgerald et al., 2017; Sunderam et al., 2018).  
In the past four decades, ART treatment has gone through waves of optimization and 
innovation, including considerable advances in the optimization of ovarian stimulation 
protocols, cryopreservation of oocytes and embryos, the advent of ICSI, improved culture 
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media formulations and a trend towards extended embryo culture, and utilization of pre-
implantation genetic testing (PGT) (Devroey et al., 2011; Gardner & Lane, 1998; Mastenbroek 
et al., 2007; Palermo et al., 1992; Quinn, 2004; Zeilmaker et al., 1984). 
Embryo cryopreservation is one of the most important developments among these 
optimizations and innovations in ART treatment. The first baby conceived following the 
transfer of a frozen-thawed embryo was born in 1984 (Zeilmaker et al., 1984). 
Cryopreservation of excess embryos allows more than one attempt of embryo transfer 
following one oocyte retrieval, which significantly reduces the reliance on fresh embryo 
transfer (Loutradi et al., 2008; Michelmann & Nayudu, 2006). It provides the opportunity for 
single embryo transfer in the stimulated cycle, which minimizes complications associated with 
multiple pregnancies (Pelkonen et al., 2010; Wennerholm et al., 2009). 
Since the mid-1980s, various cryopreservation protocols have been developed with 
different types and concentrations of cryoprotectant, cooling and thawing/warming rates, 
equilibration timing and cryopreservation equipment to maintain the functional capacity of 
cells at low temperatures and to allow the cryopreserved embryos to survive the thaw/warm 
process (Edgar & Gook, 2012; Rienzi et al., 2017). Currently, two principal approaches are 
routinely used for embryo cryopreservation: the conventional slow freezing method, where 
cryopreservation occurs at a sufficiently slow rate to minimize the intracellular ice formation 
and to allow adequate cell dehydration; and the recently more widely employed vitrification 
method, which converts the cells or tissues into a solid glass-like state without ice formation 
by reducing the temperature rapidly (Edgar & Gook, 2012; Vajta & Nagy, 2006). Vitrification 
has now become the preferred treatment for blastocysts in Australia since it was introduced 
clinically in 2006 (Costigan et al., 2007; Fitzgerald et al., 2017).  
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More recently the evolution of cryopreservation techniques towards vitrification has been 
accompanied by a shift in clinical practice towards cryopreservation of all embryos (‘freeze-
all’) for future transfer in a subsequent cycle (Barnhart, 2014; Basile & Garcia-Velasco, 2016). 
Frozen-thawed embryo transfer was no longer merely an add-on to the conventional fresh 
embryo transfer, but was being considered as one of the first-choice options to achieve better 
clinical outcomes. In 2015, more than one-fifth of autologous fresh cycles undertaken in 
Australia and New Zealand had all embryos cryopreserved with no embryo(s) transferred in 
the stimulated cycle (Fitzgerald et al., 2017). Ideally, any significant changes in routine clinical 
practice (i.e. shifting from slow freezing to vitrification, from ‘fresh transfer’ to ‘freeze-all’) 
should be evidence-based. However, ART treatment protocol and laboratory techniques are 
often adopted into clinical practice without sufficient assessment of their safety and efficacy 
due to rapid development and evolution (Harper et al., 2012). 
There has been considerable debate about clinical efficacy and safety of fresh versus 
frozen-thawed embryo transfer (Acharya et al., 2018; Ata & Seli, 2017; Barnhart, 2014; 
Coutifaris, 2017; Maheshwari et al., 2018; Roque, 2015; Roque et al., 2018; Sha et al., 2018). 
The supraphysiologic hormonal levels in the stimulated cycle may result in alteration of the 
endometrial gene expression, impaired endometrial receptivity and, consequently, embryo-
endometrium asynchrony (Labarta et al., 2011; Ullah et al., 2017; Van Vaerenbergh et al., 
2011). It has been theorized that frozen-thawed embryo transfer allowed the embryo(s) to be 
placed in a more favorable endometrium environment (‘improving the soil’) and would result 
in better pregnancy and perinatal outcomes than fresh embryo transfer (Evans et al., 2014; 
Roque et al., 2017). However, the unintended consequences of frozen-thawed embryo transfer 
should also be considered, including the additional financial cost, psychological stress 
associated with deferring transfer and, most importantly, the potential degeneration, epigenetic 
change or loss of embryos during the cryopreservation and thawing process (‘harming the 
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seed’) (Basile & Garcia-Velasco, 2016; Wong et al., 2017). It is unclear whether the more 
physiologically natural endometrium environment could balance against the possible unnatural 
changes caused by embryo cryopreservation. Population-level evidence with sufficient power 
is essential to evaluating the clinical efficacy and safety of fresh versus frozen-thawed embryo 
transfer. 
1.2 AIMS 
The overarching objective of this thesis is to inform infertile patients, clinicians and 
health policymakers regarding the clinical efficacy and safety of two types of ART treatment, 
fresh and frozen-thawed embryo transfer, in terms of maximizing the live birth rate while 
minimizing the adverse perinatal outcomes. 
The specific objectives are: 
• to investigate the impact of fresh and frozen-thawed embryo transfer on the 
birthweight for gestational age, and to develop the birthweight for gestational age 
percentile charts for babies following ART treatment 
• to investigate what type of ART treatment (fresh versus frozen-thawed cleavage 
stage embryo and blastocyst) is associated with a lower rate of ectopic pregnancy 
• to compare the cycle-based live birth rate and perinatal outcomes following fresh 
embryo transfer and two methods of embryo cryopreservation: slow freezing and 
vitrification 
• to compare the cumulative live birth rate following a ‘freeze-all’ embryo transfer 
strategy, where all embryos are cryopreserved for future transfer with a ‘fresh 
transfer’ strategy where selected embryo(s) are transferred in the stimulated cycle 
and the remaining embryos are cryopreserved for future use.  
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1.3 DATA 
The data used in this PhD thesis are a research extract obtained from the Australian and 
New Zealand Assisted Reproduction Database (ANZARD) (Studies 1–3) and the Victorian 
Assisted Reproductive Treatment Authority (VARTA) (Study 4). ANZARD was established 
in 2002 as a joint initiative of the University of New South Wales, the National Perinatal 
Epidemiology and Statistics Unit and the Fertility Society of Australia (FSA). ANZARD 
collects information on patients’ demographic characteristics, ART and donor sperm 
insemination treatments, and resulting pregnancy and birth outcomes from all fertility centers 
in Australia and New Zealand (Fitzgerald et al., 2017). VARTA is a statutory authority which 
records details of all initiated ART treatments undertaken in Victoria, including demographic 
characteristics, type of ART treatment and resulting pregnancy and birth outcomes (VARTA, 
2015). Approximately 30% of all ART treatment cycles undertaken in Australia are performed 
in Victoria (Harris et al., 2016).  
From 2009, ANZARD and VARTA were upgraded to accommodate new ART treatment 
types such as oocyte/embryo vitrification, oocyte freezing/thawing process and duration of 
thawed oocytes/embryos in storage. Furthermore, ANZARD and VARTA allow the 
identification of successive treatment cycles undertaken by one woman from 2009. The follow-
up was achieved by using two data items in the dataset: the patient unique identifier and the 
statistical linkage key (SLK). The patient unique identifier is assigned by the clinic. The SLK 
is a combination of the first two letters of a woman’s first name, the first two letters of her 
surname and her date of birth. The combination of the patient unique identifier and the SLK 
allows the tracking of women’s treatments and resulting outcomes within and between clinics. 
Patients’ demographic characteristics include the woman’s and partner’s age at 
treatment, the cause of infertility and previous pregnancies of ≥20 weeks of gestation. ART 
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treatment factors comprise the number of oocytes retrieved, source of sperm, method of 
fertilization, number of embryos transferred, stage of embryo development (cleavage stage 
embryo/blastocysts), and method of embryo cryopreservation and subsequent uses. The 
outcome measurements include clinical pregnancy, early pregnancy loss (ectopic pregnancy, 
termination and miscarriage), the method of birth, gestational age, birthweight, congenital 
abnormality and perinatal mortality. The complete data item list is found in Appendix 1. 
Ethics approval for this PhD thesis was granted by the Human Research Ethics 
Committee of the University of Technology Sydney (Reference No. 2015000341) and the 
Human Research Ethics Committee of the University of New South Wales (Reference No. 
HC12373). Access to the ANZARD data was approved by the FSA. Access to the VARTA 
data was granted by VARTA.  
1.4 THESIS OUTLINE 
This thesis describes and contextualizes the findings of four studies that evaluate the 
pregnancy and perinatal outcomes following fresh and frozen-thawed embryo transfer. The 
thesis has structured into a total of seven chapters, including this chapter, Introduction (Chapter 
1). 
Chapter 2 – Literature review provides background information regarding the history, 
types and utilization of ART treatments. It includes a detailed discussion of the clinical efficacy 
and safety of fresh embryo transfer and frozen-thawed embryo transfer.  
Chapter 3 – Study 1 Birthweight percentiles by gestational age for births following 
assisted reproductive technology describes the distribution of birthweight for gestational age 
for liveborn singletons following fresh and frozen-thawed embryo transfer. This chapter also 
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develops a national birthweight reference and derives sex-specific small for gestational age and 
large for gestational age criteria for liveborn singletons following ART treatment. 
Chapter 4 – Study 2 Risk of ectopic pregnancy lowest with transfer of single frozen 
blastocyst reports the risk of ectopic pregnancy following different ART treatment including 
transfer of fresh and frozen-thawed embryos  
Chapter 5 – Study 3 Clinical outcomes following cryopreservation of blastocysts by 
vitrification or slow freezing investigates the cycle-based live birth rate following vitrification 
of blastocysts compared with fresh blastocyst transfer and slow freezing method, and evaluates 
the associated perinatal outcomes of births following transfer of fresh, slow frozen and vitrified 
blastocysts. 
Chapter 6 – Study 4 Cumulative live birth rate following freeze-only versus conventional 
fresh transfer cycles further investigates the cumulative live birth rate following a ‘freeze-all’ 
compared with a ‘fresh transfer’ strategy by the number of oocytes retrieved in the stimulated 
cycle. 
Chapter 7 – Discussion and conclusions summarizes the findings from the doctoral 
studies and describes how the findings meet the overall objectives of the thesis. The thesis 
concludes with suggested directions for further ART research, and some general remarks about 
achieving better outcomes from ART.  
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This chapter begins with the historical background of ART treatment (section 2.1) and a 
description of the procedures involved in a typical ART treatment (section 2.2.1). This is 
followed by a description of the conventional fresh embryo transfer and literature on the 
potential issues associated with fresh embryo transfer (section 2.2.2). The ensuing section 
(section 2.2.3) discusses the increasing trend of frozen-thawed embryo transfer in ART 
practice, specifically the two principal approaches for cryopreservation, slow freezing and 
vitrification, and the increasingly favored ‘freeze-all’ strategy in Australia and worldwide. 
Section 2.3 reviews the clinical efficacy and safety of fresh versus frozen-thawed embryo 
transfer regarding minimizing the adverse outcomes in parallel with maximizing the live birth 
rate. Section 2.4 contextualizes the implications from the literature and develops the conceptual 
framework for the PhD studies. 
2.1 BACKGROUND 
Infertility is defined as the failure to achieve a clinical pregnancy after 12 months or more 
of regular unprotected sexual intercourse (Zegers-Hochschild et al., 2009). The inability to 
have a baby affects millions of families worldwide. It has been estimated that 72 million women 
are experiencing infertility and 56% of them (40 million) are seeking infertility medical care 
(Boivin et al., 2007). In Australia, approximately up to one in four women report difficulty in 
becoming pregnant at some stage of their reproductive life (Herbert et al., 2009; Marino et al., 
2011). In the United States, an estimated one in eight (12%) couples have sought some medical 
assistance to achieve pregnancy (Luke, 2017). 
The world’s first IVF baby, Louise Brown, who was born in 1978 in England, turned 40 
in July 2018 (Steptoe & Edwards, 1978). Over the last four decades, ART has revolutionized 
the treatment for couples affected by infertility, and it is estimated that over 6 million children 
have been conceived using ART treatment (Chambers et al., 2017). The most recent 
International Committee Monitoring Assisted Reproductive Technologies (ICMART) world 
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report estimated that the birth of more than one million babies was the result of ART treatment 
during the 2008–2010 triennium internationally (Dyer et al., 2016). In Australia, 1 in 25 
children born in 2015 was the result of ART treatment (Australian Institute of Health and 
Welfare, 2017; Fitzgerald et al., 2017). 
In the past four decades, in both laboratory and clinical practice, ART treatment has 
undergone rapid development, and numerous variations to the typical ART treatment have 
evolved. These procedures include optimization of ovarian stimulation protocols, utilization of 
ICSI, assisted hatching, GIFT, advancement in culture media,  pre-implantation genetic testing 
for aneuploidies (PGT-A), pre-implantation genetic testing for monogenic/single gene defects 
(PGT-M) and pre-implantation genetic testing for chromosomal structural rearrangements 
(PGT-SR), cryopreservation and storage of supernumerary embryo(s) that are not transferred 
in the stimulated cycle (Devroey et al., 2011; Gardner & Lane, 1998; Mastenbroek et al., 2007; 
Palermo et al., 1992; Quinn, 2004; Zegers-Hochschild et al., 2009; Zegers-Hochschild et al., 
2017; Zeilmaker et al., 1984).  
Notably, among these newly developed techniques and technologies is cryopreservation 
of supernumerary embryo(s), which is one of the most important developments and which has 
impacted positively on the outcomes of ART treatment. Embryo cryopreservation and transfer 
of frozen-thawed embryos provide the opportunities to maximize the efficacy of one oocyte 
retrieval and allow the possibility of single embryo transfer in the stimulated cycle, which 
subsequently reduces the complications associated with multiple pregnancies (Pelkonen et al., 
2010; Wennerholm et al., 2009). The first baby conceived following the transfer of a frozen-
thawed embryo was born in 1984 (Zeilmaker et al., 1984). In recent years, the proportion of 
frozen-thawed embryo transfer among embryo transfer cycles has markedly increased. In 2015, 
transfer of a cryopreserved embryo contributed to half (50.0%) of the embryo transfer cycles 
in Australia and New Zealand (Fitzgerald et al., 2017). 
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2.2 TYPE OF ART TREATMENT 
2.2.1 A typical ART treatment 
ART treatment includes a group of fertility procedures that involves the in vitro handling 
of human gametes (oocytes and sperm) or embryos for the purpose of establishing a pregnancy 
(Fitzgerald et al., 2017; Zegers-Hochschild et al., 2009). In general, a typical ART treatment 
involves the steps described below (Figure 2-1) (Fitzgerald et al., 2017; Sunderam et al., 2018):  
Controlled ovarian 
stimulation 
Oocyte pick-up Sperm preparation 
IVF ICSI 
Embryo(s)  
maturation 
Fresh embryo(s) 
Fresh embryo transfer: 
selected fresh 
embryo(s) transfer into 
the uterus in the 
stimulated cycle 
Frozen-thawed embryo(s) 
transferred in subsequent cycles 
Fe
rti
liz
at
io
n 
Slow freezing Vitrification 
Frozen embryo(s) 
Excess embryo(s) 
C
ry
op
re
se
rv
at
io
n 
Em
br
yo
 tr
an
sf
er
  
Figure 2-1 A typical ART treatment 
IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection 
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• Controlled ovarian stimulation and oocyte maturation: An ovarian 
stimulation regimen (i.e. hormone treatment using follicle stimulating hormone) 
is administered to induce the maturation of multiple oocytes. 
• Oocyte pick-up and sperm preparation: Matured oocytes are aspirated from 
ovarian follicles (i.e. ultrasound-guided transvaginal aspiration) and sperm is 
obtained by ejaculation or surgical procedures. 
• Fertilization: The oocytes are fertilized using either IVF, where sperm are added 
to each oocyte in a fluid medium in a laboratory, or ICSI, where a selected 
spermatozoon is injected directly into each oocyte. 
• Embryo maturation: The fertilized oocytes are cultured for 2–3 days to form a 
cleavage stage embryo or 5–6 days to form a blastocyst. 
• Embryo transfer: One or more fresh and/or frozen-thawed cleavage stage 
embryo(s) or blastocyst(s) are transferred into the uterus with the intention to 
achieve pregnancy. 
2.2.2 Fresh embryo transfer 
The conventional ‘fresh transfer’ strategy refers to the embryo transfer strategy where 
selected embryo(s) are transferred in the stimulated cycle (fresh embryo transfer), and any 
remaining embryos are cryopreserved for potential future use (Figure 2-1). Nowadays, fresh 
embryo transfer is still the norm in ART practice in Europe. In 2013, a European register of 38 
European countries with 686271 ART treatment cycles reported that a significantly higher 
proportion of fresh embryo transfers were performed than frozen-thawed embryo transfers, and 
the proportion of frozen-thawed embryo transfer cycles compared to fresh embryo transfers 
was 38.3% (European IVF Monitoring Consortium et al., 2017). In Australia and New Zealand, 
the proportion of embryo transfer cycles transferring a fresh embryo was similar to those 
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transferring a cryopreserved embryo. Of the 55357 embryo transfer cycles undertaken in 
Australia and New Zealand in 2015, 27723 (50.1%) were fresh embryo transfer cycles and 
27634 (49.9%) were frozen-thawed embryo transfer cycles (Fitzgerald et al., 2017).  
In recent years, there has been increasing concern about the potential adverse effects of 
supraphysiologic hormonal levels associated with controlled ovarian stimulation in the 
stimulated cycle (Evans et al., 2014; Roque, 2015; Roque et al., 2017; Wong et al., 2017). The 
supraphysiologic estradiol and progesterone level during controlled ovarian stimulation may 
lead to alteration of the endometrial gene expression (Horcajadas et al., 2005; Labarta et al., 
2011). Human chorionic gonadotropin (hCG) has traditionally been used to trigger final oocyte 
maturation in ART treatment (Youssef et al., 2016). Horcajadas et al. examined the endometrial 
gene expression profiles and found more than 200 genes showed a more than three-fold 
differential expression at day hCG +7 during controlled ovarian stimulation compared with 
luteinizing hormone (LH) +7 in a natural cycle (Horcajadas et al., 2005). Similarly, a functional 
genomics analysis study identified 140 genes significantly dysregulated in women with high 
circulating progesterone levels (a progesterone serum level of >1.5 ng/ml) compared with the 
control group (a progesterone serum level of <1.5 ng/ml) at the end of the follicular phase in 
controlled ovarian stimulation (Labarta et al., 2011). In addition, observational studies have 
shown that the supraphysiologic hormonal levels may cause biochemical and morphologic 
modifications in the endometrial receptivity, which lead to embryo-endometrium asynchrony 
and consequently jeopardize the embryo implantation during ART treatment (Barnhart, 2014; 
Bourgain & Devroey, 2003; Kolibianakis et al., 2002; Roque, 2015; Ullah et al., 2017; Van 
Vaerenbergh et al., 2011). Although currently there is no consensus in relation to the threshold 
of when a stimulated cycle becomes supraphysiologic and impairs the endometrial receptivity, 
it has been hypothesized that a frozen-thawed embryo transfer allows the embryo to be placed 
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in a physiologic endometrium environment which may lead to more favorable clinical 
outcomes (Barnhart, 2014; Roque, 2015).  
2.2.3 Embryo cryopreservation and frozen-thawed embryo transfer 
Embryo cryopreservation and frozen-thawed embryo transfer refers to the procedures 
whereby embryos are cryopreserved for storage, to be thawed and transferred at a later stage 
after the conclusion of the stimulated cycle. Frozen-thawed embryo transfer has become a 
routine ART practice and the proportion of frozen-thawed embryo transfer among embryo 
transfer cycles has increased worldwide. In Australia and New Zealand, the proportion of 
frozen-thawed embryo transfer cycles transferring a cryopreserved embryo increased from 
41.2% of embryo transfer cycles in 2005 to 49.9% in 2015 (Fitzgerald et al., 2017; Wang et 
al., 2007). Further, the European IVF Monitoring Consortium examined 15 years of ART 
activities in Europe with a total of 5.9 million ART cycles, and reported the proportion of 
frozen-thawed embryo transfer among the total number of ART cycles increased significantly 
from 12% in 1997 to 21% in 2011 (Ferraretti et al., 2017).  
Cryopreservation of excess embryos provides the opportunity to maximize the 
cumulative live birth rates following one oocyte retrieval. It allows more than one attempt of 
embryo transfer following the stimulated cycle, and therefore decreases the exposure of women 
to multiple episodes of ovarian stimulation, minimizes the number of hospital/clinic 
attendances for oocyte pick-up procedures and diminishes the risks associated with the 
procedures involved (Liu et al., 2013; Loutradi et al., 2008; Michelmann & Nayudu, 2006; Son 
& Tan, 2009). In addition, embryo cryopreservation offers the opportunity to limit the number 
of embryos transferred at any one time to reduce the risk of multiple pregnancies following 
ART treatment (AbdelHafez et al., 2010; Kolibianakis et al., 2009). Additionally, the use of a 
gonadotropin-releasing hormone (GnRH) antagonist protocol with the final oocyte maturation 
using GnRH agonist (instead of hCG) followed by cryopreservation of all embryos is one of 
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the most effective methods to prevent ovarian hyperstimulation syndrome (OHSS) (Devroey 
et al., 2011; Roque, 2015). 
Cryobiology 
The fundamental aim of cryobiology is to maintain the functional capacity of cells at low 
temperatures. It is critical to eliminate ice crystal formation and lethal concentrations of solutes, 
which are the main causes of cell death associated with cryopreservation (Edgar & Gook, 
2012). The formation of large quantities of intracellular ice crystal can lead to cell damage and 
developmental arrest (Bagchi et al., 2008; Loutradi et al., 2008). Cryoprotectants are used to 
facilitate expulsion of intracellular fluid, where permeable cryoprotectants permeate through 
the cell membranes and replace the intracellular water via an osmotic gradient, and non-
permeable cryoprotectants provide a continuous osmotic gradient, but do not permeate through 
the cell membranes (Edgar & Gook, 2012). 
Slow freezing versus vitrification 
Two cryopreservation methods are routinely used: slow freezing and vitrification. The 
traditional slow freezing method utilizes the equilibrium process to slowly decrease the 
temperature, which allows solution exchange between the intracellular and extracellular fluids 
to minimize ice crystal formation (Edgar & Gook, 2012; Vajta & Kuwayama, 2006). The 
controlled cooling rate in combination with low concentrations of cryoprotectants are used to 
avoid serious toxic and osmotic damage (Rezazadeh Valojerdi et al., 2009). The slow freezing 
method has become a highly standardized procedure using a programmable controlled freezing 
machine. In brief, during slow cooling, the programmable freezing machine slowly reduces the 
temperature (0.3 – 1.0°C/min) until approximately −30 to −70°C and then rapidly reduces the 
temperature (∼ −50°C/min) to around −150°C. The oocytes/embryos are then stored in liquid 
nitrogen at –196°C (Edgar & Gook, 2012; Rienzi et al., 2017; Son & Tan, 2009). 
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Vitrification is an ultra-rapid cryopreservation technique with extremely fast rates of 
cooling (15000°C – 30000°C/min) where the oocytes/embryos are transitioned from 37°C to 
−196°C in less than 1 second (Loutradi et al., 2008). The viscosity of intracellular and 
extracellular solutions increases with decreasing temperature. In vitrification, the 
oocytes/embryos are transformed into a metastable glass-like status without forming ice 
crystals when the viscosity of the solutions is high enough and the cooling of the temperature 
is extremely rapid (Bagchi et al., 2008; Youssry et al., 2008). Compared with the slow freezing 
method, vitrification is a simpler and faster method that requires no expensive programmable 
freezing machine (Liebermann & Tucker, 2006). In practice, the oocytes/embryos are exposed 
to high concentrations of cryoprotectants for a short period of time (≤1min) and are then 
plunged directly into liquid nitrogen (Rienzi et al., 2017; Vajta et al., 2015). The combination 
of ultra-rapid cooling rates and high concentrations of cryoprotectants effectively eliminates 
the ice crystal formation (Edgar & Gook, 2012).  
Vitrification was first introduced in Australia in 2006 and has now become the primary 
treatment preference for blastocysts (Costigan et al., 2007; Fitzgerald et al., 2017). The 
proportion of cycles with vitrification as the cryopreservation method has increased from 
33.3% in 2009 to 86.1% in 2015 among autologous blastocyst thaw cycles (Fitzgerald et al., 
2017; Wang et al., 2011). 
Literature has shown that vitrification is associated with significant improvement in 
embryo cryosurvival compared with slow freezing. A recent systematic review and meta-
analysis based on seven randomized controlled trials (RCTs) (slow freezing n = 2061; 
vitrification n = 1554) revealed that the embryo cryosurvival rate was significantly higher after 
vitrification compared with slow freezing (relative risk ratio: 1.59, 95% confidence interval 
(CI): 1.30 – 1.93; p < 0.001; I2 = 93%; moderate quality evidence) (Rienzi et al., 2017).  
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To date, there have been only a limited number of RCTs and observational cohort studies 
to examine the fertility and pregnancy outcomes (clinical pregnancy rate and live birth rate) 
following the transfer of slow frozen and vitrified embryos. A systematic review and meta-
analysis found a higher clinical pregnancy rate per cycle following vitrification compared with 
slow freezing based on three RCTs (Debrock et al., 2015; Kim et al., 2000; Rama Raju et al., 
2005) (relative risk ratio: 1.89, 95% CI: 1.00 – 3.58; p = 0.051; 638 cycles; I2 = 71.9%; low 
quality evidence) and eight observational cohort studies (Liebermann & Tucker, 2006; 
Rezazadeh Valojerdi et al., 2009; Sifer et al., 2012; Stehlik et al., 2005; Van Landuyt et al., 
2013; Wang et al., 2012; Wilding et al., 2010; Zhu et al., 2015) (relative risk ratio: 1.27, 95% 
CI: 1.05 – 1.55; p = 0.015; 8391 cycles; I2 = 76.5%; very low-quality evidence) (Rienzi et al., 
2017). In contrast, no differences in the live birth rate per cycle were observed between transfer 
of slow frozen and vitrified embryos based on three observational studies (Van Landuyt et al., 
2013; Wang et al., 2012; Wilding et al., 2010) (relative risk ratio: 1.05, 95% CI: 0.67 – 1.65; p 
= 0.831; 1621 cycles; I2 = 74.8%; very low-quality evidence) (Rienzi et al., 2017).  
‘Freeze-all’ embryo transfer strategy 
In recent years, the proportion of ‘fresh transfer’ strategy cycles has decreased due to the 
increasingly favored ‘freeze-all’ strategy where no fresh embryo(s) are transferred in the 
stimulated cycle and all resulting embryos are cryopreserved for future transfer in an 
unstimulated cycle (Figure 2-2). In 2015, of the 35401 autologous fresh cycles with at least one 
fertilized oocyte undertaken in Australia and New Zealand, 27065 (76.5%) were ‘fresh 
transfer’ cycles and 8336 (23.5%) were ‘freeze-all’ cycles (Fitzgerald et al., 2017). Although 
the ‘fresh transfer’ strategy is still the most common embryo transfer strategy in ART practice 
in Australia and New Zealand, the use of the ‘freeze-all’ strategy has proportionally increased 
in the last decade. In Australia and New Zealand, the proportion of cycles where all embryos 
are cryopreserved increased from 4.1% of initiated fresh cycles in 2010 to 18.1% in 2015 
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(Fitzgerald et al., 2017; Harris et al., 2016). A similar trend was observed in the United States. 
An analysis of 411811 autologous fresh ART cycles with at least one embryo cryopreserved 
showed that the proportion of embryo cryopreservation without fresh embryo transfer increased 
from 7.9% in 2004 to 40.7% in 2013, based on data reported to the United States Society for 
Assisted Reproductive Technology Clinic Outcome Reporting System (Christianson et al., 
2017). The most common reasons for adopting a ‘freeze-all’ strategy include the use of PGT-
A, PGT-M or PGT-SR to identify genetic defects with embryos prior to embryo transfer, to 
prevent the development of OHSS, to manage the premature rise in progesterone on the day of 
hCG administration for final oocyte maturation, and elective ‘freeze-all’, which allows 
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Figure 2-2 Freeze-only embryo transfer cycle 
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embryo(s) to be transferred in a more favorable endometrium environment in subsequent 
unstimulated cycles (Basile & Garcia-Velasco, 2016; Esteves et al., 2018). 
One of the reasons that justify the employment of the ‘freeze-all’ strategy was to manage 
the premature progesterone elevation on the day of hCG administration (Dieamant et al., 2017). 
Several studies have shown that elevated serum progesterone level may result in impaired 
endometrial receptivity and consequently jeopardize the embryo implantation and pregnancy 
outcomes (Huang et al., 2012; Kiliçdag et al., 2010; Venetis et al., 2015). Elevated progesterone 
level (>1.1 ng/mL) was associated with significantly decreased implantation rate (18.1 vs 
24.4%, p= 0.008) and live birth rate (27.6 vs 40%, p=0.004) compared with the control group 
(≤1.1 ng/mL) (Kiliçdag et al., 2010). A retrospective analysis of 2566 patients with GnRH 
agonist long or short protocols compared the live birth rate between groups with and without 
premature progesterone rise (Huang et al., 2012). Huang et al. (Huang et al., 2012) reported a 
decreased live birth rate in the premature progesterone rise group (cutoff value of 1.2 ng/mL 
for long protocol and 2.0 ng/mL for short protocol, respectively) following fresh cycle for both 
long (29.8% vs 40.7%, p=0.004) and short protocols (23.5% vs 30.2%, p=0.083). In contract, 
no statistically significant difference was observed in live birth rate following frozen-thawed 
embryo transfer cycles between groups with and without premature progesterone rise (25.4% 
vs 29.3%, p=0.213, long protocol; 24.2% vs 24.8%, p=0.881, short protocol, respectively) 
(Huang et al., 2012). However, the negative association between elevated progesterone level 
and live birth rate may not be extrapolate to all kinds of ovarian response. A pooled analysis 
of six clinical trials showed that progesterone elevation (>1.5 ng/mL) was associated with a 
decreased chance of pregnancy in low (1 – 5 oocytes) to normal (6 – 18 oocytes) responders, 
but not in high (>18 oocytes) responders (Griesinger et al., 2013). Similarly, a retrospective 
cohort study of 2850 women with ≥20 oocytes retrieved or estradiol levels ≥3000 pg/ml 
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concluded that elevated progesterone level (>1.8 ng/mL) did not have detrimental effect on 
implantation and pregnancy rates in high responder women (Requena et al., 2014). 
The pathophysiologic rationale behind the elective ‘freeze-all’ strategy is to place the 
embryos in a more favorable endometrium environment in an unstimulated cycle (Roque, 
2015). The success of ART treatment is associated with not only the quality of the embryo, but 
also the endometrial receptivity and the embryo-endometrium interaction (Dieamant et al., 
2017; Roque et al., 2017). The supraphysiological hormonal levels in the stimulated cycle may 
lead to defective endometrial receptivity and have a negative impact on embryo implantation 
(Kilicdag et al., 2010; Shapiro et al., 2011a). In contrast, in the ‘freeze-all’ strategy, the 
endometrium is artificially primed or allowed to develop naturally in response to ovulation, 
and the embryo is transferred in an unstimulated cycle without controlled ovarian stimulation 
or supraphysiological hormonal levels. The different endometrium environment in the ‘freeze-
all’ strategy may contribute to the differences in obstetric and perinatal outcomes when 
comparing frozen-thawed embryo transfer to fresh embryo transfer (Roque et al., 2017). 
2.3 FRESH VERSUS FROZEN-THAWED EMBRYO TRANSFER 
Conflicting results have been reported by studies comparing the pregnancy, obstetric and 
perinatal outcomes following fresh and frozen-thawed embryo transfer (Acharya et al., 2018; 
Maheshwari et al., 2018; Sha et al., 2018). Safety concerns have been raised in relation to the 
potential degeneration, epigenetic changes or loss of embryos during the cryopreservation and 
thawing process in frozen-thawed embryo transfer cycles (Isikoglu, 2016; Pinborg et al., 2014). 
Other work suggests that because embryos are placed in a more physiologically natural 
endometrium environment in frozen-thawed embryo transfer, babies conceived following 
frozen-thawed embryo transfer are expected to have better perinatal outcomes compared with 
those conceived following fresh embryo transfer (Barnhart, 2014; Roque et al., 2017). The 
following sections review the current literature on the comparison between fresh and frozen-
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thawed embryo transfer for the following clinical outcome measurements: baby birthweight 
(low birthweight, small and large for gestational age), ectopic pregnancy, pregnancy-induced 
hypertension and pre-eclampsia, OHSS, multiple birth, congenital abnormality, perinatal 
mortality and live birth rate.  
2.3.1 Low birthweight and small/large for gestational age 
Low birthweight (<2500 g), small for gestational age (SGA, defined as birthweight less 
than the 10th centile for that gestation) and large for gestational age (LGA, defined as 
birthweight more than the 90th centile for that gestation) births have an increased risk of 
morbidity and mortality in the fetal and neonatal periods and beyond (Bickle Graz et al., 2015; 
Chiavaroli et al., 2016; Lee et al., 2017; Wennerstrom et al., 2015).  
A higher proportion of low birthweight births was observed among babies born following 
ART treatment compared with the general population. In the United States, approximately 
8.7% of ART singletons had low birthweight, compared with 6.4% among all singletons born 
in the total birth population in 2015 (Sunderam et al., 2018). Similarly, in Australia and New 
Zealand, low birthweight was reported for 6.8% of ART singletons compared with 5.0% of 
singleton births in Australia in 2015 (Australian Institute of Health and Welfare, 2017; 
Fitzgerald et al., 2017).  
Low birthweight is one of the most studied outcome measurements when comparing the 
perinatal outcomes following fresh and frozen-thawed embryo transfer. An earlier systematic 
review and meta-analysis of nine cohort studies conducted between 1994 to 2011 found that 
babies born following frozen-thawed embryo transfer had a significantly lower risk of low 
birthweight compared with those born following fresh embryo transfer (relative risk (RR): 
0.69, 95% CI: 0.62 – 0.76) (Maheshwari et al., 2012). Although the statistically significant 
reduced risk reported in the Maheshwari et al. 2012 systematic review and meta-analysis was 
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mainly attributed to three large cohort studies (Pelkonen et al., 2010; Pinborg et al., 2010; Wang 
et al., 2005), consistent findings were reported by two meta-analyses published in 2018. Both 
concluded that frozen-thawed embryo transfer was associated with a reduced risk of low 
birthweight compared with fresh embryo transfer (Maheshwari et al., 2018; Sha et al., 2018). 
Although birthweight is an important indicator to assess the risk of newborns at birth, it 
does not take into account gestational age. As low birthweight is closely associated with 
preterm birth, and ART births have a greater risk of being born prematurely (Fitzgerald et al., 
2017; McDonald et al., 2009; Sunderam et al., 2018), it is important to differentiate whether a 
baby is small because it was born early (preterm birth) or is SGA. Babies born SGA may have 
different health issues to those born prematurely. Suspected SGA fetuses may be associated 
with fetal growth restriction secondary to placental dysfunction and are at increased risk of 
stillbirth (Clausson et al., 2001; Madden et al., 2018; Mlynarczyk et al., 2017; Moraitis et al., 
2014; Pilliod et al., 2012). Babies born SGA are at increased risk of neonatal and infant 
mortality, respiratory distress syndrome, severe acidosis at birth, neonatal sepsis and admission 
to a neonatal intensive care unit (NICU) (Madden et al., 2018; Mendez-Figueroa et al., 2016; 
Mlynarczyk et al., 2017; Ota et al., 2014). LGA births also have related health issues, with an 
increased need for resuscitation, and increased risk of admission to a NICU, developing insulin 
resistance, diabetes and subsequent childhood and adult obesity as well as cardiovascular 
disease later in life (Boney et al., 2005; Das & Sysyn, 2004; Dietz, 2004; Giapros et al., 2007; 
Hediger et al., 1999; Ng et al., 2010). 
Unlike the well-studied low birthweight, SGA and LGA were not reported as key 
outcome measurements when comparing fresh and frozen-thawed embryo transfer in the 
literature until 2010 (Pelkonen et al., 2010; Wikland et al., 2010). Mixed results were reported 
by these two earlier studies. Wikland et al. examined the neonatal outcomes of babies born 
after transfer of vitrified blastocysts (n = 106) and fresh blastocysts (n = 207) (Wikland et al., 
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2010). Compared with fresh blastocyst transfer, vitrified blastocyst transfer resulted in a 
significantly lower proportion of SGA births (12.1% vs 3.0%, p = 0.0085), but a similar 
proportion of LGA birth (6.9% vs 7.0%, p = 0.5666) (Wikland et al., 2010). The register-based 
cohort study conducted by Pelkonen et al. examined the perinatal outcomes of babies born 
following fresh (n = 4151) and frozen-thawed (n = 2293) embryo transfer in Finland between 
1995 and 2006 (Pelkonen et al., 2010). The Finnish cohort study showed that babies born 
following frozen-thawed embryo transfer had a significantly decreased risk of being SGA 
(adjusted odds ratio (AOR): 0.63, 95% CI: 0.49 – 0.83), but significantly increased risk of 
being LGA (AOR: 1.70, 95% CI: 1.21 – 2.40) compared with babies born following fresh 
embryo transfer (Pelkonen et al., 2010).  
Since 2010, nine cohort studies, including Study 3 in this PhD thesis (Li et al., 2014b), 
have examined outcomes following fresh and frozen-thawed embryo transfer in terms of small 
and large gestational age (Ishihara et al., 2014; Kato et al., 2012; Li et al., 2014b; Luke et al., 
2017; Pelkonen et al., 2010; Pinborg et al., 2014; Sazonova et al., 2012; Wennerholm et al., 
2013; Wikland et al., 2010). Interestingly, although these studies adopted different study 
designs (i.e. definition of small/large for gestational age, method of cryopreservation used in 
frozen-thawed embryo transfer, and stage of embryo transfer (cleavage stage 
embryo/blastocyst) etc.), consistent findings were reported by all nine studies, which concluded 
that frozen-thawed embryo transfer was associated with a statistically significant reduced risk 
of SGA birth but significantly increased risk of LGA compared with fresh embryo transfer 
(Ishihara et al., 2014; Kato et al., 2012; Li et al., 2014b; Luke et al., 2017; Pelkonen et al., 
2010; Pinborg et al., 2014; Sazonova et al., 2012; Wennerholm et al., 2013; Wikland et al., 
2010). 
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2.3.2 Ectopic pregnancy 
An ectopic pregnancy is defined as a pregnancy implanted outside the endometrial lining 
of the uterus (McQueen, 2011). Ectopic pregnancy is one of the recognized complications 
following ART treatment. The rate of ectopic pregnancy following ART treatment was 
previously reported as ranging from 2% to 8.6%, and up to 11% among women with tubal-
related infertility (Clayton et al., 2006; Dubuisson et al., 1991; Nazari et al., 1993) and has 
decreased over time. In the United States, the ectopic pregnancy rate following ART treatment 
declined from 2.0% in 2001 to 1.6% in 2011, a rate similar to the general population of 2% 
(Perkins et al., 2015). Similar trends are observed in Australia and New Zealand. The 
Australian and New Zealand data suggests that the ectopic pregnancy rate declined from 1.9% 
of clinical pregnancies following ART treatment in 2002 to 1.0% in 2015 (Bryant et al., 2004; 
Fitzgerald et al., 2017).  
The association between ectopic pregnancy and ART treatment is complex. 
Theoretically, it could be expected that ART treatment reduces the risk of ectopic pregnancy 
as the embryo transfer procedure, where embryo(s) are placed directly into the uterus, would 
bypass the fallopian tube. However, the infertility history of women undergoing ART treatment 
is associated with increased risk of ectopic pregnancy. Tubal factor infertility, pelvic 
inflammatory disease, endometriosis and previous history of ectopic pregnancy have been 
identified as the most prominent risk factors for ectopic pregnancy among pregnancies 
following ART treatment (Brady & Ginsburg, 2017; Chang & Suh, 2010; Refaat et al., 2015). 
The technical aspects of ART treatment also have a significant impact on the risk of ectopic 
pregnancy, such as fresh versus frozen-thawed embryo transfer, the number of embryos 
transferred, assisted hatching, and cleavage stage embryo transfer versus blastocyst transfer. 
For many ART procedures, the findings are inconsistent in the literature (Brady & Ginsburg, 
2017; Chang & Suh, 2010; Refaat et al., 2015). 
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The association between frozen-thawed embryo transfer and ectopic pregnancy is 
inconclusive in the literature. Some earlier studies found a higher or similar ectopic pregnancy 
rate following frozen-thawed embryo transfer compared with fresh embryo transfer (Check et 
al., 2005; Jee et al., 2009; Jun & Milki, 2007; Silva et al., 2003). A systematic review and meta-
analysis of seven comparative studies, comprising 2125 pregnancies following frozen-thawed 
embryo transfer and 10934 pregnancies following fresh embryo transfer, reported a non-
statistically significant increased risk of ectopic pregnancy following frozen-thawed embryo 
transfer compared with fresh embryo transfer (2.3% vs 1.5%, odds ratio (OR): 1.66, 95% CI 
0.62 – 4.41) (Jee et al., 2009). One of the theories that may explain the higher ectopic pregnancy 
in frozen-thawed embryo transfer cycles is the supraphysiological progesterone level in fresh 
embryo cycles may result in better uterine relaxation, which leads to the improved chance of 
implantation in the uterine cavity rather than migration into the fallopian tubes (Chang & Suh, 
2010).  
In contrast, several recent studies reported that the rate of ectopic pregnancy is lower 
following frozen-thawed embryo transfer compared with the transfer of fresh embryos (Huang 
et al., 2014; Ishihara et al., 2011; Londra et al., 2015; Perkins et al., 2015; Shapiro et al., 2012). 
A United States study using data from the Centers for Disease Control and Prevention's 
National ART Surveillance System found the ectopic pregnancy rate following autologous 
frozen-thawed transfer was 1.3%, which was significantly lower than the 2.0% ectopic 
pregnancy rate following fresh autologous transfer (AOR: 0.65, 95% CI: 0.61 – 0.96) (Perkins 
et al., 2015). Similarly, a retrospective cohort study using the U.S. Society for Assisted 
Reproductive Technologies registry found a 65% lower odds of ectopic pregnancy following 
frozen-thawed embryo transfer compared with fresh embryo transfer in women who had an 
autologous cycle (AOR: 0.35, 95% CI: 0.29 – 0.42) (Londra et al., 2015). It has been theorized 
that the controlled ovarian hyperstimulation in the fresh cycle may have a negative impact on 
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the endometrial receptivity (Brady & Ginsburg, 2017). In addition, the increased uterine 
contractility in a fresh stimulated cycle compared with a frozen-thawed non-stimulated cycle 
could result in embryo migration into the fallopian tubes (Brady & Ginsburg, 2017). 
2.3.3 Ovarian hyperstimulation syndrome 
OHSS is a potentially lethal iatrogenic complication that is associated with controlled 
ovarian stimulation during ART cycles. OHSS is clinically characterized by an increase in 
vascular permeability, resulting in a fluid shift from intravascular space to the extravascular 
space (Kwik & Maxwell, 2016; Mourad et al., 2017). Clinical presentation of OHSS includes 
a spectrum of symptoms and signs, such as abdominal tenderness and swelling, ovarian 
enlargement, ascites, hemoconcentration, intravascular volume depletion, and electrolyte 
imbalances (Humaidan et al., 2016; Nelson, 2017). Severe OHSS can incur the risk of acute 
renal insufficiency, pleural effusion, respiratory distress and venous thromboembolism 
(Mourad et al., 2017; Practice Committee of the American Society for Reproductive Medicine, 
2016). The mild form of OHSS occurs in approximately 20% to 30% of all stimulation cycles, 
and the more clinically relevant moderate or severe OHSS affects an estimated 1% to 8% of 
stimulation cycles (Kupka et al., 2016; Mourad et al., 2017; Papanikolaou et al., 2006; Practice 
Committee of the American Society for Reproductive Medicine, 2016). In Australia, 
approximately 0.5% of women who had oocyte retrieval cycles in 2015 were reported to have 
OHSS that required hospitalization (Fitzgerald et al., 2017). The incidence of OHSS is 
declining in recent years due to the developed understanding of OHSS risks, improved cycle 
monitoring and the emergence of new stimulation regiment and triggering medications 
(Mourad et al., 2017).  
Women with polycystic ovarian syndrome, elevated anti-müllerian hormone value >3.4 
ng/ml, elevated antral follicle count >24, multifollicular development and had a high number 
 Chapter 2: Literature review 34 
of oocytes retrieved are associated with an increased risk of OHSS (Lee et al., 2008; Practice 
Committee of the American Society for Reproductive Medicine, 2016; Steward et al., 2014). 
The use of a GnRH antagonist protocol whereby GnRH antagonists are used to prevent 
premature luteinizing hormone surges, and a GnRH agonist is administrated for final oocyte 
maturation, is considered as one of the most effective methods to prevent OHSS (Devroey et 
al., 2011). However, a shortened luteal phase following GnRH agonist triggering may reduce 
the pregnancy rate in the stimulated fresh cycle (Fatemi & Garcia-Velasco, 2015; Kwik & 
Maxwell, 2016). Therefore, the combination of GnRH antagonist protocol followed by a 
‘freeze-all’ strategy where all embryos are cryopreserved for future transfer in a subsequent 
cycle(s) is now recognized as a promising option for women with a high risk of OHSS 
(Blockeel et al., 2016; Eldar-Geva et al., 2007). Other strategies proposed by the Australasian 
Certificate of Reproductive Endocrinology and Infertility (CREI) Consensus Expert Panel on 
Trial evidence (ACCEPT) group included adjusted dose of follicle-stimulating hormone used 
during ovarian stimulation, concomitant use of metformin, concomitant use of aspirin, 
administration of hydroxyethyl starch at or around the time of OPU and use of cabergoline 
after oocyte collection (Boothroyd et al., 2015).  
2.3.4 Multiple birth 
Multiple birth as a result of ART is a prominent adverse outcome following ART 
treatment (Healy, 2004; Min et al., 2004). In Australia, the proportion of multiple birth rose 
from to 1.3% in 1992 to 1.5% in 2015 (Australian Institute of Health and Welfare, 2017; 
Lancaster et al., 1995). Similarly, the twin birth rate in the United States increased by more 
than three-quarters, from 1.9% in 1980 to 3.3% in 2009 (Martin et al., 2012). The rise in the 
multiple birth rate was associated with the introduction and increased use of ART treatment 
and the advanced maternal age (Domingues et al., 2014; Kulkarni et al., 2013). Although the 
use of single embryo transfer has been advocated in the last two decades, the multiple birth rate 
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remains significantly higher among ART births compared to those conceived naturally. A large 
European registry of 609973 ART treatment cycles in 33 countries reported that the multiple 
delivery rate was 19.2% after IVF and ICSI cycles in 2011 (Kupka et al., 2016). It is estimated 
that approximately 36% of twins and 77% of higher order multiple births in the United States 
resulted from ART treatment in 2011 (Domingues et al., 2014). 
The high rate of multiple birth following ART treatment is largely explained by the 
number of embryos transferred for both fresh and frozen-thawed embryo transfer. In Australia 
and New Zealand, a similar multiple birth rate was observed following fresh (4.6%) and frozen-
thawed (4.3%) embryo transfer in 2015 (Fitzgerald et al., 2017). Of deliveries following double 
embryo transfer (DET) cycles, more than one-fifth (21.2% of fresh and 23.5% of frozen-thawed 
embryo transfer) were multiple births, markedly higher than the proportion following single 
embryo transfer (SET) (1.9% and 2.3% respectively) (Fitzgerald et al., 2017). A similar trend 
was observed in the United States, where most multiple births resulted from the transfer of two 
or more embryos in both fresh (81.2%) and frozen-thawed (82.1%) embryo transfer cycles in 
2012 (Kissin et al., 2015).  
Limiting the number of embryos transferred is critical for reducing multiple births 
following ART treatment (Kulkarni et al., 2013). The balance between the need for a higher 
success (live birth) rate and a lower multiple birth rate remains very delicate. A Cochrane 
review found one cycle of SET was associated with a significantly lower rate of live birth (OR: 
0.48, 95% CI: 0.39 – 0.60, nine studies, n = 1564, I2 = 0%) compared with a single cycle of 
DET (Pandian et al., 2013). However, the cumulative live birth rate after two cycles of SET 
was not significantly different from the rate following one cycle of DET (OR: 0.82, 95% CI: 
0.62 – 1.09, three studies, n = 811, I2= 0%), and the rate of multiple pregnancy was significantly 
lower in the repeated SET group compared with the DET group (OR: 0.03, 95% CI: 0.01 – 
0.13, three studies, n = 811, I2 = 23%) (Pandian et al., 2013). The authors concluded that a 
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policy of repeated SET might contribute to the reduction in the multiple birth rate while 
maintaining the live birth rate (Pandian et al., 2013). Cryopreservation of supernumerary 
embryo(s) provides the opportunity for SET in the stimulated cycle and subsequent frozen-
thawed embryo transfer cycle, which minimizes the risk of multiple birth (Pelkonen et al., 
2010; Wennerholm et al., 2009).  
2.3.5 Congenital abnormality 
Several systematic reviews and meta-analyses have reported a 30–40% increased risk of 
congenital abnormalities in infants conceived following ART treatment compared with infants 
conceived spontaneously (Hansen et al., 2013; Qin et al., 2015a; Rimm et al., 2004; Wen et al., 
2012). Hansen et al. conducted a systematic review and meta-analysis of 45 cohort studies, 
comprising approximately 4 million infants (92671 ART infants vs 3870760 spontaneously 
conceived infants) and found a significantly increased risk of congenital abnormalities among 
ART infants (RR 1.32, 95% CI 1.30 – 1.43) compared with those conceived spontaneously 
(Hansen et al., 2013). The risk further increased when analyses were restricted to studies 
evaluating major congenital abnormalities (n = 16 studies, RR 1.42, 95% CI 1.29 – 1.56) or 
singletons only (n = 23 studies, RR 1.36, 95% CI 1.30 – 1.43) (Hansen et al., 2013). A few 
large registry-based studies have been conducted since the meta-analysis was published and 
the findings were similar to those reported by Hansen et al. (Boulet et al., 2016; Getz et al., 
2014; Shechter-Maor et al., 2018). The most recent cohort study comprising 11862780 live 
births (71050 ART births vs 11791730 spontaneously conceived births) in the United States 
between 2011 and 2013 reported a significantly greater risk of congenital abnormality in the 
ART group compared with the spontaneous pregnancy group (0.77% vs 0.25%, OR 2.14, 95% 
CI 1.94 – 2.35) (Shechter-Maor et al., 2018). The most common congenital malformations 
associated with ART treatment were cyanotic heart defects, cleft lip and/or palate and 
hypospadias (Shechter-Maor et al., 2018). 
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The elevated risk of congenital abnormalities associated with ART births was partially 
explained by the higher proportion of multiple births among ART births. A mediation analysis 
on 17829 ART births and 445080 births to fertile women in Massachusetts, United States, 
showed that approximately 36% of the association between ART and congenital abnormalities 
was due to multiple births (Liberman et al., 2017). In addition, other intertwined factors, such 
as the demographic characteristics of couples seeking ART treatment and the underlying causes 
of infertility, may also contribute to the increased risk of congenital abnormalities in ART 
births (Turkgeldi et al., 2016). A cohort study using the Danish national birth registry found an 
increased risk of congenital malformations among singletons to infertile couples who 
conceived following ART treatment compared with singletons born to fertile couples (time to 
pregnancy ≤12 months) (hazard ratio 1.39, 95% CI 1.23 – 1.57) or infertile couples who 
conceived naturally (time to pregnancy >12 months) (hazard ratio 1.20, 95% CI 1.00 – 1.36) 
(Zhu et al., 2006). Rimm et al. argued that these findings suggested infertility contributed to 
approximately 40% of the increased risk of congenital malformations among births following 
ART treatment (Rimm et al., 2011). Rimm et al. re-analysed their previously published meta-
analysis by reducing 40% of the odds ratio in each study and found no significantly increased 
risk of major malformations associated with ART treatment (AOR 1.01, 95% CI 0.82 – 1.23) 
(Rimm et al., 2004; Rimm et al., 2011). 
There was no difference in the risk of congenital abnormalities between babies conceived 
following fresh and frozen-thawed embryo transfer. A cumulative meta-analysis of six studies 
reported comparable risk of congenital abnormalities (RR: 1.01, 95% CI: 0.87 – 1.16, I2 = 28%) 
following transfer of frozen-thawed (n = 25789 pregnancies) versus fresh embryos (n = 107692 
pregnancies) (Maheshwari et al., 2018). None of the six studies detected the statistically 
significant difference between the two groups (Belva et al., 2008; Kato et al., 2012; 
Maheshwari et al., 2016; Pelkonen et al., 2010; Shih et al., 2008; Wikland et al., 2010). In 
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contrast, an Australian data linkage study reported a significantly higher risk of defects of 
blastogenesis following fresh embryo transfer compared with frozen-thawed embryo transfer 
(AOR 2.41, 95% CI 1.03 – 5.65) (Halliday et al., 2010). 
2.3.6 Perinatal mortality 
Singleton pregnancies resulting from ART treatment presented higher rates of perinatal 
mortality compared with spontaneously conceived singleton pregnancies. In Australia and New 
Zealand, the perinatal mortality for singletons born following ART treatment was 11.5 per 
1000 births compared to 8.6 per 1000 births among all singleton births in Australia in 2014 
(Australian Institute of Health and Welfare, 2016; Harris et al., 2016). A recent systematic 
review and meta-analysis of 22 cohort studies, comprising 106267 ART and 1262997 
spontaneously conceived singleton pregnancies, concluded that ART singleton pregnancies 
had a significantly increased risk of perinatal mortality (RR 1.64, 95% CI 1.41 – 1.90; I2= 45%) 
compared with spontaneously conceived singleton pregnancies (Qin et al., 2016a). 
The increased risk of perinatal mortality among ART singletons is in part explained by 
the reproductive health characteristics of women, including older maternal age, recurrent 
miscarriages, infertility and medical co-morbidities, which are more prevalent among women 
undergoing ART compared to non-ART women (Palomba et al., 2016; Pandey et al., 2012; 
Pelkonen et al., 2010). A population-based cohort study of 393491 singletons reported that 
although the overall perinatal mortality rate was significantly higher for ART singletons 
compared with non-ART singletons (11.6 vs 10.5 per 1000 births, AOR 1.24, 95% CI 1.04 – 
1.48), the gestational age-specific perinatal mortality rate of ART singletons was lower or 
comparable to non-ART singletons for very preterm births (<32 weeks gestation) (342.4 vs 
489.1 per 1000 births, AOR 0.67, 95% CI 0.54 – 0.82), moderate to late preterm births (32–36 
weeks gestation) (15.2 vs 22.3 per 1000 births, AOR 0.85, 95% CI 0.49 – 1.47), and term births 
(≥ 37 weeks gestation) (2.3 vs 2.3 per 1000 births, AOR 0.98, 95% CI 0.65 – 1.48) (Chughtai 
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et al., 2018). The authors concluded that the excess overall perinatal mortality among ART 
singletons was mainly attributed to the higher proportion of preterm births among ART 
singletons compared to non-ART singletons (Chughtai et al., 2018).  
Contrary to singleton births, multiple births following ART treatment are associated with 
an unchanged or reduced risk of perinatal mortality compared with spontaneously conceived 
multiple births (Helmerhorst et al., 2004; McDonald et al., 2005; Qin et al., 2017; Qin et al., 
2016b). A meta-analysis of 22 cohort studies found that multiple pregnancies following ART 
treatment were not associated with increased risk of perinatal mortality (RR 1.04, 95% CI: 0.87 
– 1.24, p =.66) compared with spontaneously conceived multiples (Qin et al., 2015b). The 
Massachusetts Outcomes Study of Assisted Reproductive Technologies (MOSART) found that 
the births following ART treatment had half the risk of perinatal death compared with births to 
fertile women, and an 85% lower risk compared with births to subfertile women without ART 
treatment (AOR 0.55, 95% CI 0.34 – 0.89; and AOR 0.15, 95% CI 0.09 – 0.25 respectively) 
(Declercq et al., 2015). The lower perinatal mortality among ART twins may be associated 
with the lower proportion of monochorionic twins in ART pregnancies (Jauniaux et al., 2013). 
In addition, healthcare professionals and parents may give extra attention to ART births which 
contribute to more favorable outcomes (Srebnik et al., 2013). 
More than 20 studies have investigated the perinatal mortality following fresh versus 
frozen-thawed embryo transfer (Aflatoonian et al., 2010; Bai et al., 2016; Belva et al., 2016; 
Chen et al., 2016; Feng et al., 2012; Ishihara et al., 2014; Kato et al., 2012; Li et al., 2014b; Liu 
et al., 2013; Ozgur et al., 2015; Pelkonen et al., 2010; Pinborg et al., 2010; Roy et al., 2014; 
Sazonova et al., 2012; Schwarze et al., 2015; Shi et al., 2012; Shih et al., 2008; Spijkers et al., 
2017; Wada et al., 1994; Wennerholm et al., 2013; Wikland et al., 2010). As perinatal mortality 
was a relatively rare event, none of these studies detected a statistically significant difference 
between the two groups, except Shih et al. (2008) who found a significantly decreased risk of 
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perinatal mortality among singleton first births following frozen-thawed embryo transfer 
compared with fresh embryo transfer (1.0% vs 1.8%, p = 0.027). Interestingly, two recent 
systematic reviews and meta-analyses draw different conclusions due to the inclusion of 
different studies in the analysis. Maheshwari et al. (2018) found no difference in perinatal 
mortality (RR: 0.92, 95% CI: 0.78 – 1.08, 12 studies, I2= 0.80%) in singleton pregnancies after 
frozen-thawed embryo transfer (n = 25203 pregnancies) compared with fresh embryo transfer 
(n = 77280 pregnancies). In contrast, Sha et al. (2018) examined the literature that reported 
perinatal mortality of singletons and twins and concluded that frozen-thawed embryo transfer 
(n = 84584 pregnancies) was associated with lower risk of perinatal mortality than fresh 
embryo transfer (n = 128945 pregnancies) (risk ratio: 0.88, 95% CI: 0.78 – 1.08, 17 studies on 
singletons and 4 studies on twins, I2 = 11.4%).  
2.3.7 Live birth  
In recent years, the use of frozen-thawed embryo transfer has increased in consideration 
of the lower risk of adverse perinatal outcomes compared to fresh embryo transfer, such as 
decreased risk of low birthweight and preterm delivery. However, the choice of fresh or frozen-
thawed embryo transfer should also be evaluated using broader success measures of ART 
treatment. The ICMART and World Health Organization (WHO) definitions (Zegers-
Hochschild et al., 2009) of successful outcomes of ART treatment include: 
• Clinical pregnancy: a pregnancy diagnosed by ultrasonographic visualization of one 
or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic 
pregnancy. Multiple gestational sacs are counted as one clinical pregnancy. 
• Live birth: the complete expulsion or extraction from its mother of a product of 
fertilization, irrespective of the duration of the pregnancy, which, after such 
separation, breathes or shows any other evidence of life, such as heartbeat, umbilical 
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cord pulsation, or definite movement of voluntary muscles, irrespective of whether 
the umbilical cord has been cut or the placenta is attached. 
Cycle-based live birth rate 
Although clinical pregnancy is an important interim outcome when evaluating the 
efficacy of ART treatment, ultimately a commonly accepted success measure of ART treatment 
is live birth. Conventionally, the success of ART treatment has been reported by live birth rate 
per ART cycle. The cycle-based live birth rate is expressed as the number of deliveries that 
resulted in at least one liveborn baby per 100 initiated cycles (an ART cycle in which the 
woman receives specific medication for ovarian stimulation with the intention to treat, 
irrespective of whether oocyte retrieval is attempted, or a thaw cycle where frozen embryos are 
thawed with the intention to transfer) or embryo transfer cycles (an ART cycle in which one or 
more embryos are transferred into the uterus or fallopian tube) (Zegers-Hochschild et al., 
2009). 
Prior to the adoption of the ‘freeze-all’ strategy in ART practice, the majority of studies 
reported a lower cycle-based live birth rate following frozen-thawed embryo transfer than fresh 
embryo transfer. A retrospective population-based study of 150,376 autologous embryo 
transfer cycles undertaken in Australia between 2002 and 2006 found there was a significantly 
lower live birth rate following transfer of frozen-thawed blastocysts (16.3%) or blastocysts 
cultured from frozen-thawed cleavage embryos (22.0%) compared with transfer of fresh 
blastocysts (27.9%) (AOR: 0.50, 95% CI: 0.47 – 0.54; AOR: 0.71, 95% CI: 0.64 – 0.79 
respectively) (Wang et al., 2010). Aflatoonian et al. examined the pregnancy and neonatal 
outcomes of 700 pregnancies following fresh and frozen-thawed embryo transfer cycles and 
reported a significantly higher live birth rate following fresh embryo transfer than frozen-
thawed embryo transfer (66% vs 56%; OR: 1.49, 95% CI: 1.06 – 2.03) (Aflatoonian et al., 
2010). Similar findings were reported by the European registries. In 2009, the European ART 
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registers of 34 European countries with 537463 cycles reported that the live delivery rate was 
20.6% per aspiration for fresh IVF cycles, 19.3% for fresh ICSI cycles and 13.3% per thawing 
for frozen-thawed cycles (Ferraretti et al., 2013).  
Two critical issues should be considered when examining these earlier studies on cycle-
based live birth rate following fresh and frozen-thawed embryo transfer. Firstly, women with 
a supernumerary embryo available for cryopreservation would be expected to have a better 
prognosis than women who had only one embryo available for fresh embryo transfer (Wang et 
al., 2010). Secondly, the frozen-thawed embryo transfer is generally being carried out 
following the transfer of higher quality embryo(s) in the fresh cycle, and most of the women 
who returned for frozen-thawed embryo transfer did not achieve a successful pregnancy and/or 
live birth in their fresh cycles. Therefore, women undergoing a frozen-thawed embryo transfer 
cycle would be expected to have a relatively poorer clinical prognosis than women who had a 
fresh embryo transfer and had an excess of embryos for cryopreservation. In such cases, to 
provide better evidence on evaluating the clinical efficacy of fresh and frozen-thawed embryo 
transfer, it is critical to examine the live birth rate following a ‘fresh transfer’ versus ‘freeze-
all’ strategy which requires assessing the cumulative live birth rate rather than cycle-based live 
birth rate.  
Cumulative live birth rate 
In recent years, cumulative live birth rate is increasingly recommended as the method of 
assessing the success of ART treatment due to the widespread adoption of single embryo 
transfer and frozen-thawed embryo transfers (Luke et al., 2012; Maheshwari et al., 2015; 
McLernon et al., 2016; Smith et al., 2015; Stern et al., 2010). In Australia and New Zealand, 
the use of single embryo transfer has been advocated over the last 10 to 15 years to reduce the 
risk of twins and higher order multiple births following ART treatment (Reproductive 
Technology Accreditation Committee, 2005). The proportion of single embryo transfer 
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increased from 29.6% of fresh and thawed embryo transfer in 2002 to 85.7% in 2015 in 
Australia and New Zealand (Bryant et al., 2004; Fitzgerald et al., 2017). The increasing use of 
single embryo transfer means that the chance of live birth from a stimulated fresh cycle is 
spread across multiple embryo transfer cycles. Therefore, for patients who undergo multiple 
cycles, the cumulative live birth rate, which incorporates the contribution of the fresh embryo 
transfer and all subsequent frozen-thawed cycles, is more comprehensive, relevant and 
meaningful than the live birth rate per initiated/embryo transfer cycle (Maheshwari et al., 
2015). 
The concept of cumulative live birth rate is appealing, but defining cumulative live birth 
rate can be a major challenge. Currently, there is no consensus on the most appropriate 
numerator and denominator for the cumulative live birth rate. The numerator could be the first 
live delivery with at least one liveborn baby (Luke et al., 2012; Stern et al., 2010) or all live 
deliveries (Li et al., 2014a) per woman undergoing ART treatment. The denominator could be 
women who initially sought treatment, women who have undergone ovarian stimulation 
(irrespective of whether oocyte retrieval is attempted), or all of those who have undergone 
oocyte retrieval (Maheshwari et al., 2015). The period of follow-up is another important 
component of computing the cumulative live birth rate. Maheshwari et al. proposed a three-
step approach to report short, medium and long-term cumulative live birth rates (Maheshwari 
et al., 2015). The short-term estimate accounts for the first live birth over a two-year period per 
woman from one oocyte retrieval; the medium-term estimate accounts for all live deliveries 
over a five-year period from one oocyte retrieval; and the long-term estimate accounts for all 
live deliveries over a 10-year period per women from three oocyte retrievals. 
To date, seven RCTs have examined the live birth rate following a ‘freeze-all’ strategy 
compared with a ‘fresh transfer’ strategy (Chen et al., 2016; Coates et al., 2017; Ferraretti et 
al., 1999; Shapiro et al., 2011a, 2011b; Shi et al., 2018; Vuong et al., 2018). A Cochrane review 
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and meta-analysis based on four of the earlier RCTs (Chen et al., 2016; Ferraretti et al., 1999; 
Shapiro et al., 2011a, 2011b) reported a comparable cumulative live birth rate between the 
‘freeze-all’ strategy and the conventional ‘fresh transfer’ strategy (OR:1.09, 95% CI: 0.91 – 
1.31; 4 trials; 1892 women; I2 = 0%; moderate-quality evidence) (Wong et al., 2017). Of the 
three RCTs published since the Cochrane review was conducted, two RCTs reported that the 
live birth rate did not differ significantly between the ‘freeze-all’ and ‘fresh transfer’ group 
among women without polycystic ovary syndrome (33.8% vs 31.5%; risk ratio: 1.07, 95% CI: 
0.88 – 1.31) (Vuong et al., 2018) and ovulatory women (48.7% vs 50.2%, RR: 0.97, 95% CI: 
0.89 – 1.06) (Shi et al., 2018). The third RCT investigating 179 women undergoing PGS found 
the live birth rate was significantly higher in the ‘freeze-all’ group with blastocysts biopsied on 
day 5 or day 6 compared with the ‘fresh transfer’ group with blastocysts biopsied on day 5 
(77% vs 59%) (Coates et al., 2017). However, no statistical significance was detected when 
subgroup analysis was restricted to women who had at least one day 5 embryo to biopsy (66% 
vs 55%, p = 0.1) (Coates et al., 2017). 
All seven RCTs were performed in high responders where the minimum average number 
of oocytes retrieved in the stimulated cycle was 12 in both the ‘fresh transfer’ and freeze-only’ 
group. However, in real-world clinical practice, the majority of women undergoing ART 
treatment had considerably fewer oocytes retrieved. In Australia and New Zealand, three- fifths 
(60.0%) of women undergoing oocyte retrieval in 2015 had less than 10 oocytes retrieved in a 
stimulated cycle, and only one in six (16.4%) had 15 or more oocytes retrieved (Fitzgerald et 
al., 2017). Therefore, it is important to investigate the live birth rate following a ‘fresh transfer’ 
versus ‘freeze-all’ strategy among suboptimal and normal responders.  
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2.4 SUMMARY OF LITERATURE REVIEW AND IMPLICATIONS 
Limited evidence on the risk of SGA and LGA births following fresh versus frozen-
thawed embryo transfer, and the need to develop birthweight for gestational age 
percentile charts for babies following ART treatment 
Frozen-thawed embryo transfer is associated with reduced risk of low birthweight 
compared with fresh embryo transfer. It is unclear whether the lower proportion of low 
birthweight babies following frozen-thawed embryo transfer is attributable to the decreased 
risk of preterm birth or SGA birth. Limited and inconsistent evidence was available on the risk 
of SGA and LGA births following fresh and frozen-thawed embryo transfer (at the time studies 
1 and 3 of this PhD thesis were conducted). Population-based evidence derived from large 
cohort data should be provided. 
Pregnancies with suspected SGA/LGA fetuses and SGA/LGA births are at increased risk 
of morbidity and mortality during pregnancy, the neonatal period and later in adolescent and 
adult life. Correct identification of SGA and LGA births following fresh and frozen-thawed 
embryo transfer using a birthweight percentile chart allows the detection of high-risk neonates 
and assists in decision-making for appropriate care and management. However, the use of a 
birthweight percentile chart derived from general population data may result in the incorrect 
allocation of the ‘normality’ of babies following fresh and frozen-thawed embryo transfer. 
Firstly, demographic and obstetric characteristics of women undergoing ART treatment differ 
from the general population who conceive naturally. The underlying maternal characteristics 
(older age, parity, hypertension and causes of infertility etc.) are associated with increased 
likelihood of babies born following ART treatment being small (Centers for Disease Control 
and Prevention, 2010; Luke, 2017; Romundstad et al., 2008). Secondly, babies born following 
frozen-thawed embryo transfer are significantly heavier than those born following fresh 
embryo transfer. The epigenetic changes during the cryopreservation and thawing process may 
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influence the intrauterine growth potential and shift the birthweight for gestational age 
distribution of babies born following frozen-thawed embryo transfer (Pinborg et al., 2014). 
Defining high-risk neonates based on general population data may lead to over/underestimation 
of the ‘high-risk’ group following fresh and frozen-thawed embryo transfer. Birthweight for 
gestational age percentile charts derived specifically for babies born following ART treatment 
are hence required. 
Inconsistent evidence on the risk of ectopic pregnancy following fresh versus frozen-
thawed embryo transfer 
Ectopic pregnancy is a common complication of pregnancy that affected approximately 
1% of clinical pregnancies following ART treatment in Australia and New Zealand in 2015. 
Characteristics of women undergoing ART treatment (i.e. tubal factor infertility, previous 
history of ectopic pregnancy etc.) and type of ART treatment have a significant impact on the 
ectopic pregnancy rate following ART treatment. Following both fresh and frozen-thawed 
embryo transfer, women could be expected to have a lower risk of ectopic pregnancy than 
women who conceive naturally, as the embryos are placed directly into the uterus, bypassing 
the fallopian tube. However, conflicting findings were reported when comparing the risk of 
ectopic pregnancy following fresh versus frozen-thawed embryo transfer. A systematic review 
and meta-analysis published in 2009 reported a non-statistically significant increased risk of 
ectopic pregnancy following frozen-thawed embryo transfer compared with fresh embryo 
transfer. In contrast, several studies conducted since the meta-analysis was published reported 
a lower risk of ectopic pregnancy following frozen-thawed embryo transfer. Findings based on 
large population-based cohort data would add to the body of evidence about minimizing 
adverse outcomes following fresh versus frozen-thawed embryo transfer. 
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Slow freezing versus vitrification: which is the preferred method of cryopreservation? 
Slow freezing and vitrification are the two routinely used methods of cryopreservation. 
Compared with the conventional slow freezing method, vitrification is an ultra-rapid 
cryopreservation technique which requires no expensive programmable controlled-rate 
freezing equipment. Since it was first introduced in Australia in 2006, vitrification has now 
become the primary treatment preference for blastocysts with more than five-sixths of 
autologous blastocyst thaw cycles adopting vitrification in Australia in 2015.  
Low to moderate quality evidence has shown that vitrification is associated with a 
significant improvement in embryo cryosurvival and clinical pregnancy rate. Although embryo 
cryosurvival and clinical pregnancy are important interim outcomes, ultimately the clinical 
efficacy of vitrification versus slow freezing should be measured by the live birth rate. There 
have been only a limited number of RCTs and observational cohort studies to examine the live 
birth rate following transfer of slow frozen and vitrified embryos. The safety of vitrification 
should be assessed due to the concerns about the potential contamination via direct liquid 
nitrogen contact and potential cytotoxicity associated with high concentrations of 
cryoprotectants. Studies on perinatal outcomes of babies born after slow freezing and 
vitrification are thus required. 
The cumulative live birth rate among suboptimal and normal responders: is it time for 
a universal ‘freeze-all’ strategy? 
In recent years, there has been a trend towards cryopreservation of all embryos in the 
stimulated cycle for future transfer in subsequent cycles in clinical practice. The use of the 
‘freeze-all’ strategy progressively increased from 4.1% of initiated stimulated cycles in 2010 
to 18.1% in 2015 in Australia and New Zealand. Prior to the adoption of the ‘freeze-all’ 
strategy, cycle-based studies have shown that frozen-thawed embryo transfer resulted in a 
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lower live birth rate compared with fresh embryo transfer. There is potential selection bias 
associated with the cycle-based studies, as the majority of women undergoing frozen-thawed 
embryo transfer do not achieve a successful live birth in their fresh cycle and therefore would 
be expected to have a poorer prognosis than women undergoing fresh embryo transfer. 
Comparison of the cumulative live birth rate following a ‘fresh transfer’ and ‘freeze-all’ 
strategy would overcome this potential selection bias. 
There was limited evidence on the cumulative live birth rate following a ‘fresh transfer’ 
and ‘freeze-all’ strategy among suboptimal and normal responders. In Australia and New 
Zealand, the majority of women (60.0%) had less than 10 oocytes retrieved in a stimulated 
cycle in 2015. To date, all RCTs were performed in high responders. The comparable 
cumulative live birth rate observed in RCTs based on high responders may not apply to all 
patterns of ovarian response. Optimally, changes in embryo transfer strategy in clinical practice 
should be evidence-based with sufficient assessment of their safety and efficacy. However, 
practice is shifting, with the ‘freeze-all’ strategy increasingly favored in current ART practice. 
Investigation of the live birth rate following a ‘fresh transfer’ versus ‘freeze-all’ strategy among 
suboptimal and normal responders would significantly contribute to the knowledge of clinical 
efficacy of fresh and frozen-thawed embryo transfer.  
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3.1 ABSTRACT 
Study question: What is the standard of birthweight for gestational age for babies following 
assisted reproductive technology (ART) treatment? 
Summary answer: Birthweight for gestational age percentile charts were developed for 
singleton births following ART treatment using population-based data. 
What is known already: Small for gestational age (SGA) and large for gestational age (LGA) 
births are at increased risks of perinatal morbidity and mortality. A birthweight percentile chart 
allows the detection of neonates at high risk, and can help inform the need for special care if 
required. 
Study design, size, duration: This population study used data from the Australian and New 
Zealand assisted reproduction database (ANZARD) for 72 694 live born singletons following 
ART treatment between January 2002 and December 2010 in Australia and New Zealand.  
Participants/materials, setting, methods: A total of 69315 births (35580 males and 33735 
females) following ART treatment were analyzed for the birthweight percentile. Exact 
percentiles of birthweight in grams were calculated for each gestational week between week 
25 and 42 for fresh and thaw cycles by infant sex. Univariate analysis was used to determine 
the exact birthweight percentile values. Student t-test was used to examine the mean 
birthweight difference between male and female infants, between single embryo transfer (SET) 
and double embryo transfer (DET) and between fresh and thaw cycles.  
Main results and the role of chance: Preterm births (birth before 37 completed weeks of 
gestation) and low birthweight (<2500 g) were reported for 9.7 and 7.0% of live born singletons 
following ART treatment. The mean birthweight was 3280 g for live born singletons following 
fresh cycles (3338 g for male infants and 3217 g for female infants) and 3413 g for live born 
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singletons following thaw cycles (3475 g for male infants and 3349 g for female infants). The 
proportion of SGA for male ART births following thaw cycles at 35 – 41 weeks gestation was 
signiﬁcantly lower than for the Australian general population, ranging from 3.8% (95% 
conﬁdence interval (CI): 1.3%, 6.2%) at 35 weeks gestation to 7.9% (95% CI: 6.3%, 9.5%) at 
41 weeks gestation. The proportion of LGA for male ART births following thaw cycles was 
signiﬁcantly higher than for the Australian general population between 33 weeks (17.1%, 95% 
CI: 8.9%, 25.2%) and 41 weeks (14.4%, 95% CI: 12.3%, 16.5%). A similar trend was shown 
for female infants following thaw cycles. The live born singletons following SET were, on 
average, 45 g heavier than live born singletons following DET (p< 0.001). Overall, SGA was 
reported for 8.9% (95% CI: 8.6%, 9.1%) of live born singletons following SET and for 9.9% 
(95% CI: 9.5%, 10.3%) of live born singletons following DET. 
Limitations, reasons for caution: Birthweight percentile charts do not represent fetal growth 
standards but only the weight of live born infants at birth. 
Wider implications of the findings: The comparison of birthweight percentile charts for ART 
births and general population births provide evidence that the proportion of SGA births 
following ART treatment was comparable to the general population for set fresh cycles and 
signiﬁcantly lower for thaw cycles. Both fresh and thaw cycles showed better outcomes for 
singleton births following SET compared with DET. Policies to promote single embryo transfer 
should be considered in order to minimize the adverse perinatal outcomes associated with ART 
treatment. 
Study funding/competing interest(s): No speciﬁc funding was obtained. The authors have no 
conﬂicts of interest to declare. 
Key words: assisted reproductive technology / birthweight / gestational age / small for 
gestational age / single embryo transfer  
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3.2 INTRODUCTION 
Small for gestational age (SGA, defined as a birthweight below the 10th percentile for the 
gestational age) and large for gestational age (LGA, defined as a birthweight greater than the 
90th percentile for gestational age) births are at increased risk of complications during the fetal 
and neonatal periods and subsequent mortality and developmental delay (Glinianaia et al., 
2011; Grisaru-Granovsky et al., 2012; Vashevnik et al., 2007). Correct identification of such 
liveborn babies using a birthweight percentile chart allows the detection of neonates at high 
risk and assists in the assessment of these babies need for further care. Several national 
birthweight percentile charts have been developed based on population data (Bonellie et al., 
2008; Dobbins et al., 2012; Visser et al., 2009) but none are available for births following 
Assisted Reproductive Technology (ART) treatment.  
The maternal characteristics for women following ART treatment differ from pregnant 
women who conceive naturally. Women seeking fertility treatment are older, with a higher 
proportion of women aged 40 years or more, than those who conceive naturally (Li et al., 2012; 
Macaldowie et al., 2012). In addition, those who conceive after ART are more likely to be first 
time mothers, and less likely to smoke (Li et al., 2012). The mean birthweight of ART births 
is lower than the mean birthweight among the general birth population for both singletons and 
twins (Hansen et al., 2009; Hayashi et al., 2012; Henningsen et al., 2011; Macaldowie et al., 
2012). Compared with the general birth population, births following ART treatment were 
reported to have a higher proportion of low birthweight (<2,500 grams) and preterm birth (<37 
weeks) (D'Angelo et al., 2011; Schieve et al., 2007; Sunderam et al., 2012).  
Therefore, the use of birthweight percentile charts established from general population 
data to define the ‘normality’ of births following ART treatment may result in the incorrect 
allocation of babies to a ‘high risk’ group. Current population-based birthweight percentile 
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charts derived specifically for births to women who conceive as a result of ART treatment are 
hence required. While the variations in fetal growth are not fully understood, the underlying 
maternal characteristics (e.g. maternal age, parity, subfertility etc.) of women undergoing ART 
treatment and potentially the treatment are associated with an increased risk of adverse 
perinatal outcomes (Bower & Hansen, 2005; Centers for Disease & Prevention, 2009). 
Establishing and comparing ART-specific birthweight percentiles by gestational age with the 
general population is important for identifying the impact of these differences in maternal 
characteristics as well as the ART treatment on fetal growth. 
We have developed a national birthweight reference for liveborn singletons following 
fresh and thaw cycles, derived sex-specific SGA and LGA criteria for singleton births 
following ART treatment and contrasted the ART-specific 10th and 90th percentiles of 
birthweight for gestational age with the corresponding percentiles from the Australian general 
population. 
3.3 MATERIALS AND METHODS 
3.3.1 Data 
Data on population-based liveborn singletons following ART treatment between January 
2002 and December 2010 were obtained from the Australian and New Zealand Assisted 
Reproduction Database (ANZARD). Data for ANZARD are collected annually from all 
fertility centers within Australia and New Zealand. The ANZARD data includes information 
on ART treatment procedures and information on resulting pregnancy and birth outcomes. 
3.3.2 Study factors 
A live birth was defined as a baby born showing signs of life of ≥20 weeks gestation or 
≥ 400 grams birthweight. Gestational week was calculated in completed weeks based on the 
 
 
Chapter 3: Study 1 Birthweight percentiles by gestational age for births following Assisted Reproductive Technology 84 
stage of embryo development (cleavage stage embryos and blastocysts stage embryos), embryo 
transfer date and baby’s date of birth.  
Woman's age was calculated in completed years of age. Cause of infertility was classified 
as: male factor only infertility (a male factor problem was diagnosed and not any female factor 
problem), female factor only infertility (tubal disease, endometriosis or another female factor 
problem was diagnosed and not any male factor problem), combined male–female factor 
infertility (both male and female factor problems were diagnosed), and unexplained infertility 
(neither a male nor female factor problem was diagnosed). Fresh cycle was defined as ART 
treatment cycles that used embryo(s) that have not been cryopreserved (frozen), while thaw 
cycle was defined as ART treatment cycles in which cryopreserved embryos were thawed for 
performing embryo transfer.  
3.3.3 Inclusions and exclusions 
Inclusion criteria 
The inclusion criteria for calculating the birthweight-by-gestation percentiles were: liveborn 
singletons of determinate sex following autologous cycles or donor cycles with both available 
birthweight and gestational age. An autologous cycle is defined as an ART treatment cycle in 
which a woman uses her own oocytes and a donor cycle is defined as an ART treatment cycle 
in which a woman uses donated oocytes/embryos. 
Exclusion criteria 
 Liveborn singletons following gamete intrafallopian transfer (GIFT) cycles where 
mature oocytes and sperm were placed directly into a woman’s fallopian tubes so that in vivo 
fertilization may take place; donor insemination (DI) cycles where artificial insemination was 
performed using sperm not from the woman’s partner, and surrogacy cycles where the 
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gestational carrier agreed to carry a child for the intended parents with the intention that the 
child would be raised by the intended parents, were excluded from the birthweight-by-
gestational age percentiles analyses. Live singletons born before 25 weeks gestation were 
excluded from the analyses due to very small numbers of births. 
After excluding records with missing birthweight, infant sex and gestational age values, 
records with a birthweight value outside the valid range for each gestational week were 
identified using Tukey’s methodology (Tukey, 1977) based on the interquartile range. For each 
gender and gestational age combination, birthweights that fell below the first quartile minus 
twice the interquartile range (lower Tukey limit) or above the third quartile plus twice the 
interquartile range (higher Tukey limit) were considered outliers and were excluded from the 
analyses.  
3.3.4 Comparison between ART births and general population 
The Australian birthweight percentile charts for general population were adapted from 
recently published Australian birthweight percentile charts based on 1998-2007 Australian 
National Perinatal Data Collection (NPDC) data (Dobbins et al., 2012). The NPDC collects 
information on all live births and stillbirths of at least 400 grams birthweight or at least 20 
weeks gestation in Australia. In the NPDC, approximately 4% of women received ART 
treatment.  
3.3.5 Statistical analyses 
Univariate analysis was used to examine the birthweight distributions and to determine 
the interquartile range for each gestational age for births following ART treatment. After 
removing outliers, the univariate procedure was used to determine the exact birthweight 
percentile values. Exact percentiles of birth weight in grams were calculated for each 
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gestational week between 25 and 42 for fresh and thaw cycles by infant sex, for which there 
were at least 100 records to plot the 3rd and 97th percentile and 50 records to plot the 10th and 
90th percentile, consistent with previously published Australian birthweight percentiles 
(Dobbins et al., 2012; Roberts & Lancaster, 1999).  
Differences between male and female infants, single embryo transfer (SET) and double 
embryo transfer (DET) as well as fresh and thaw cycles, were assessed by Student t – test. 
Binomial test was used to compare the proportion of SGA and LGA among liveborn singletons 
following ART treatment to general population. Linear regression was used to examine the 
temporal trends in mean birthweight for male and female liveborn singletons following ART 
treatment between 2002 and 2010. Significance was assumed at p<0.05. All analyses were 
carried out using SAS for Windows, version 9.3 (SAS Inc, Cary, NC). 
3.3.6 Ethical approval  
Ethics approval for this study was granted by the Human Research Ethics Advisory Panel 
of the University of New South Wales, Australia.  
3.4 RESULTS  
Between 2002 and 2010, there were 72694 liveborn singletons following ART treatment 
recorded in Australia and New Zealand (Table 3-1). Of these infants, 9.7% were born preterm 
(birth before 37 completed weeks of gestation) while 6.9% were low birthweight (< 2500 g) 
and 1.5% very low birthweight (< 1500 g) (Table 3-1).  
Excluding 112 births (0.2%) following GIFT cycles, 1,792 births (2.5%) following DI 
cycles, and 79 surrogacy cycles (0.1%) gave a total of 70,711 births. 973 births (1.4%), 
including 163 births with gestational age less than 25 weeks and 106 with gestational age more 
than 42 weeks, were excluded from further analysis where one or more of the key variables — 
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sex, birthweight and gestational age were missing. Of 69738 liveborn singletons following 
ART treatment with gestational age between 25 and 42 weeks and available data on sex and 
birthweight, 423 (0.6%) births were removed as outliers, with 308 (0.4%) being above the 
higher Tukey limit and 115 (0.2%) being below the lower Tukey limit.  
A total of 69315 births (35580 males and 33735 females) following ART treatment were 
analyzed for the birthweight percentile. The mean birthweight (±standard deviation (SD)) for 
male liveborn singletons (3384 ± 594 grams) was significantly heavier than female liveborn 
singletons (3263 ± 558 grams) (p<0.0001) (Table 3-1). The mean birthweight of liveborn 
singletons following thaw cycles was 3413 grams, which was significantly heavier than 3280 
grams for liveborn singletons following fresh cycles (p<0.0001) (Table 3-1).  
Figure 3-1 and Figure 3-2 show birthweight percentiles by gestational age for liveborn 
singletons following fresh and thaw cycles by infant sex; exact birthweight percentiles are 
shown in Table 3-2 to Table 3-5. The trend of increased birthweight by gestational age was 
similar for both male and female liveborn singletons. 10.6% (95% CI: 10.2%, 11.0%) of male 
and 10.9% (95% CI: 10.4%, 11.3%) of female liveborn singletons following fresh cycles were 
classified as SGA births using Australian national cut-offs generated from general population 
data, while 9.2% (95% CI: 8.9%, 9.6%) of male and 8.7% (95% CI: 8.3%, 9.1%) of female 
liveborn singletons following fresh cycles were classified as LGA births. For liveborn 
singletons following thaw cycles, the proportion of SGA births was significantly lower among 
male liveborn singletons between 35 weeks and 41 weeks gestation than the general population, 
using Australian national cut-offs generated from general population data (Table 3-4). The 
proportion of SGA for male liveborn singletons following thaw cycles ranged from 3.8% (95% 
CI: 1.3%, 6.2%) at 35 weeks gestation to 7.9 % (95% CI: 6.3%, 9.5%) at 41 weeks gestation, 
compared with 10% of SGA among general population. Significantly higher proportion of 
 
 
Chapter 3: Study 1 Birthweight percentiles by gestational age for births following Assisted Reproductive Technology 88 
LGA was found for male liveborn singletons following thaw cycles between 33 and 41 weeks 
gestation than the general population (Table 3-4). The proportion of LGA ranged from 13.8% 
(95% CI: 12.5%, 15.2%) at 40 weeks gestation to 20.4% (95% CI: 15.3%, 25.5%) at 35 weeks 
gestation, compared with 10% of LGA among general population. A similar trend was shown 
for female infants following thaw cycles (Table 3-5). 
Figure 3-3 shows the mean birthweight for liveborn singletons by infant sex and number 
of embryos transferred from 2002 to 2010. The mean birthweight gradually increased from 
3362 grams in 2002 to 3387 grams in 2010 for male singletons (p<0.01) and from 3239 grams 
in 2002 to 3262 grams in 2010 for female singletons (p<0.05). The proportion of liveborn 
singletons following thaw cycles increased from 30.7% in 2002 to 37.6% while the proportion 
of liveborn singletons following fresh cycles decreased from 69.3% in 2002 to 62.4% in 2010. 
Liveborn singletons following SET were heavier than those following DET for both male 
and female infants (p<0.05) (Figure 3-3). The mean birthweight of liveborn singletons 
following thaw cycles increased as the number of embryo transferred decreased (p<0.0001) 
(Table 3-6). The liveborn singletons following thaw cycles with SET were, on average, 43 
grams heavier than liveborn singletons following DET (mean birthweight 3427 grams and 3384 
grams respectively) (Table 3-6). A similar trend was found for liveborn singletons following 
fresh cycles. The mean birthweight for liveborn singletons following DET fresh cycles was 
3254 grams which was lower than the 3295 grams of those following SET fresh 
cycles(p<0.0001) (Table 3-6). The proportion of small for gestational age births was 8.9% 
(95% CI: 8.6%, 9.1%) among liveborn singletons following SET and 9.9% (95% CI: 9.5%, 
10.3%) among liveborn singletons following DET (Table 3-6) using SGA cut-offs derived from 
Australian general population data. Significantly higher proportion of LGA was reported for 
liveborn singletons following SET (11.0 %, 95% CI: 10.7%, 11.3%) and DET (10.5 %, 95% 
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CI: 10.1%, 10.9%) than the 10% of LGA births among general population (Table 3-6). The 
proportion of LGA for liveborn singletons following thaw cycles was significantly higher than 
the general population for both single (14.7%, 95% CI: 14.1%, 15.2%) and double embryo 
transfer (13.7 %, 95% CI: 12.9%, 14.4%).  
3.5 DISCUSSION 
This study provides the first national population-based birthweight percentile charts for 
male and female liveborn singletons following ART treatment. Birthweight percentile charts 
are valuable tools in perinatal epidemiological research and for clinical detection of babies who 
are at higher risk of neonatal morbidity and mortality (Bertino et al., 2007; Zaw et al., 2003). 
The percentile charts of birthweight for gestational age presented in this study provide a sex-
specific population norm for liveborn singletons following ART treatment in Australia and 
New Zealand.  
When comparing the percentile charts produced from ANZARD data to the recently 
published Australian national charts (Dobbins et al., 2012), we observe that the 10th percentile 
for birthweight of male liveborn singletons following thaw cycles was 50-220 grams greater 
than general population births from 35 to 41 weeks. A similar trend was found for female 
infants. In addition, 50th percentile (median) and 90th percentile birthweight of ART births 
following thaw cycles at 35-41 weeks were heavier than general population births for both 
males and females. The proportion of SGA for ART births following thaw cycles was 
significantly lower than the Australian general population between 36 and 40 weeks gestation, 
except for female singletons of 36 weeks gestation. In our study, the risk of SGA births 
observed for liveborn singletons following SET fresh cycles was comparable with the general 
population, while increased risk of SGA births was observed for liveborn singletons following 
DET fresh cycles. This may suggest that the increased risk of SGA births for liveborn 
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singletons following fresh cycles were in part associated with vanishing twin gestations. This 
finding is consistent with a previous study that showed a higher risk of being SGA for ART 
singletons from vanishing twin gestations compared with singletons from a single gestation in 
early pregnancy (Pinborg et al., 2007).Compared with the general population, the lower or 
comparable proportion of SGA ART births were also associated with known risk factors such 
as smoking (Okah et al., 2005; Ricketts et al., 2005) the incidence of which was significantly 
lower among women who received ART treatments than women who did not receive ART 
treatments (Li et al., 2012). Other factors including personal behavior or lifestyle-related 
factors may affect perinatal outcome. Women who received ART treatment have been observed 
to make significant improvements in lifestyle habits and behavior (Domar et al., 2012).  
The comparison of birthweight percentile charts for ART births and general population 
births in Australia provides evidence at a population level that singleton births following ART 
treatment are not associated with excess risk of SGA. Two earlier systematic reviews and meta-
analyses on birth outcomes of births following ART treatment reported an approximate 50% 
increase in SGA, compared with naturally conceived infants (Helmerhorst et al., 2004; Jackson 
et al., 2004). However, other recent studies have shown similar findings to those reported here. 
A Finnish cohort study suggested a decreased risk (adjusted odd ratio (AOR) 0.71, 95% 
confidence interval (CI) 0.54-0.92) of SGA for births following frozen embryo transfer 
compared with naturally conceived births, and no significantly elevated risk of SGA for births 
following fresh embryo transfer (AOR 1.12: 0.93-1.35) (Pelkonen et al., 2010). Similarly, a 
Japanese study using the registry database of the Japan Society of Obstetrics and Gynaecology 
found no evidence that in vitro fertilization (IVF) treatment increased the risk of SGA 
compared with natural conceptions (Fujii et al., 2010). A population-based cohort study in 
Norway found a higher risk of SGA compared with natural conception (Odds ratio (OR) 1.26: 
95% CI: 1.10-1.44) among ART births compared with natural conception, but no increase in 
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risk of SGA (OR 0.99: 0.62-1.57) when compared with their naturally conceived siblings. The 
authors suggested that the adverse outcomes could be attributable to the factors leading to 
infertility, rather than to factors related to the ART treatment (Romundstad et al., 2008). 
Significantly higher proportion of LGA births was reported for both male and female 
liveborn singletons following thaw cycles between 34 and 41 weeks gestation than the liveborn 
singletons following fresh cycles and the general population. This finding is consistent with 
previous studies that have demonstrated increasing proportion of LGA following thaw cycles 
(Pelkonen et al., 2010; Pinborg et al., 2011; Sazonova et al., 2012). Pelkonen and colleagues 
found the births following frozen embryo transfer had significantly increased risk of being 
LGA (AOR 1.70:1.21-2.40) compared with births following fresh embryo transfer (Pelkonen 
et al., 2010). Similarly, a recent Swedish study reported increased proportion of LGA for 
cryopreserved SET/DET singletons compared with those from fresh cycles and the general 
population (Sazonova et al., 2012). The underlying mechanism of higher proportion of LGA 
singletons following frozen embryo transfer is not yet known. Pinborg and colleagues 
suggested that the intrauterine growth potential of the offspring might be influenced by the 
epigenetic changes in the very early embryonic stage during freezing and thawing (Pinborg et 
al., 2011). Further studies are required to identify the long-term consequences of LGA births 
following ART treatment. 
The mean birthweight of singleton births following ART treatment significantly 
decreased with increased number of embryos transferred. Both fresh and thaw cycles showed 
a better outcome for singleton births following SET. Data from the United States show that the 
live delivery rate following DET is almost double the rate following SET (43.7% and 22.0% 
respectively) (Centers for Disease & Prevention, 2009). However, DET results in a 
significantly higher rate of multiple gestation pregnancies compared with SET (Centers for 
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Disease Control and Prevention, 2010; Pandian et al., 2004). Multiple gestation pregnancies 
were associated with substantial increased risk of perinatal mortality and morbidity as well as 
a substantial increase in obstetric complications (ESHRE, 2000; Ledger et al., 2006; Sullivan 
et al., 2012).  
The use of SET has been advocated by the Reproductive Technology Accreditation 
Committee (RTAC) of the Fertility Society of Australia since 2002 and a SET policy has been 
formally implemented in 2005 (Reproductive Technology Accreditation Committee, 2005). In 
Australia and New Zealand, SET was reported for 69.6% of fresh and thawed embryo transfer 
cycles in 2010, compared with 28.8% in 2002. The proportion of DET decreased from 65.4% 
in 2002 to 29.6% in 2010, and the multiple delivery rate declined from 18.9% in 2002 to 7.9% 
in 2010 (Bryant et al., 2004; Macaldowie et al., 2012). In all likelihood this change in practice 
partially explains the increase in mean birthweight for singleton births following ART 
treatment from 2002 to 2010, while the mean birthweights were relatively stable over the period 
among general population births (Dobbins et al., 2012).  
The proportion of thaw cycles among embryo transfer cycles was stable between 2002 
and 2010 (Macaldowie et al., 2013; Wang et al., 2008). However, the live delivery rate per 
embryo transfer cycle following thaw cycles gradually increased from 14.8% in 2002 for non-
donor cycles to 20.0% in 2010 for all cycles, while live delivery rate per embryo transfer cycle 
following fresh cycles remained steady (Bryant et al., 2004; Macaldowie et al., 2012). 
Therefore, although the use of frozen embryo transfer didn’t increase during the study period, 
the proportion of liveborn singletons following thaw cycles rose which partially explains the 
increase in mean birthweight for singleton births following ART treatment from 2002 to 2010.  
Previous studies shown that customized birthweight percentiles adjusting for maternal 
physiological factors improved the prediction of adverse neonatal outcome compared with 
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birthweight percentiles generated from general population (Clausson et al., 2001; Figueras et 
al., 2007). However, it should be noted that the ART-specific birthweight percentiles by 
gestational age should be used with caution in clinical settings as the mechanism of the 
variations in fetal growth is not fully understood. Although more SGA births would be 
identified using ART-specific birthweight percentile charts than general population-based 
standard, neonates classified as SGA/LGA births by general population-based standard only 
should also be considered as high risk group which might require obstetric intervention. Further 
studies are required to analyze the risk of perinatal morbidity and mortality of ART births 
classified as SGA/LGA and non-SGA/LGA births using ART-specified and general 
population-based birthweight percentile charts. 
A major limitation of this study is the fact that birthweight percentile charts do not 
represent fetal growth standards but only weight at birth. The birthweight of preterm infants 
were likely to be affected by the pathological process leading to early delivery and are therefore 
likely to differ from those remaining in utero until term (Cooke, 2007; Ehrenkranz, 2007). 
Intrauterine growth curves based upon estimated fetal weight (EFW) have been considered a 
better indication of fetal growth. However, to date, there is no Australian standard based on 
well-designed studies for determining fetal size for gestation due to the inherent inaccuracies 
and methodological controversies related to sonographic standards for EFW (Hui, 2008). In 
such cases, the population-based birthweight percentile charts presented in this study provide 
a valuable reference for clinicians and researchers assessing intrauterine growth and the 
prognosis of births following ART treatment.  
3.6 CONCLUSION  
This study presents the first national population-based birthweight percentile charts for 
male and female liveborn singletons following ART treatment in Australia and New Zealand. 
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The proportion of SGA births following ART treatment was comparable to the general 
population for SET fresh cycles and significantly lower for thaw cycles. Both fresh and thaw 
cycles showed a better outcomes for singleton births following SET compared with DET. The 
significantly lower rate of SGA following SET provides further evidence of the value of SET. 
From a public health perspective, policies to promote single embryo transfer should be 
supported to minimize adverse perinatal outcomes associated with ART treatment. 
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Table 3-1 Maternal, infant and treatment characteristics of liveborn singletons following ART, Australia and New Zealand, 2002-2010 
 Fresh Thaw Total 
  
Number 
& 
percentage 
Mean(st.dev) 
birthweight (g) 
(excluding 
outliers) 
Number 
& 
percentage 
Mean(st.dev) 
birthweight (g) 
(excluding 
outliers) 
Number 
& 
percentage 
Mean(st.dev) 
birthweight (g) 
(excluding outliers) 
Total 
46,626 
(100.0%) 3279.6(589.4) 
24,276 
(100.0%) 3412.8(569.4) 72,694 (100.0%) 3324.8(588.1) 
       
Sex of infant       
Male 24,022 (51.5%) 3338.1(592.1) 12,312 (50.7%) 3474.5(586.6) 37,263 (51.3%) 3384.0(594.1) 
Female 22,545 (48.4%) 3217.4(561.0) 11,931 (49.1%) 3349.1(543.8) 35,336 (48.6%) 3262.6(558.3) 
Birthweight (g)       
<1500 747 (1.6%)  292 (1.2%)  1,061(1.5%)  
1500-2499 2,879 (6.2%)  1,023 (4.2%)  3,969(5.5%)  
2500-4499 41,997 (90.1%)  22,159 (91.3%)  65,772(90.5%)  
≥4500 580 (1.2%)  578 (2.4%)  1,204(1.7%)  
Gestational age (weeks)       
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20-27 370 (0.8%) 869.2(289.6) 156 (0.6%) 924.5(216.9) 531(0.7%) 886.2(213.4) 
28-31 554 (1.2%) 1402.7(365.8) 211 (0.9%) 1429.1(358.2) 779(1.1%) 1408.0(366.7) 
32-36 3,857 (8.3%) 2538.3(533.7) 1,787 (7.4%) 2692.8(557.2) 5,765(7.9%) 2587.8(544.1) 
≥37 41,819 (89.7%) 3382.3(462.1) 22,111 (91.1%) 3497.4(475.3) 65,581(90.2%) 3421.7(468.1) 
Maternal age (years)       
<25 484 (1.0%) 3322.2(536.5) 176 (0.7%) 3484.7(543.8) 686(0.9%) 3365.9(542.9) 
25-29 5,490 (11.8%) 3279.9(594.5) 2,275 (9.4%) 3403.9(558.9) 8,007(11.0%) 3315.8(587.2) 
30-34 16,119 (34.6%) 3277.3(582.6) 8,190 (33.7%) 3418.7(568.6) 24,937(34.3%) 3324.8(581.5) 
35-39 17,926 (38.4%) 3281.6(578.2) 9,861 (40.6%) 3425.8(561.8) 28,504(39.2%) 3332.2(576.4) 
≥40 6,579 (14.1%) 3277.2(572.6) 3,763 (15.5%) 3367.3(595.9) 10,520(14.5%) 3309.4(583.3) 
Cause of Infertility       
Male factors only 13,872 (29.8%) 3305.2(578.7) 6,716 (27.7%) 3431.8(545.5) 21,293 (29.3%) 3346.1(571.8) 
Female factors only 14,198 (30.5%) 3267.4(592.5) 8,355 (34.4%) 3396.6(584.3) 23,125 (31.8%) 3315.7(592.1) 
Combined male-female factors 6,683 (14.3%) 3272.2(581.6) 3,109 (12.8%) 3392.7(591.7) 9,878 (13.6%) 3310.2(587.4) 
Unexplained 10,231 (21.9%) 3268.2(568.5) 5,049 (20.8%) 3422.8(558.5) 15,550 (21.4%) 3318.3(569.4) 
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Table 3-2 Birthweight percentile for live singleton male births following fresh cycles, Australia and New Zealand, 2002-2010 
Gestation  
(weeks) 
No. 
of  
births 
Mean (SD)  
birthweight (g) 
Birthweight percentile (g) % of SGA 
(95% CI)a 
(%) 
% of LGA 
(95% CI)b 
(%) 
Australian normc 
Birthweight percentile 
(g) 
p3 p5 p10 p25 p50 p75 p90 p95 p97 p10 p50 p90 
25 26 709(136) – – – 630 700 793 – – – – – 620 785 944 
26 33 886(189) – – – 756 920 1000 – – – – – 680 900 1078 
27 38 1047(200) – – – 952 1089 1205 – – – – – 752 1030 1250 
28 45 1105(197) – – – 945 1100 1260 – – – – – 844 1165 1395 
29 54 1258(322) – – 870 1030 1300 1452 1680 – – 24.1(12.7,35.5)* 13.0(4.0,21.9) 964 1311 1620 
30 78 1404(263) – – 1040 1240 1385 1610 1760 – – 12.8(5.4,20.2) 3.8(0.0,8.1) 1091 1498 1800 
31 103 1708(306) 1090 1120 1345 1532 1738 1940 2026 2154 2200 8.7(3.3,14.2) 9.7(4.0,15.4) 1270 1680 2028 
32 123 1827(418) 1091 1180 1340 1550 1795 2070 2353 2528 2915 15.4(9.1,21.8)* 13.0(7.1,19.0) 1430 1880 2270 
33 199 2108(436) 1400 1445 1554 1814 2100 2350 2640 2900 3055 13.6(8.8,18.3) 15.1(10.1,20.0)* 1638 2106 2560 
34 312 2354(431) 1508 1656 1810 2068 2390 2600 2950 3035 3120 11.5(8.0,15.1) 14.7(10.8,18.7)* 1860 2340 2810 
35 457 2571(411) 1740 1843 2060 2310 2580 2830 3090 3240 3425 12.0(9.1,15.0) 9.8(7.1,12.6) 2080 2578 3095 
36 971 2852(451) 2040 2135 2300 2540 2850 3119 3440 3610 3740 8.8(7.0,10.5) 12.4(10.3,14.4)* 2295 2820 3360 
37 2239 3102(449) 2250 2370 2550 2800 3090 3400 3680 3859 3980 9.4(8.2,10.6) 10.1(8.9,11.4) 2540 3080 3670 
38 5485 3319(425) 2526 2630 2800 3035 3300 3600 3870 4035 4150 10.0(9.2,10.8) 8.4(7.6,9.1)* 2800 3330 3910 
39 6235 3464(430) 2698 2780 2930 3175 3450 3742 4020 4200 4330 10.5(9.7,11.2) 9.2(8.5,9.9)* 2950 3470 4040 
40 5028 3610(429) 2828 2920 3070 3318 3600 3890 4160 4340 4451 10.5(9.7,11.4) 8.9(8.1,9.7)* 3090 3620 4195 
41 1973 3726(449) 2900 3010 3154 3420 3720 4000 4300 4490 4600 13.1(11.6,14.6)* 8.4(7.2,9.6)* 3220 3755 4340 
42 127 3682(477) 2730 2840 3050 3400 3710 3980 4290 4495 4600 20.5(13.5,27.5)* 5.5(1.5,9.5) 3250 3820 4430 
a SGA was defined as a birthweight below the Australian norm 10th percentile for the gestational age  
b LGA was defined as a birthweight greater than the Australian norm 90th percentile for gestational age  
c Adapted from (Dobbins, Sullivan, Roberts and Simpson, 2012). © Copyright 2012 The Medical Journal of Australia–adapted with permission. 
SD, standard deviation; SGA, small for gestational age; CI, confidence interval; LGA, large for gestational age; *,significant at the .05 level 
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Table 3-3 Birthweight percentile for live singleton female births following fresh cycles, Australia and New Zealand, 2002-2010 
Gestation 
(weeks) 
No. 
of 
births 
Mean (SD) 
birthweight (g) 
Birthweight percentile (g) % of SGA 
(95% CI)a 
(%) 
% of LGA 
(95% CI)b 
(%) 
Australian normc 
Birthweight percentile 
(g) 
p3 p5 p10 p25 p50 p75 p90 p95 p97 p10 p50 p90 
25 30 745(128) – – – 690 750 825 – – – – – 559 740 884 
26 25 791(181) – – – 675 833 920 – – – – – 594 840 1026 
27 40 933(188) – – – 780 981 1059 – – – – – 675 965 1175 
28 50 1029(219) – – – 900 1027 1216 – – – – – 764 1090 1347 
29 43 1245(244) – – – 1100 1250 1405 – – – – – 870 1240 1494 
30 61 1394(253) – – 1060 1205 1425 1559 1676 – – 9.8(2.4,17.3) 9.8(2.4,17.3) 1030 1400 1715 
31 82 1594(391) – – 1011 1383 1613 1814 1933 – – 17.1(8.9,25.2)* 8.5(2.5,14.6) 1190 1590 1948 
32 89 1730(347) – – 1280 1550 1756 1928 2105 – – 11.2(4.7,17.8) 7.9(2.3,13.5) 1348 1780 2170 
33 144 1988(403) 1300 1335 1425 1750 1998 2220 2430 2721 2800 14.6(8.8,20.3) 9.0(4.3,13.7) 1560 2011 2450 
34 253 2238(422) 1436 1520 1730 1988 2210 2495 2730 3033 3119 11.1(7.2,14.9) 10.7(6.9,14.5) 1764 2240 2705 
35 390 2434(422) 1622 1708 1924 2180 2430 2700 2954 3118 3200 12.3(9.0,15.6) 9.0(6.1,11.8) 1980 2480 2995 
36 821 2756(436) 1970 2045 2200 2460 2764 3033 3320 3500 3595 9.3(7.3,11.2) 12.4(10.2,14.7)* 2198 2710 3250 
37 1899 2990(427) 2200 2300 2455 2700 2990 3250 3550 3742 3850 8.7(7.4,10.0) 10.0(8.7,11.4) 2430 2965 3545 
38 5139 3179(414) 2400 2500 2667 2910 3175 3447 3714 3890 4000 10.6(9.8,11.4) 8.2(7.4,8.9)* 2690 3200 3770 
39 5859 3317(411) 2595 2682 2800 3040 3294 3585 3856 4026 4146 11.0(10.2,11.8)* 8.8(8.1,9.5)* 2830 3340 3890 
40 4969 3458(413) 2722 2800 2948 3175 3445 3726 4000 4167 4280 11.1(10.3,12.0)* 8.3(7.5,9.0)* 2975 3480 4030 
41 2038 3567(427) 2810 2900 3048 3280 3540 3850 4111 4300 4400 11.8(10.4,13.2)* 8.1(7.0,9.3)* 3090 3605 4170 
42 132 3541(453) 2800 2848 2970 3200 3490 3813 4100 4390 4649 15.9(9.7,22.1)* 6.1(2.0,10.1) 3110 3650 4240 
a SGA was defined as a birthweight below the Australian norm 10th percentile for the gestational age  
b LGA was defined as a birthweight greater than the Australian norm 90th percentile for gestational age  
c Adapted from (Dobbins, Sullivan, Roberts and Simpson, 2012). © Copyright 2012 The Medical Journal of Australia–adapted with permission.  
SD, standard deviation; SGA, small for gestational age; CI, confidence interval; LGA, large for gestational age; *, significant at the .05 level 
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Table 3-4 Birthweight percentile for live singleton male births following thaw cycles, Australia and New Zealand, 2002-2010 
Gestation  
(weeks) 
No. of 
births 
Mean (SD) 
birthweight (g) 
Birthweight percentile (g) % of SGA 
(95% CI)a 
(%) 
% of LGA 
(95% CI)b 
(%) 
Australian normc 
Birthweight percentile (g) 
p3 p5 p10 p25 p50 p75 p90 p95 p97 p10 p50 p90 
25 15 857(224) – – – 740 870 960 – – – – – 620 785 944 
26 10 788(147) – – – 740 795 890 – – – – – 680 900 1078 
27 25 1067(171) – – – 1000 1085 1200 – – – – – 752 1030 1250 
28 18 1172(264) – – – 965 1220 1305 – – – – – 844 1165 1395 
29 28 1320(261) – – – 1111 1368 1510 – – – – – 964 1311 1620 
30 43 1587(380) – – – 1370 1526 1845 – – – – – 1091 1498 1800 
31 26 1540(213) – – – 1440 1546 1640 – – – – – 1270 1680 2028 
32 56 1946(278) – – 1500 1785 1999 2121 2275 – – 7.1(0.4,13.9) 10.7(2.6,18.8) 1430 1880 2270 
33 82 2248(382) – – 1750 2010 2270 2490 2700 – – 7.3(1.7,13.0) 17.1(8.9,25.2)* 1638 2106 2560 
34 123 2432(489) 1400 1673 1815 2120 2450 2700 2950 3240 3610 12.2(6.4,18.0) 17.9(11.1,24.7)* 1860 2340 2810 
35 240 2767(407) 2041 2130 2300 2500 2750 3020 3336 3527 3572 3.8(1.3,6.2)* 20.4(15.3,25.5)* 2080 2578 3095 
36 467 3017(472) 2200 2268 2445 2710 3000 3298 3610 3825 4082 5.8(3.7,7.9)* 20.3(16.7,24.0)* 2295 2820 3360 
37 1177 3251(467) 2350 2500 2655 2950 3240 3556 3820 4020 4195 6.3(4.9,7.7)* 17.5(15.3,19.7)* 2540 3080 3670 
38 3094 3448(435) 2684 2784 2915 3150 3435 3720 4020 4185 4300 5.2(4.5,6.0)* 14.3(13.0,15.5)* 2800 3330 3910 
39 3039 3598(434) 2805 2920 3035 3300 3600 3880 4156 4335 4480 5.8(5.0,6.6)* 14.4(13.2,15.7)* 2950 3470 4040 
40 2423 3713(432) 2945 3030 3156 3412 3700 4000 4281 4450 4570 6.5(5.5,7.5)* 13.8(12.5,15.2)* 3090 3620 4195 
41 1104 3854(467) 3050 3125 3270 3518 3840 4160 4451 4610 4820 7.9(6.3,9.5)* 14.4(12.3,16.5)* 3220 3755 4340 
42 72 3888(473) – – 3280 3565 3930 4138 4550 – – 8.3(1.9,14.7) 11.1(3.9,18.4) 3250 3820 4430 
a SGA was defined as a birthweight below the Australian norm 10th percentile for the gestational age  
b LGA was defined as a birthweight greater than the Australian norm 90th percentile for gestational age  
c Adapted from (Dobbins, Sullivan, Roberts and Simpson, 2012). © Copyright 2012 The Medical Journal of Australia–adapted with permission. 
SD, standard deviation; SGA, small for gestational age; CI, confidence interval; LGA, large for gestational age; *,significant at the .05 level 
  
  
Chapter 3: Study 1 Birthweight percentiles by gestational age for births following Assisted Reproductive Technology 107 
Table 3-5 Birthweight percentile for live singleton female births following thaw cycles, Australia and New Zealand, 2002-2010 
Gestation 
(weeks) 
No. of 
births 
Mean (SD) 
birthweight (g) 
Birthweight percentile (g) % of SGA 
(95% CI)a 
(%) 
% of LGA 
(95% CI)b 
(%) 
Australian normc 
Birthweight percentile (g) 
p3 p5 p10 p25 p50 p75 p90 p95 p97 p10 p50 p90 
25 11 720(125) – – – 600 703 820 – – – – – 559 740 884 
26 10 940(218) – – – 810 951 1154 – – – – – 594 840 1026 
27 14 990(194) – – – 796 1008 1188 – – – – – 675 965 1175 
28 11 1026(252) – – – 840 964 1280 – – – – – 764 1090 1347 
29 20 1230(242) – – – 1000 1228 1460 – – – – – 870 1240 1494 
30 15 1392(189) – – – 1300 1420 1512 – – – – – 1030 1400 1715 
31 32 1648(406) – – – 1410 1685 1837 – – – – – 1190 1590 1948 
32 35 1834(357) – – – 1600 1843 2100 – – – – – 1348 1780 2170 
33 63 2001(389) – – 1600 1780 1986 2200 2590 – – 7.9(1.3,14.6) 12.7(4.5,20.9) 1560 2011 2450 
34 109 2416(468) 1690 1710 1800 2140 2360 2675 3140 3405 3430 7.3(2.4,12.2) 22.0(14.2,29.8)* 1764 2240 2705 
35 171 2614(463) 1840 1900 2037 2300 2584 2870 3180 3380 3714 7.0(3.2,10.8) 20.5(14.4,26.5)* 1980 2480 2995 
36 382 2846(458) 2007 2070 2260 2550 2840 3125 3430 3600 3700 8.4(5.6,11.2) 17.3(13.5,21.1)* 2198 2710 3250 
37 1091 3100(433) 2268 2400 2562 2830 3090 3380 3626 3800 3970 5.7(4.3,7.1)* 13.5(11.4,15.5)* 2430 2965 3545 
38 3041 3304(428) 2510 2610 2780 3015 3290 3585 3856 4010 4165 6.4(5.5,7.2)* 13.7(12.5,15.0)* 2690 3200 3770 
39 2995 3457(427) 2700 2800 2925 3170 3440 3725 4000 4200 4310 6.0(5.2,6.9)* 15.0(13.7,16.2)* 2830 3340 3890 
40 2512 3553(414) 2835 2900 3040 3269 3535 3826 4100 4255 4400 6.5(5.6,7.5)* 12.2(10.9,13.5)* 2975 3480 4030 
41 1089 3664(440) 2900 2980 3100 3340 3640 3965 4225 4430 4536 9.1(7.4,10.8) 12.8(10.8,14.7)* 3090 3605 4170 
42 75 3682(534) – – 3010 3390 3580 4030 4450 – – 14.7(6.7,22.7) 17.3(8.8,25.9)* 3110 3650 4240 
a SGA was defined as a birthweight below the Australian norm 10th percentile for the gestational age  
b LGA was defined as a birthweight greater than the Australian norm 90th percentile for gestational age  
c Adapted from (Dobbins, Sullivan, Roberts and Simpson, 2012). © Copyright 2012 The Medical Journal of Australia–adapted with permission.  
SD, standard deviation; SGA, small for gestational age; CI, confidence interval; LGA, large for gestational age; *, significant at the .05 level
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Table 3-6 Birthweight for liveborn singletons following ART treatment, by number of 
embryos transferred and type of ART treatment, Australia and New Zealand, 2002-2010 
Type of treatment 
Number 
& percentage 
Mean (SD) 
birthweight (g) 
% of SGA(a)  
(95% CI) (%) 
% of LGA(b)  
(95% CI) (%) 
SET     
Fresh 27,542 (37.9%) 3295.2(573.8) 10.3(9.9,10.6) 9.1(8.7,9.4)* 
Thaw 15,279 (21.0%) 3426.6(566.5) 6.3(5.9,6.7)* 14.7(14.1,15.2)* 
Total 42,821 (58.9%) 3341.9(574.6) 8.9(8.6,9.1)* 11.0(10.7,11.3)* 
DET     
Fresh 17,757 (24.4%) 3254.1(593.4) 11.5(11.0,12.0)* 8.9(8.5,9.4)* 
Thaw 8,764 (12.1%) 3383.7(566.7) 6.7(6.2,7.2)* 13.7(12.9,14.4)* 
Total 26,521 (36.5%) 3296.8(587.9) 9.9(9.5,10.3) 10.5(10.1,10.9)* 
 a SGA was defined as a birthweight below the Australian norm 10th percentile for the gestational age 
 b LGA was defined as a birthweight greater than the Australian norm 90th percentile for gestational 
age 
SD, standard deviation; SGA, small for gestational age; CI, confidence interval; LGA, large for 
gestational age; SET, single embryo transfer; DET, double embryo transfer; *, significant at the .05 
level 
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Figure 3-1 Birthweight percentiles for liveborn singletons following fresh cycles, Australia 
and New Zealand, 2002-2010 
 
 
* Australian norm 10th and 90th percentile. Adapted from (Dobbins, Sullivan, Roberts and 
Simpson, 2012). © Copyright 2012 The Medical Journal of Australia–adapted with permission. 
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Figure 3-2 Birthweight percentiles for liveborn singletons following thaw cycles, Australia 
and New Zealand, 2002-2010  
 
 
* Australian norm 10th and 90th percentile. Adapted from (Dobbins, Sullivan, Roberts and 
Simpson, 2012). © Copyright 2012 The Medical Journal of Australia–adapted with permission.  
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Figure 3-3 Mean birthweight of liveborn singletons, by sex and number of embryos 
transferred, 2002-2010, Australia and New Zealand 
 
 
SET: Single Embryo Transfer, DET: Double Embryo Transfer 
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Chapter 4: Study 2 Risk of ectopic pregnancy 
lowest with transfer of single frozen 
blastocyst 
 
 
 
 
 
 
 
 
 
 
 
This chapter appears as the following published paper in Human Reproduction:  
Li, Z., Sullivan, E. A., Chapman, M., Farquhar, C., & Wang, Y. A. (2015). Risk of ectopic 
pregnancy lowest with transfer of single frozen blastocyst. Human Reproduction, 30(9), 
2048-2054. 
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4.1 ABSTRACT 
Study question: What type of transferred embryo is associated with a lower rate of ectopic 
pregnancy? 
Summary answer: The lowest risk of ectopic pregnancy was associated with the transfer of 
blastocyst, frozen and single embryo compared with cleavage stage, fresh and multiple 
embryos. 
What is known already: Ectopic pregnancy is a recognized complication following assisted 
reproductive technology (ART) treatment. It has been estimated that the rate of ectopic 
pregnancy is doubled in pregnancies following ART treatment compared with spontaneous 
pregnancies. However, it was not clear whether the excess rate of ectopic pregnancy following 
ART treatment is related to the underlying demographic factors of women undergoing ART 
treatment, the number of embryos transferred or the developmental stage of the embryo. 
Study design, size, duration: A population-based cohort study of pregnancies following 
autologous treatment cycles between January 2009 and December 2011 were obtained from 
the Australian and New Zealand Assisted Reproduction Technology Database (ANZARD). 
The ANZARD collects ART treatment information and clinical outcomes annually from all 
fertility centers in Australia and New Zealand.  
Participants/materials, setting, methods: Between 2009 and 2011, a total of 44102 
pregnancies were included in the analysis. The rate of ectopic pregnancy was compared by 
demographic and ART treatment factors. Generalized linear regression of Poisson distribution 
was used to estimate the likelihood of ectopic pregnancy. Odds ratios, adjusted odds ratios 
(AOR) and 95% confidence intervals (CI) were calculated. 
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Main results and the role of chance: The overall rate of ectopic pregnancy was 1.4% for 
women following ART treatment in Australia and New Zealand. Pregnancies following single 
embryo transfers had 1.2% ectopic pregnancies, significantly lower than double embryo 
transfers (1.8%)(p<0.01). The highest ectopic pregnancy rate was 1.9% for pregnancies from 
transfers of fresh cleavage embryo, followed by transfers of frozen cleavage embryo (1.7%), 
transfers of fresh blastocyst (1.3%), and transfers of frozen blastocyst (0.8%). Compared with 
fresh blastocyst transfer, the likelihood of ectopic pregnancy was 30% higher for fresh cleavage 
stage embryo transfers (AOR 1.30, 95% CI 1.07-1.59) and was consistent across subfertility 
groups. Transfer of frozen blastocyst was associated with a significantly decreased risk of 
ectopic pregnancy (AOR 0.70, 95% CI 0.54-0.91) compared with transfer of fresh blastocyst. 
Limitations, reason for caution: A limitation of this population-based study is the lack of 
information available on clinical- specific protocols and processes for embryo transfer (i.e. 
embryo quality, cryopreservation protocol, and transfer techniques, etc.) and the potential 
impact on outcomes. 
Wider implications of the findings: The lowest risk of ectopic pregnancy was associated with 
the transfer of a single frozen blastocyst. This finding adds to the increasing evidence of better 
perinatal outcomes following frozen embryo transfers. The approach of freezing all embryos 
in the initiated fresh cycle and transfer of a single frozen blastocyst in the subsequent thaw 
cycle may improve the overall pregnancy and birth outcomes following ART treatment, in part 
by reducing the ectopic pregnancy rate. 
Study funding/competing interest(s): There is no funding for this study. Authors declared no 
competing interest related to this study. 
Key words: assisted reproductive technology, ectopic pregnancy, single embryo transfer, 
blastocyst, cryopreservation  
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4.2 INTRODUCTION 
An ectopic pregnancy is a pregnancy where the developing embryo implants outside the 
endometrial lining of the uterus (McQueen, 2011). It is a common complication of pregnancy 
that affects about 1 in 50-80 pregnancies (Creanga et al., 2011; Farquhar, 2005). The most 
common place for an ectopic pregnancy is one of the Fallopian tubes, but it can occur in many 
other sites such as the cervix, ovaries, and abdomen. Ectopic pregnancy can be life-threatening 
due to internal haemorrhage, and remains an important cause of maternal morbidity and 
mortality worldwide (Farquhar, 2005; Sullivan et al., 2004). It may also compromise future 
fertility, which is especially problematic for women undergoing assisted reproductive 
technology (ART) treatment for their subfertility (Fernandez & Gervaise, 2004).  
The rate of ectopic pregnancy following ART treatment ranges from 2% to 11% among 
women with tubal related subfertility (Clayton et al., 2006; Dubuisson et al., 1991), higher than 
the estimated rate of 1-2% for the general population (Creanga et al., 2011; Farquhar, 2005; 
Strandell et al., 1999). It was observed that the subfertility requiring ART treatment is one of 
the independent risk factors for ectopic pregnancy (Chang & Suh, 2010). Theoretically it could 
be expected that ART treatment reduces the risk of ectopic pregnancy since neither fertilization 
nor embryo transfer involves the Fallopian tubes. Typically one or two embryos are placed 
directly into the patient's uterus. Therefore the impaired tubal transport mechanisms, which are 
thought to predispose to ectopic in spontaneous pregnancy, should be bypassed in ART 
treatment (Jun & Milki, 2004; Revel et al., 2008).  
Among pregnancies following ART treatment, the reproductive health characteristics of 
women including tubal factor subfertility, endometriosis, previous pelvic inflammatory disease 
and previous ectopic pregnancy history have been identified as the most prominent risk factors 
for ectopic pregnancy (Chang & Suh, 2010; Strandell et al., 1999). The type of ART procedures 
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can also have a significant impact on ectopic pregnancy, such as stage of embryo development 
(cleavage stage embryo versus blastocysts), the number of embryos transferred, and fresh or 
frozen/thawed embryo transfer. However, for many procedures the findings are inconsistent in 
the literature (Bouyer et al., 2003; Chang & Suh, 2010; Jee et al., 2009). This study aims to add 
to the body of evidence regarding the relationship between ectopic pregnancy and fresh/frozen 
embryo at either cleavage or blastocyst stage using Australian and New Zealand population 
data of pregnancies following autologous ART treatment. 
4.3 MATERIALS AND METHODS 
4.3.1 Data 
Population-based data on 44102 pregnancies following autologous treatment cycles 
between January 2009 and December 2011 were obtained from the Australian and New 
Zealand Assisted Reproduction Technology Database (ANZARD). ART Treatment 
information and clinical outcomes are collected annually from all fertility centers in Australia 
and New Zealand to monitor the clinical outcomes following ART treatments and to access the 
effectiveness of ART treatments.  
4.3.2 Study factors and outcome measurements  
Pregnancies were grouped by following transfers of fresh cleavage embryo, transfers of 
frozen cleavage embryo, transfers of fresh blastocyst and transfers of frozen blastocyst. 
Maternal age was based on the completed years of age at time of treatment, and was classified 
into four groups: less than 30 years, 30 to 34 years, 35 to 39 years, and over 40 years. Cause of 
subfertility was classified as female only if it was the result of tubal disease, endometriosis or 
sub-fertility which the treating clinician believed to be due to ‘other female factors’ such as 
fibroids or ovulation disorders. Other classifications of cause of subfertility were male factors 
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only, combined male and female factors, and cause of subfertility unknown. Parity was 
classified as nulliparous, multiparous and not stated. 
Pregnancy was defined as a pregnancy that met at least one of the following criteria: 
known to be ongoing at 20 weeks; evidence by ultrasound of an intrauterine sac with or without 
a fetal heart; examination of products of conception revealing chorionic villi; or a definite 
ectopic pregnancy that has been diagnosed laparoscopically or by ultrasound. Ectopic 
pregnancy within ANZARD is recorded as either ectopic or combined ectopic and uterine 
pregnancy (heterotopic). The rates of ectopic pregnancy were measured per number of 
pregnancies.  
4.3.3 Statistical analysis 
Generalized linear regression using the Poisson distribution was used to estimate the 
likelihood of ectopic pregnancy following embryo transfer cycles. Potential confounders 
identified in the literature, including maternal age, parity, cause of subfertility, number of 
embryos transferred and method of fertilization (IVF/ ICSI) were controlled in multivariate 
analysis. Odds ratios (OR), adjusted odds ratios (AOR) and 95% confidence intervals (CI) were 
calculated. Findings with a CI not including 1 were considered statistically significant. All 
statistical analysis was performed using IBM SPSS Statistics 20.0 software (Armonk, NY, 
USA: IBM Corp.). 
4.3.4 Ethical approval  
Ethics approval for this study was granted by the Human Research Ethics Committee 
(HC12373) of the University of New South Wales, Australia.  
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4.4 RESULTS 
Between 2009 and 2011, of the 44102 pregnancies included in the analysis, 620 were 
reported as ectopic pregnancies, 8 of which were heterotopic pregnancies. The overall rate of 
ectopic pregnancy was 1.4% for women following ART treatment in Australia and New 
Zealand (Table 4-1). The ectopic pregnancy rate was higher among women with tubal factor 
subfertility (2.2%) or endometriosis (1.7%), compared with couples with male factor only 
subfertility (1.4%). The ectopic pregnancy rate for single embryo transfer was 1.2%, which 
was significantly lower than the 1.8% for double embryo transfer and 2.8% for transfer of three 
or more embryos (p<0.01) (Table 4-1). 
More than two-thirds (67.8%) of women who had fresh cleavage embryos transferred 
were first time mothers, compared with 57.2% among fresh blastocyst transfer group, 57.4% 
among frozen cleavage embryos transfer group and 53.3% among frozen blastocyst transfer 
group. Rates of double and three or more embryo transfer were also highest for fresh cleavage 
embryo transfer group. Within the fresh cleavage embryo transfer group, 55.5% of transfers 
were single embryo transfer, 43.3% were double embryo transfers, and 1.2% involved the 
transfer of three or more embryos. While 78.5% of women with fresh blastocyst transfer and 
85.0% of women with frozen blastocyst transfer had single embryo transfer (Table 4-2).  
Overall, the highest ectopic pregnancy rate by type of embryos transferred was 1.9% for 
fresh cleavage embryos, followed by 1.7% for frozen cleavage embryos, 1.3% for fresh 
blastocysts, and 0.8% for frozen blastocysts. The ectopic pregnancy rate following single 
embryo transfer is lower than that of double embryo transfer for all types of embryos 
transferred (1.7% versus 2.1% for fresh cleavage embryos, 1.1% versus 1.9% for fresh 
blastocysts, 0.8% versus 1.1% for frozen blastocysts, respectively), except for frozen cleavage 
embryos (1.9% versus 1.4%, respectively) (Table 4-3).  
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Compared with fresh blastocyst transfer, the likelihood of ectopic pregnancy was 30% 
higher for fresh cleavage stage embryo transfers (AOR 1.30, 95% CI 1.07-1.59) and was 
consistent across subfertility groups. The increased risk of ectopic pregnancy following fresh 
cleavage embryo transfer compared with fresh blastocyst ranged from 27% in couples with 
male only or unexplained subfertility to 37% in couples with tubal factor subfertility (Table 
4-4). Transfer of frozen blastocyst resulted in significantly decreased risk of ectopic pregnancy 
(AOR 0.70, 95% CI 0.54-0.91) compared with transfer of fresh blastocyst (Table 4-4). 
4.5 DISCUSSION  
This large population-based study found that the ectopic pregnancy rate following ART 
treatment was 1.4% in Australia and New Zealand. The ectopic pregnancy rate was lower 
following single embryo transfer, blastocyst transfer and frozen embryo transfer. These 
findings suggest that transfer of single frozen/thawed blastocyst was accompanied by a reduced 
risk of ectopic pregnancy.  
The ectopic pregnancy rate in our population-based study (1.4%) was similar to the 
ectopic pregnancy rate reported for single embryo transfer in the Japanese Registry of Assisted 
Reproductive Medicine (1.4%) (Ishihara et al., 2011), and the 1.6% reported in the American 
Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry 
(Society for Assisted Reproductive & American Society for Reproductive, 2007). As ectopic 
pregnancies in the general population are increasingly being treated medically in outpatient 
settings it is difficult to establish current population estimates of ectopic pregnancy incidence 
rates from hospital admission data (Farquhar, 2005; Trabert et al., 2011; Zane et al., 2002). 
However, a trend analysis of incidence of ectopic pregnancy in New South Wales suggested 
that the incidence is decreasing or stabilizing in Australia. The overall ectopic pregnancy rate 
decreased from 17.4 per 1000 births in 1990–1991 to 16.2 per 1000 births in 1997–1998 in 
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New South Wales (Boufous et al., 2001). Similarly, the incidence of ectopic pregnancy 
following ART treatment in the USA (1.6%) compares favorably with the estimated overall 
US ectopic pregnancy rate of 2% per pregnancy, which might be associated with the decreased 
proportion of couples with tubal factor subfertility and increased proportion of couples with 
male factor subfertility (Society for Assisted Reproductive & American Society for 
Reproductive, 2007).  
The results of this study showed that blastocyst transfers have a significantly reduced 
ectopic pregnancy rate compared with cleavage stage embryo transfer. Previous small single-
center studies have reported inconsistent results for comparison between transfer of cleavage 
embryo and blastocyst regarding ectopic pregnancy rate. An earlier study of 956 clinical 
pregnancies found that the ectopic pregnancy rate is not reduced following blastocyst transfer 
compared to cleavage stage embryo transfer (3.9% versus 3.5%, p = 0.8) (Milki & Jun, 2003). 
Two US studies (Keegan et al., 2007; Rosman et al., 2009) based on the same fertility centre 
data reported a significant increase in the ectopic pregnancy rate in blastocyst embryo transfer 
compared with cleavage stage embryo transfer (1.6% versus 0.5%, p = 0.006; and 1.3% versus 
0.4%, p = 0.002, respectively). The lower ectopic pregnancy rate than the US national ectopic 
pregnancy rate seen in these two studies might be associated with the aggressive management 
of documented tubal disease with salpingectomy in their practice. A more recent retrospective 
analysis of Japanese Registry of Assisted Reproductive Medicine data has shown similar 
findings to those reported here, that blastocyst transfer results in a decreased rate of ectopic 
pregnancy compared with cleavage stage embryo transfer (Ishihara et al., 2011). Multiple 
hypotheses have been offered to explain the decreased risk of ectopic pregnancy in blastocyst 
transfer. These include that the larger diameter of the blastocyst would reduce the chances of 
blastocysts from migrating to the Fallopian tube (Chang & Suh, 2010; Schoolcraft et al., 2001), 
the cleavage stage embryos are not prepared temporarily for immediate implantation and could 
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migrate within the reproductive tract before implantation (Ishihara et al., 2011; Milki & Jun, 
2003), and uterine contractility decreases progressively in the luteal phase and reaches a nearly 
quiescent status at the time of blastocyst transfer which would assist blastocyst implantation 
and not promote migration of the transferred embryo (Fanchin et al., 2001; Lesny & Killick, 
2004). 
Compared with fresh blastocyst transfer, the likelihood of ectopic pregnancy was 
significantly lower for frozen blastocyst transfer. Two earlier studies and one meta-analysis 
suggested that the ectopic pregnancy rate for fresh embryo transfer cycles was not statistically 
significant different from that for frozen embryo transfer cycles (Check et al., 2005; Jee et al., 
2009; Jun & Milki, 2007). However, other recent studies have shown similar findings to those 
reported here. An analysis of single embryo transfer cycles in Japan found that frozen-thawed 
transfer has a significantly reduced ectopic pregnancy rate compared with fresh transfer for 
both cleavage stage embryo and blastocyst (Ishihara et al., 2011). Similarly, a retrospective 
cohort study of 8-year data reported that a significantly reduced incidence of ectopic pregnancy 
was associated with frozen-thawed embryo transfer relative to fresh transfer (Shapiro et al., 
2012). Changes in the uterine environment could be expected to impact ectopic pregnancy rates 
when frozen embryos are transferred compared with fresh embryo transfer due to the influence 
of natural versus medicated cycle factors on endometrial receptivity (Jun & Milki, 2007). The 
increased risk of ectopic pregnancy following a fresh cycle might indicate the negative effect 
of ovarian stimulation on endometrial receptivity (Ishihara et al., 2011; Shapiro et al., 2012). 
Another mechanism behind this lower ectopic pregnancy rate following a frozen cycle might 
be the increased uterine contractility in stimulated cycles compared with non-stimulated cycles. 
Increased uterine contractility in stimulated cycles may favor migration of the embryos into the 
Fallopian tubes and decrease implantation within the uterine cavity (Jee et al., 2009; Polyzos 
& Devroey, 2012).  
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It has been suggested that the number of embryos transferred in each cycle is an important 
underlying factor in the aetiology of ectopic pregnancy following ART treatment. As each 
embryo has independent potential to implant, the risk of ectopic pregnancy could increase with 
increasing number of embryos transferred (Ishihara et al., 2011). In the present study, the 
likelihood of ectopic pregnancy was lowest with single embryo transfer and was highest when 
three or more embryos transferred. A similar finding was reported by Yanaihara and 
colleagues, that double embryo transfer resulted in a significantly higher rate of ectopic 
pregnancy than single embryo transfer (4.4% versus 1.2%, p<0.05) (Yanaihara et al., 2008). In 
addition, a retrospective study in Austria found that the number of embryos transferred 
increased the probability of an ectopic pregnancy (p = 0.0018) (Weigert et al., 2009). However, 
a systematic review of comparison between elective single embryo transfer and double embryo 
transfer showed no statistically significant difference in the ectopic pregnancy rate (Relative 
Risk 0.39, 95% CI 0.08-1.99) (Gelbaya et al., 2010). This is probably due to the small sample 
size, in that only 5 ectopic pregnancies were reported in the three clinical trials included in 
meta-analysis.  
A major limitation of this population-based study is the lack of information available on 
clinic- specific protocols and processes for embryo transfer (i.e. embryo quality, 
cryopreservation protocol, and transfer techniques, etc.). In addition, the ANZARD data lacks 
medical and treatment history of previous ectopic pregnancy. Further data from RCTs 
comparing differing treatment protocols, for example, single embryo transfer versus double 
embryo transfer, cleavage versus blastocyst and fresh versus frozen transfers are required to 
evaluate the underlying mechanisms of ectopic pregnancy following ART treatment reported 
here. Another potential concern about using the registry data is the accuracy and completeness 
of ectopic pregnancy reporting in the ART Registry (Clayton et al., 2006). It is possible that 
women with an ectopic pregnancy after ART treatment have been diagnosed and treated in 
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outpatient settings and so not reported to the ART clinic. This would lead to an underestimate 
of ectopic pregnancy rate following ART procedures. However, as discussed, the ectopic 
pregnancy rate in our population-based study was consistent with the Japanese Registry and 
US Registry (Ishihara et al., 2011; Society for Assisted Reproductive & American Society for 
Reproductive, 2007). The slightly lower ectopic pregnancy rate seen in our study compared 
with US data could be explained by the high proportion of single embryo transfer, transfer of 
blastocyst, and transfer of frozen embryos in Australia and New Zealand (Macaldowie, 2012; 
Marsh et al., 2012; Society for Assisted Reproductive & American Society for Reproductive, 
2007). The high proportion of single embryo transfer could also partially explain the low 
heterotopic pregnancies rate seen in our study.  
In clinical settings, the decision to transfer fresh or frozen embryos at cleavage or 
blastocyst stage should be made to maximize clinical efficacy and to minimize adverse clinical 
outcomes. Of the data for this study, the efficacy measured by clinical pregnancy rate per 
transfer cycle was 35.9% for transfers of fresh blastocysts and 29.4% for transfers of frozen 
blastocysts, higher than the 24.4% for transfers of fresh cleavage embryos and 22.6% for 
transfers of frozen cleavage embryos. This is supported by a number of review papers which 
also demonstrated a comparable or higher clinical pregnancy and live delivery rate following 
transfer of blastocysts than cleavage stage embryos, frozen embryos than fresh embryos, and 
single embryo transfer than double embryo transfer (Glujovsky et al., 2012; McLernon et al., 
2010; Papanikolaou et al., 2008; Roque et al., 2013). In addition to the higher efficacy 
following transfer of blastocyst, frozen, and single embryo, our population-based study showed 
a significantly lower risk of ectopic pregnancy following transfer of a single frozen blastocyst. 
From a public health perspective, transfer of a single frozen blastocyst should be supported to 
minimize ectopic pregnancy associated with ART treatment, given that ectopic pregnancy is 
one of the few life threatening complications following ART. 
  
Chapter 4: Study 2 Risk of ectopic pregnancy lowest with transfer of single frozen blastocyst 124 
4.6 ACKNOWLEDGEMENTS 
The Fertility Society of Australia is the funding body for the ANZARD. The authors 
acknowledge the contribution of Australian and New Zealand fertility clinics in the provision 
of data to ANZARD.  
4.7 AUTHORS’ ROLES 
All the authors were involved in the design of the study. Z. Li and Y.A. Wang drafted 
the manuscript and conducted the data analysis. E.A. Sullivan, M. Chapman, and C. Farquhar 
have revised the manuscript critically for important intellectual content. The final version of 
the manuscript was approved by all the authors. 
4.8 FUNDING 
No specific funding was received to undertake this study. 
4.9 CONFLICT OF INTEREST  
None.  
  
Chapter 4: Study 2 Risk of ectopic pregnancy lowest with transfer of single frozen blastocyst 125 
4.10 REFERENCE  
Boufous, S., Quartararo, M., Mohsin, M., & Parker, J. (2001). Trends in the incidence of 
ectopic pregnancy in New South Wales between 1990-1998. Australian and New 
Zealand Journal of Obstetrics and Gynaecology, 41(4), 436-438.  
Bouyer, J., Coste, J., Shojaei, T., Pouly, J.-L., Fernandez, H., Gerbaud, L., . . . Job - Spira, N. 
(2003). Risk Factors for Ectopic Pregnancy: A Comprehensive Analysis Based on a 
Large Case-Control, Population-based Study in France. American Journal of 
Epidemiology, 157(3), 185-194.  
Chang, H. J., & Suh, C. S. (2010). Ectopic pregnancy after assisted reproductive technology: 
what are the risk factors? Current Opinion in Obstetrics and Gynecology, 22(3), 202-
207. doi:10.1097/GCO.0b013e32833848fd 
Check, J. H., Choe, J. K., Katsoff, B., Krotec, J. W., & Nazari, A. (2005). Ectopic pregnancy 
is not more likely following fresh vs frozen embryo transfer. Fertility and Sterility, 
82(S2), S149.  
Clayton, H. B., Schieve, L. A., Peterson, H. B., Jamieson, D. J., Reynolds, M. A., & Wright, 
V. C. (2006). Ectopic pregnancy risk with assisted reproductive technology 
procedures. Obstetrics and Gynecology, 107(3), 595-604.  
Creanga, A. A., Shapiro-Mendoza, C. K., Bish, C. L., Zane, S., Berg, C. J., & Callaghan, W. 
M. (2011). Trends in ectopic pregnancy mortality in the United States: 1980-2007. 
Obstetrics and Gynecology, 117(4), 837-843. doi:10.1097/AOG.0b013e3182113c10 
Dubuisson, J. B., Aubriot, F. X., Mathieu, L., Foulot, H., Mandelbrot, L., & de Joliere, J. B. 
(1991). Risk factors for ectopic pregnancy in 556 pregnancies after in vitro 
fertilization: implications for preventive management. Fertility and Sterility, 56(4), 
686-690.  
  
Chapter 4: Study 2 Risk of ectopic pregnancy lowest with transfer of single frozen blastocyst 126 
Fanchin, R., Ayoubi, J. M., Righini, C., Olivennes, F., Schonauer, L. M., & Frydman, R. 
(2001). Uterine contractility decreases at the time of blastocyst transfers. Human 
Reproduction, 16(6), 1115-1119.  
Farquhar, C. M. (2005). Ectopic pregnancy. The Lancet, 366(9485), 583-591.  
Fernandez, H., & Gervaise, A. (2004). Ectopic pregnancies after infertility treatment: modern 
diagnosis and therapeutic strategy. Human Reproduction Update, 10(6), 503-513. 
doi:10.1093/humupd/dmh043 
Gelbaya, T. A., Tsoumpou, I., & Nardo, L. G. (2010). The likelihood of live birth and 
multiple birth after single versus double embryo transfer at the cleavage stage: a 
systematic review and meta-analysis. Fertility and Sterility, 94(3), 936-945.  
Glujovsky, D., Blake, D., Farquhar, C., & Bardach, A. (2012). Cleavage stage versus 
blastocyst stage embryo transfer in assisted reproductive technology. Cochrane 
Database of Systematic Reviews, 7, CD002118. 
doi:10.1002/14651858.CD002118.pub4 
Ishihara, O., Kuwahara, A., & Saitoh, H. (2011). Frozen-thawed blastocyst transfer reduces 
ectopic pregnancy risk: an analysis of single embryo transfer cycles in Japan. Fertility 
and Sterility, 95(6), 1966-1969.  
Jee, B. C., Suh, C. S., & Kim, S. H. (2009). Ectopic pregnancy rates after frozen versus fresh 
embryo transfer: a meta-analysis. Gynecologic and Obstetric Investigation, 68, 53-57.  
Jun, S. H., & Milki, A. A. (2004). Assisted hatching is associated with a higher ectopic 
pregnancy rate. Fertility and Sterility, 81(6), 1701-1703.  
Jun, S. H., & Milki, A. A. (2007). Ectopic pregnancy rates with frozen compared with fresh 
blastocyst transfer. Fertility and Sterility, 88(3), 629-631.  
  
Chapter 4: Study 2 Risk of ectopic pregnancy lowest with transfer of single frozen blastocyst 127 
Keegan, D. A., Morelli, S. S., Noyes, N., Flisser, E. D., Berkeley, A. S., & Grifo, J. A. 
(2007). Low ectopic pregnancy rates after in vitro fertilization: do practice habits 
matter? Fertility and Sterility, 88(3), 734-736. doi:10.1016/j.fertnstert.2006.11.169 
Lesny, P., & Killick, S. R. (2004). The junctional zone of the uterus and its contractions. 
BJOG:an international journal of obstetrics and gynaecology, 111(11), 1182-1189. 
doi:10.1111/j.1471-0528.2004.00350.x 
Macaldowie, A., Wang, YA, Chambers, GM, Sullivan EA. (2012). Assisted reproductive 
technology in Australia and New Zealand. Retrieved from Canberra:  
Marsh, C. A., Farr, S. L., Chang, J., Kissin, D. M., Grainger, D. A., Posner, S. F., . . . 
Jamieson, D. J. (2012). Trends and factors associated with the Day 5 embryo transfer, 
assisted reproductive technology surveillance, USA, 2001-2009. Human 
Reproduction, 27(8), 2325-2331. doi:10.1093/humrep/des168 
McLernon, D. J., Harrild, K., Bergh, C., Davies, M. J., de Neubourg, D., Dumoulin, J. C., . . . 
Bhattacharya, S. (2010). Clinical effectiveness of elective single versus double 
embryo transfer: meta-analysis of individual patient data from randomised trials. 
BMJ, 341, c6945. doi:10.1136/bmj.c6945 
McQueen, A. (2011). Ectopic pregnancy: risk factors, diagnostic procedures and treatment. 
Nursing Standard, 25(37), 49-56; quiz 58.  
Milki, A. A., & Jun, S. H. (2003). Ectopic pregnancy rates with day 3 versus day 5 embryo 
transfer: a retrospective analysis. BMC Pregnancy and Childbirth, 3(1), 7.  
Papanikolaou, E. G., Kolibianakis, E. M., Tournaye, H., Venetis, C. A., Fatemi, H., Tarlatzis, 
B., & Devroey, P. (2008). Live birth rates after transfer of equal number of 
blastocysts or cleavage-stage embryos in IVF. A systematic review and meta-analysis. 
Human Reproduction, 23(1), 91-99. doi:10.1093/humrep/dem339 
  
Chapter 4: Study 2 Risk of ectopic pregnancy lowest with transfer of single frozen blastocyst 128 
Polyzos, N. P., & Devroey, P. (2012). Significantly lower ectopic pregnancy rates after 
frozen embryo transfer: implications toward segmentation of invitro fertilization 
treatment. Fertility and Sterility, 98(6), 1419-1420.  
Revel, A., Ophir, I., Koler, M., Achache, H., & Prus, D. (2008). Changing etiology of tubal 
pregnancy following IVF. Human Reproduction, 23(6), 1372-1376. 
doi:10.1093/humrep/den018 
Roque, M., Lattes, K., Serra, S., Sola, I., Geber, S., Carreras, R., & Checa, M. A. (2013). 
Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a 
systematic review and meta-analysis. Fertil Steril, 99(1), 156-162. 
doi:10.1016/j.fertnstert.2012.09.003 
Rosman, E. R., Keegan, D. A., Krey, L., Liu, M., Licciardi, F., & Grifo, J. A. (2009). Ectopic 
pregnancy rates after in vitro fertilization: a look at the donor egg population. Fertility 
and Sterility, 92(5), 1791-1793. doi:10.1016/j.fertnstert.2009.05.041 
Schoolcraft, W. B., Surrey, E. S., & Gardner, D. K. (2001). Embryo transfer: techniques and 
variables affecting success. Fertility and Sterility, 76(5), 863-870.  
Shapiro, B. S., Daneshmand, S. T., De Leon, L., Garner, F. C., Aguirre, M., & Hudson, C. 
(2012). Frozen-thawed embryo transfer isassociated with a significantly reduced 
incidence of ectopic pregnancy. Fertility and Sterility, 98(6), 1490-1494.  
Society for Assisted Reproductive, T., & American Society for Reproductive, M. (2007). 
Assisted reproductive technology in the United States: 2001 results generated from 
the American Society for Reproductive Medicine/Society for Assisted Reproductive 
Technology registry. Fertility and Sterility, 87(6), 1253-1266. 
doi:10.1016/j.fertnstert.2006.11.056 
Strandell, A., Thorburn, J., & Hamberger, L. (1999). Risk factors for ectopic pregnancy in 
assisted reproduction. Fertility and Sterility, 71(2), 282-286.  
  
Chapter 4: Study 2 Risk of ectopic pregnancy lowest with transfer of single frozen blastocyst 129 
Sullivan, E. A., Ford, J. B., Chambers, G., & Slaytor, E. K. (2004). Maternal mortality in 
Australia, 1973-1996. Australian and New Zealand Journal of Obstetrics and 
Gynaecology, 44(5), 452-457; discussion 377. doi:10.1111/j.1479-
828X.2004.00313.x 
Trabert, B., Holt, V. L., Yu, O., Van Den Eeden, S. K., & Scholes, D. (2011). Population-
Based Ectopic Pregnancy Trends, 1993–2007. American Journal of Preventive 
Medicine, 40(5), 556-560.  
Weigert, M., Gruber, D., Pernicka, E., Bauer, P., & Feichtinger, W. (2009). Previous tubal 
ectopic pregnancy raises the incidence of repeated ectopic pregnancies in in vitro 
fertilization-embryo transfer patients. Journal of Assisted Reproduction and Genetics, 
26(1), 13-17. doi:10.1007/s10815-008-9278-2 
Yanaihara, A., Yorimitsu, T., Motoyama, H., Ohara, M., & Kawamura, T. (2008). Clinical 
outcome of frozen blastocyst transfer; single vs. double transfer. Journal of Assisted 
Reproduction and Genetics, 25(11-12), 531-534.  
Zane, S., Kieke, B., Kendrick, J., & Bruce, C. (2002). Surveillance in a Time of Changing 
Health Care Practices: Estimating Ectopic Pregnancy Incidence in the United States. 
Maternal and Child Health Journal, 6(4), 227-236. doi:10.1023/a:1021106032198 
 
  
  
Chapter 4: Study 2 Risk of ectopic pregnancy lowest with transfer of single frozen blastocyst 130 
Table 4-1. Rate of ectopic pregnancies following autologous embryo transfer cycles, by 
demographic and treatment characteristics, Australia and New Zealand, 2009-2011 
 
No. Pregnancies No. Ectopic Pregnancies 
Ectopic rate 
per Pregnancy  
% (95% CI) 
Total 44102 620 1.4(1.3,1.5) 
Maternal age    
<30 years 6266 79 1.3(1.0,1.5) 
30-34 years 15234 190 1.2(1.1,1.4) 
35-39 years 17002 266 1.6(1.4,1.8) 
>40 years 5600 85 1.5(1.2,1.8) 
Cause of infertility    
Male only 10350 140 1.4(1.1,1.6) 
Female only 14128 227 1.6(1.4,1.8) 
Combined male/female 6028 72 1.2(0.9,1.5) 
Unexplained 11519 126 1.1(0.9,1.3) 
Not stated 2077 55 2.6(1.9,3.3) 
Female only with tubal diseasea 3190 70 2.2(1.7,2.7) 
Female only with endometriosisb 4544 75 1.7(1.3,2.0) 
Parity    
Nulliparous 26087 415 1.6(1.4,1.7) 
Multiparous 13021 144 1.1(0.9,1.3) 
Not stated 4994 61 1.2(0.9,1.5) 
Number of embryos transferred    
One 31617 391 1.2(1.1,1.4) 
Two 12273 223 1.8(1.6,2.1) 
Three or more 212 6 2.8(0.6,5.1) 
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Fertilization procedure    
IVF 16749 241 1.4(1.3,1.6) 
ICSI 26869 377 1.4(1.3,1.5) 
Not stated 484 2 0.4(0.0,1.0) 
a Including tubal disease and other female factor infertility. 
b Including endometriosis and other female factor infertility. 
CI: confidence interval 
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Table 4-2 Demographic and treatment characteristics of women who were pregnant following 
autologous embryo transfer cycles, Australia and New Zealand, 2009-2011 
  Fresh CL Fresh BL Frozen CL Frozen BL 
 No.  % No.  % No.  % No.  % 
Maternal age 
    
    
<30 years 1550 13.5 2702 16.0 814 12.7 1200 12.9 
30-34 years 3590 31.2 6137 36.4 2148 33.5 3359 36.0 
35-39 years 4533 39.4 6200 36.8 2572 40.1 3697 39.6 
>40 years 1838 16.0 1806 10.7 875 13.7 1081 11.6 
Cause of infertility         
Male only 2653 23.0 4043 24.0 1459 22.8 2195 23.5 
Female only 3895 33.8 5257 31.2 2270 35.4 2706 29.0 
Combined male/female 1360 11.8 2766 16.4 479 7.5 1423 15.2 
Unexplained 2661 23.1 4570 27.1 1400 21.8 2888 30.9 
Not stated 942 8.2 209 1.2 801 12.5 125 1.3 
Female only with tubal diseasea 821 7.1 1238 7.3 447 7.0 684 7.3 
Female only with endometriosisb 1494 13.0 1445 8.6 894 13.9 711 7.6 
Parity         
Nulliparous 7802 67.8 9630 57.2 3681 57.4 4974 53.3 
Multiparous 3077 26.7 4268 25.3 2444 38.1 3232 34.6 
Not stated 632 5.5 2947 17.5 284 4.4 1131 12.1 
Number of embryos transferred         
One 6389 55.5 13221 78.5 4073 63.6 7934 85.0 
Two 4986 43.3 3587 21.3 2302 35.9 1398 15.0 
Three or more 136 1.2 37 0.2 34 0.5 5 0.1 
Fertilization procedure         
IVF 4054 35.2 6057 36.0 2630 41.0 4008 42.9 
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ICSI 7457 64.8 10788 64.0 3702 57.8 4922 52.7 
Not stated 0 0.0 0 0.0 77 1.2 407 4.4 
a Including tubal disease and other female factor infertility. 
b Including endometriosis and other female factor infertility. 
CL, cleavage stage embryo; BL, blastocyst  
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Table 4-3 Rate of ectopic pregnancies following autologous embryo transfer cycles, by type 
of assisted reproductive technology treatment, Australia and New Zealand, 2009-2011 
  No. Pregnancies No. Ectopic Pregnancies 
Ectopic rate  
per Pregnancy  
% (95% CI) 
SET    
Fresh CL 6389 109 1.7(1.4,2.0) 
Fresh BL 13221 144 1.1(0.9,1.3) 
Frozen CL 4073 76 1.9(1.4,2.3) 
Frozen BL 7934 62 0.8(0.6,1.0) 
Total  31617 391 1.2(1.1,1.4) 
DET    
Fresh CL 4986 107 2.1(1.7,2.6) 
Fresh BL 3587 68 1.9(1.4,2.3) 
Frozen CL 2302 32 1.4(0.9,1.9) 
Frozen BL 1398 16 1.1(0.6,1.7) 
Total  12273 223 1.8(1.6,2.1) 
Alla    
Fresh CL 11511 219 1.9(1.7,2.2) 
Fresh BL 16845 215 1.3(1.1,1.4) 
Frozen CL 6409 108 1.7(1.4,2.0) 
Frozen BL 9337 78 0.8(0.6,1.0) 
Total  44102 620 1.4(1.3,1.5) 
 a Includes transfer cycles where three or more embryos were transferred. 
SET, single embryo transfer; CL, cleavage stage embryo; BL, blastocyst; DET, double embryo 
transfer.  
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Table 4-4 Risk of ectopic pregnancy following autologous embryo transfer cycles, by cause 
of infertility, stage of embryo transferred, and cryopreservation methods, Australia and New 
Zealand, 2009-2011 
  
No. 
Pregnancies 
No. Ectopic 
Pregnancies 
Rate (%) OR (95% CI) AORa(95% CI) 
Any tubal diseaseb 
Fresh CL 1079 34 3.2 1.47(0.92,2.35) 1.37(0.84,2.25) 
Fresh BL 1636 35 2.1 1 1 
Frozen CL 556 16 2.9 1.35(0.75,2.41) 1.33(0.73,2.45) 
Frozen BL 889 11 1.2 0.58(0.30,1.13) 0.59(0.30,1.17) 
Any female factors 
Fresh CL 5255 106 2.0 1.46(1.12,1.90) 1.29(0.97,1.73) 
Fresh BL 8023 111 1.4 1 1 
Frozen CL 2749 43 1.6 1.13(0.80,1.60) 1.07(0.74,1.54) 
Frozen BL 4129 39 0.9 0.68(0.47,0.98)  0.75(0.52,1.09) 
Male factors only/ Unexplained  
Fresh CL 5314 81 1.5 1.31(0.98,1.76) 1.27(0.94,1.71) 
Fresh BL 8613 100 1.2 1 1 
Frozen CL 2859 47 1.6 1.42(1.00,2.00) 1.42(0.99,2.04) 
Frozen BL 5083 38 0.7 0.64(0.44,0.93) 0.66(0.46,0.97) 
All 
Fresh CL 11511 219 1.9 1.49(1.24,1.80) 1.30(1.07,1.59) 
Fresh BL 16845 215 1.3 1 1 
Frozen CL 6409 108 1.7 1.32(1.05,1.66) 1.19(0.92,1.52) 
Frozen BL 9337 78 0.8 0.65(0.51,0.85) 0.70(0.54,0.91) 
a Adjusted for maternal age, parity, cause of infertility, fertilization procedure and number of embryos 
transferred. 
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b Including tubal disease only and combined tubal disease with other cause of infertility. 
 OR, odds ratio; AOR, adjusted odds ratio  
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5.1 ABSTRACT 
Study question: What are the clinical efficacy and perinatal outcomes following transfer of 
vitrified blastocysts compared with fresh blastocyst transfer and slow freezing methods? 
Summary answer: Compared with slow frozen blastocysts, vitrified blastocysts resulted in a 
significantly higher clinical pregnancy and live delivery rates with comparable perinatal 
outcomes at population level. 
What is known already: Although vitrification has been reported to be associated with 
significantly increased post-thaw survival rates compared with slow freezing, there has been a 
lack of general consensus over which method of cryopreservation (vitrification versus slow 
freezing) is most appropriate for blastocysts. 
Study design, size, duration: A population-based cohort of autologous fresh and thaw cycles 
performed between January 2009 and December 2011 in Australia and New Zealand was 
evaluated retrospectively. A total of 46890 fresh blastocyst transfer cycles, 12852 initiated slow 
frozen blastocyst thaw cycles, and 20887 initiated vitrified blastocyst warming cycles were 
included in the data analysis. 
Participants/materials, setting, methods: Pairwise comparisons were made between the 
vitrified blastocyst group and slow frozen or fresh blastocyst group. A Chi-square test was used 
for categorical variables and t-test was used for continuous variables. Cox regression was used 
to examine the pregnancy outcomes (clinical pregnancy rate, miscarriage rate, and live delivery 
rate) and perinatal outcomes (preterm delivery, low birthweight births, small for gestational 
age (SGA) births, large for gestational age (LGA) births, and perinatal mortality) following 
transfer of fresh, slow frozen and vitrified blastocysts. 
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Main results and the role of chance: The 46890 fresh blastocyst transfers, 11644 slow frozen 
blastocyst transfers, and 19978 vitrified blastocyst transfers resulted in 16845, 2766, and 6537 
clinical pregnancies, which led to 13049, 2065 and 4955 live deliveries, respectively. 
Compared with slow frozen blastocyst transfer cycles, vitrified blastocyst transfer cycles 
resulted in a significantly higher clinical pregnancy rate (Adjusted relative risk (ARR): 1.47, 
95% confidence intervals (CI): 1.39-1.55) and live delivery rate (ARR: 1.41, 95% CI: 1.34-
1.49). Compared with singletons born after transfer of fresh blastocysts, singletons born after 
transfer of vitrified blastocysts were at 14% less risk of being born preterm (ARR: 0.86, 95% 
CI: 0.77-0.96), 33% less risk of being low birthweight (ARR: 0.67, 95% CI: 0.58-0.78), and 
40% less risk of being SGA (ARR: 0.60, 95% CI: 0.53-0.68). 
Limitations, reasons for caution: A limitation of this population-based study is the lack of 
information available on clinic-specific cryopreservation protocols and processes for slow 
freezing-thaw and vitrification-warm of blastocysts and the potential impact on outcomes. 
Wider implications of the findings: This study presents population-based evidence on clinical 
efficacy and perinatal outcomes associated with transfer of fresh, slow frozen and vitrified 
blastocysts. Vitrified blastocyst transfer resulted in significantly higher clinical pregnancy and 
live delivery rates with comparable perinatal outcomes compared with slow frozen blastocyst 
transfer. Comparably better perinatal outcomes were reported for singletons born after transfer 
of vitrified blastocysts than singletons born after transfer of fresh blastocysts. Elective 
vitrification could be considered as an alternative embryo transfer strategy to achieve better 
perinatal outcomes following Assisted Reproduction Technology (ART) treatment. 
Study funding/competing interest(s): No specific funding was obtained. The authors have no 
conflicts of interest to declare. 
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5.2 INTRODUCTION 
Embryo cryopreservation is considered a vital part of a successful Assisted Reproduction 
Technology (ART) treatment. Compared with the traditional slow freezing method, clinical 
embryo vitrification is a recently introduced ultra-rapid cryopreservation method that prevents 
ice formation within the suspension which is converted to a glasslike solid, avoiding damage 
to the cells or tissues (Liebermann & Tucker, 2006; Son & Tan, 2009; Zegers-Hochschild et 
al., 2009). Vitrification is relatively simple, inexpensive and potentially faster as the ultra-rapid 
cooling technique requires no expensive programmable controlled-rate freezing equipment 
(Loutradi et al., 2008; Youssry et al., 2008). Embryo vitrification was first introduced clinically 
in Australia in 2006 and is now used for almost three-quarters of autologous thaw/warm cycles 
where a blastocyst is transferred (Costigan et al., 2007; Macaldowie et al., 2013).  
Vitrification was reported to be associated with significantly increased post-thaw 
survival rate than slow freezing in two literature reviews and meta-analysis. Loutradi and 
colleagues found that survival rates of blastocysts were significantly higher after vitrification 
compared with slow freezing (odds ratio (OR): 2.20, 95% confidence interval (CI): 1.53-3.16) 
(Loutradi et al., 2008). Similarly, Kolibianakis and colleagues reported better post-thaw 
survival rates for embryos vitrified at the blastocyst stage compared with slow freezing (OR: 
4.09, 95% CI: 2.45-6.84) (Kolibianakis et al., 2009). However, although post-thaw survival 
rate is an important end-point when evaluating the efficacy of vitrification versus slow freezing, 
the success of ART treatment should ultimately be defined by clinical efficacy (Edgar & Gook, 
2012). 
The recent UK Association of Clinical Embryologists consensus meeting reported that 
there was lack of consensus over which method of cryopreservation (vitrification versus slow 
freezing) is most appropriate for cleavage stage embryos and blastocysts (Brison et al., 2012). 
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A systematic review and meta-analysis of controlled clinical trials suggested there was a 
significantly higher clinical pregnancy rate and ongoing pregnancy rate with vitrification 
compared with slow freezing (OR: 1.55, 95% CI: 1.03–2.32, OR: 1.82, 95% CI: 1.04–3.20, 
respectively), but no statistically significant difference in livebirth rate was found (AbdelHafez 
et al., 2010). Another systematic review and meta-analysis could not detect significant 
difference in clinical pregnancy rates per transfer between the vitrification and slow freezing 
cryopreservation methods (Kolibianakis et al., 2009).  
The need for follow-up studies on babies born after vitrification of blastocysts was 
highlighted due to concerns about the potential cytotoxicity related to high concentrations of 
cryoprotectants and potential contamination via liquid nitrogen contact associated with 
vitrification (Gosden, 2011; Wang et al., 2012). To date, there have been only a limited number 
of single-center studies using single center data to investigate the perinatal outcomes of births 
following vitrification of blastocysts when compared with the slow freezing method and 
appropriate fresh controls (Feng et al., 2012; Stehlik et al., 2005; Takahashi et al., 2005; 
Wikland et al., 2010).  
Our population-based study was designed to determine the clinical efficacy of 
vitrification of blastocysts compared with fresh blastocyst transfer and slow freezing methods 
and the associated perinatal outcomes of births following transfer of fresh, slow frozen and 
vitrified blastocysts.  
5.3 MATERIALS AND METHODS 
5.3.1 Data 
A population-based cohort of autologous fresh and thaw cycles performed between 
January 2009 and December 2011 in Australia and New Zealand was evaluated retrospectively. 
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ART treatment information and perinatal outcomes following fresh, slow frozen and vitrified 
blastocyst transfer cycles were obtained from the Australian and New Zealand Assisted 
Reproduction Database (ANZARD). Data for ANZARD are collected annually from all 
fertility centers within Australia and New Zealand to monitor the perinatal outcomes of births 
following ART treatments and to access the effectiveness of ART treatments.  
Between January 2009 and December 2011, there were 177813 autologous fresh and 
thaw cycles performed in Australia and New Zealand. Of the autologous cycles, blastocyst 
transfers made up approximately 50% of fresh cycles and 60% of thaw cycles. Mixed 
fresh/thawed embryo transfer cycles (0.1%), mixed slow freezing/vitrified embryo transfer 
cycles (0.3%), mixed cleavage/blastocyst embryo transfer cycles (0.2%) and fresh cycles with 
no embryo transferred (7.7%) were excluded. A total of 46890 fresh blastocyst transfer cycles, 
12852 initiated slow frozen blastocyst thaw cycles and 20887 initiated vitrified blastocyst 
warming cycles were included in the data analysis. 
5.3.2 Study factors and outcome measurements  
In cycles with transfer of fresh blastocysts, maternal age was calculated in completed 
years of age at treatment, i.e. by subtracting the mother’s date of birth from the date where the 
stimulation drug was administrated for stimulated cycles or the date of the last menstrual period 
for natural fresh cycles. In thaw cycles with transfer of slow frozen or vitrified blastocysts, 
maternal age was calculated in completed years of age at embryo freezing, i.e., by subtracting 
the mother’s date of birth from the freezing date of the thawed embryos. Cause of infertility 
was classified as: male factor only infertility, female factor only infertility, combined male–
female factor infertility, and unexplained infertility where neither a male nor female factor 
problem was diagnosed.  
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Clinical pregnancy was defined as a pregnancy that met at least one of the following 
criteria: known to be ongoing at 20 weeks; evidence by ultrasound of an intrauterine sac with 
or without a fetal heart; examination of products of conception revealing chorionic villi; or a 
definite ectopic pregnancy that has been diagnosed laparoscopically or by ultrasound. Births 
were defined as live births or still births of ≥20 weeks gestation or ≥ 400 grams birthweight. A 
live delivery was defined as the delivery of one or more liveborn infants, with the birth of twins 
or higher order multiples counted as one live delivery. Low birthweight was defined as weight 
at birth <2500g. Small for gestational age (SGA) was defined as a birthweight below the 10th 
percentile for the gestational age and large for gestational age (LGA) was defined as a 
birthweight greater than the 90th percentile for gestational age of the Australian population 
norm (Dobbins et al., 2012). Gestational week was calculated in completed weeks based on the 
embryo transfer date and baby’s date of birth. Preterm birth was defined as birth before 37 
completed weeks of gestation. Perinatal deaths included fetal deaths of at least 400 grams 
birthweight or 20 weeks gestation and neonatal deaths occurred within 28 days after birth.  
5.3.3 Statistical analysis 
Pairwise comparisons were made between the vitrified blastocyst group and slow frozen 
or fresh blastocyst group. A Chi-square test was used for categorical variables and t-test was 
used for continuous variables. Cox regression was used to examine the pregnancy outcomes 
(clinical pregnancy rate, miscarriage rate and live delivery rate) and perinatal outcomes 
(preterm delivery, low birthweight births, SGA and LGA births, and perinatal mortality) 
following transfer of fresh, slow frozen and vitrified blastocysts. Adjusted rate relative risk 
(ARR) and 95% confidence intervals (95% CI) were calculated. Adjustment was made for 
maternal age, cause of infertility, parity, duration of embryo storage, number of embryos 
thawed/transferred and method of fertilization. Findings with a P-value <0.05 or a CI not 
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including 1 was considered statistically significant. All statistical analysis was performed using 
SPSS 20.0 software (Armonk, NY: IBM Corp.). 
5.3.4 Ethical approval  
Ethics approval for this study was granted by the Human Research Ethics Committee of 
the University of New South Wales, Australia. 
5.4 RESULTS  
Between 2009 and 2011, there were 46890 fresh blastocyst transfer cycles and 33739 
initiated thaw blastocyst cycles (12852 slow freezing and 20887 vitrification cycles). Table 5-1 
presents the maternal demographic and obstetric characteristics in the fresh, slow frozen and 
vitrified blastocyst groups. The mean maternal age was 35.2 ±4.7 years for the fresh group, 
33.6±4.4 years for the slow freezing group and 34.2 ±4.4 years for the vitrification group (Table 
5-1). Due to the large sample size, all differences between the fresh, slow freezing, and 
vitrification group were highly significant (p<0.001) (Table 5-1). 
95.6% of the initiated vitrified blastocyst warming cycles resulted in embryo transfer, 
which was significantly higher than the 90.6% in the slow freezing group (ARR: 1.05, 95% CI: 
1.03-1.08, P<0.001) (Table 5-2, Table 5-4). On average, 1.3 ±0.6 vitrified blastocysts were 
warmed per cycle, while 1.5 ±0.8 slow frozen blastocysts were thawed per cycle. A higher 
proportion of single embryo transfer was reported in the vitrification group (88.6%), compared 
with 83.8% in the slow freezing group and 75% in the fresh group (Table 5-2).  
The 46890 fresh blastocyst transfers, 11644 slow frozen blastocyst transfers and 19978 
vitrified blastocyst transfers resulted in 16845, 2766, and 6537 clinical pregnancies, which led 
to 13049, 2065 and 4955 live deliveries, respectively (Table 5-3). The clinical pregnancy rate 
and live delivery rate per embryo transfer cycle were highest in the fresh blastocyst transfer 
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group (35.9% and 27.8%, respectively) (Table 5-3). The vitrified blastocyst group had a 
significantly higher clinical pregnancy rate per thaw cycle compared with the slow frozen 
blastocyst group (31.3% and 21.5%, respectively; ARR: 1.43, 95% CI: 1.37-1.50) and clinical 
pregnancy rate per embryo transfer cycle (32.7% and 23.8%, respectively; ARR: 1.38, 95% 
CI: 1.32-1.45) (Table 5-3, Table 5-4). The likelihood of a live delivery per thaw cycle was 47% 
higher for vitrified blastocyst transfer cycles compared with slow frozen blastocyst transfer 
cycles (ARR: 1.47, 95% CI: 1.39-1.55). Similarly, of vitrified blastocyst transfer cycles, 24.8% 
resulted in a live delivery. This was significantly higher (ARR: 1.41, 95% CI: 1.34-1.49) than 
the proportion in the slow frozen blastocyst group (17.7%) (Table 5-3, Table 5-4). 
The perinatal outcomes of singletons following transfer of fresh, slow frozen and vitrified 
blastocysts are presented in Table 5-5.The mean birthweight of singletons following vitrified 
blastocyst transfer (3421.6±590.5g) was significantly heavier than that of singletons following 
fresh blastocyst transfers (3276.2±611.6g) (p<0.001) (Table 5-5). Significantly lower 
proportion of low birthweight singletons were reported in the vitrified blastocyst group 
compared with the fresh blastocyst group (ARR: 0.67, 95% CI: 0.58-0.78). Compared with 
singletons born after transfer of fresh blastocysts, the likelihood of SGA births was 40% lower 
for singletons born after transfer of vitrified blastocysts (ARR: 0.60, 95% CI: 0.53-0.68), and 
36% lower for singletons born after slow frozen blastocysts(ARR: 0.64, 95% CI: 0.53-0.78). 
Both slow frozen and vitrified blastocyst transfer group resulted in higher risk of LGA births 
compared with the fresh blastocyst transfer group (ARR: 1.77, 95% CI: 1.57-2.00, ARR: 1.54, 
95% CI: 1.40–1.69, respectively) (Table 5-6). The mean gestational age was comparable in 
singletons after transfer of fresh, slow frozen and vitrified blastocysts (38.4 weeks, 38.5 weeks, 
and 38.5 weeks, respectively) (Table 5-5). The risk of preterm birth (less than 37 completed 
weeks of gestation) decreased among singletons in the vitrified blastocyst group compared with 
the fresh blastocyst group (ARR: 0.86, 95% CI: 0.77-0.96) (Table 5-6). 
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5.5 DISCUSSION 
This study provides evidence at a population level that vitrification of blastocysts can 
achieve a higher clinical pregnancy rate and live delivery rate with comparable perinatal 
outcomes to those following conventional slow freezing methods. This is the first country-level 
population-based study to investigate the clinical efficacy and perinatal outcomes following 
transfer of fresh, slow frozen and vitrified blastocysts.  
Compared with slow frozen blastocyst transfer cycles, vitrified blastocyst transfer cycles 
resulted in an almost fifty percent higher clinical pregnancy rate and forty percent higher live 
delivery rate. Previous single-center studies have reported comparable if not better clinical 
pregnancy rates of transfer of vitrified blastocysts than those obtained in slow frozen blastocyst 
transfer cycles. A retrospective US study found that the pregnancy rate of vitrified day 5 
blastocysts are significantly increased relative to slow frozen day 5 blastocysts (Stehlik et al., 
2005). A meta-analysis based on four randomized controlled trials (RCTs) of both cleavage 
stage embryos and blastocysts found a significantly higher clinical pregnancy rate (89/230 
versus 128/387; Odds ratio (OR): 1.55, 95% CI: 1.05-2.32) with vitrification compared with 
slow freezing, but no statistically significant difference in the clinical pregnancy rate was found 
between vitrification and slow freezing in sub-analyses for cleavage stage embryos (OR: 2.22, 
95% CI: 0.91-5.43) and blastocysts (OR: 1.32, 95% CI: 0.81-2.17) (AbdelHafez et al., 2010). 
Significantly higher pregnancy rates, delivery rates and implantation rates were reported with 
vitrification compared with slow freezing for both cleavage stage embryos and blastocysts 
(Wong & Wong, 2011). 
The results of this study showed that compared with singletons born after transfer of fresh 
blastocysts, singletons born after transfer of vitrified blastocysts were at 14% less risk of being 
born preterm (ARR: 0.86, 95% CI: 0.77-0.96), 33% less risk of being low birthweight (ARR: 
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0.67, 95% CI: 0.58-0.78), and 40% less risk of being SGA (ARR: 0.60, 95% CI: 0.53-0.68). 
Cohort studies of comparison between perinatal outcomes after fresh blastocyst transfers and 
vitrification of blastocysts are relatively rare. Wikland and colleagues reported significantly 
higher median birthweight (adjusted P-value = 0.0362) and lower proportion of SGA (adjusted 
P-value = 0.0085) among singletons born after transfer of vitrified blastocysts compared to 
those of the fresh blastocysts group after adjusting for maternal body mass index (BMI) and 
parity (Wikland et al., 2010). No significant difference was found for the rate of preterm births 
between the fresh and vitrified blastocysts group in the Wikland study. This was probably 
attributable to the small number of preterm births with only nine preterm births reported in the 
fresh blastocyst group and seven reported in the vitrified blastocyst group. A recent study of 
604 fresh blastocyst transfer cycles and 384 vitrified blastocyst transfer cycles found that babies 
in the vitrified group were heavier than those in fresh group (mean birthweight 3155.35 ± 
590.09g and 3103.81 ± 515.55g, respectively) but no statistically significant difference was 
detected (Feng et al., 2012). A 4-year follow-up study of perinatal outcome following vitrified 
blastocyst transfer found no statistical differences between neonates born after fresh and 
vitrified blastocyst transfer for birthweight and gestational age (Takahashi et al., 2005). As the 
Takahashi study did not distinguish the perinatal outcomes of singletons from multiple births, 
the difference between their findings and those in our study could partially be explained by the 
multiple birth rate of 32.9%.  
Compared with singletons following fresh blastocyst transfer, the likelihood of low 
birthweight births and SGA births were significantly lower for singletons following transfer of 
both slow frozen and vitrified blastocysts. This finding is consistent with previous studies that 
have demonstrated decreased risk of low birthweight and SGA births following cryopreserved 
cycles (Pelkonen et al., 2010; Sazonova et al., 2012) and suggest that this phenomenon is 
related to the nature of cryopreserved cycles rather than the method of cryopreservation (slow 
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freezing or vitrification). A register-based cohort study in Sweden reported significantly 
decreased risks of low birthweight (Adjusted odd ratio (AOR): 0.74, 95% CI: 0.62-0.88) and 
SGA (AOR: 0.63, 95% CI: 0.49-0.83) among births born after frozen embryo transfer 
compared with the fresh embryo transfer group (Pelkonen et al., 2010). Similarly, Sazonova 
and colleagues found a lower rate of low birthweight births among singletons following 
cryopreserved cycles when compared with singletons following fresh cycles (Sazonova et al., 
2012). Our study found the risk of being LGA increased among singletons following transfer 
of slow frozen (ARR: 1.77, 95% CI: 1.57-2.00) and vitrified (ARR: 1.54, 95% CI: 1.40-1.69) 
blastocysts. The underlying mechanism of decreased risk of low birthweight and SGA births, 
and increased risk of LGA births following transfer of slow frozen and vitrified blastocyst is 
not yet known and further studies are required to evaluate the long-term consequences.  
In the present study, the clinical pregnancy rate and live delivery rate following transfer 
of vitrified blastocysts were lower compared to fresh blastocyst transfer cycles. This may be 
because, in clinical settings, slow freezing or vitrification will usually be carried out following 
the selection of the ‘best’ embryo(s) for fresh transfer. Therefore, the cryopreserved embryos 
are on average of poorer quality and correction for quality of embryos are required for 
comparisons of outcomes from fresh and thaw cycles (Edgar & Gook, 2012). Recent studies 
reported similar clinical outcomes from transfer of vitrified blastocysts compared to those of 
fresh blastocyst transfer cycles when similar quality of blastocysts were transferred (Feng et 
al., 2012; Zhu et al., 2011). Feng and colleagues found that fresh and vitrified single-blastocyst 
transfers yield similar clinical pregnancy rates (52.15% and 46.61%, respectively) when a 
similar cohort of blastocysts graded ≥ 3BB was transferred (Feng et al., 2012). Similarly, when 
good quality blastocysts were vitrified, significantly higher clinical pregnancy rate and 
implantation rate were reported in the vitrified group compared with the fresh group for women 
aged less than 40 years undergoing blastocyst transfer cycles (Zhu et al., 2011). A recent 
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systematic review and meta-analysis showed that frozen embryo transfer results in significantly 
higher ongoing pregnancy rates and clinical pregnancy rates compared with fresh embryo 
transfer (Roque et al., 2013).The improved pregnancy rate and perinatal outcomes seen after 
transfer of frozen embryos compared with transfer of fresh embryos maybe related to the 
adverse effects of ovarian hyperstimulation on endometrial receptivity in fresh cycles (Roque 
et al., 2013; Shapiro et al., 2011). However, it should be noted that in clinical practice women 
with an excess of appropriate embryos available for cryopreservation would be expected to 
have better prognosis than women who have only one suitable good quality embryo available 
for a fresh cycle (Wang et al., 2010). Future RCTs should be conducted to investigate whether 
an elective freeze all policy with vitrification can be considered as an alternative embryo 
transfer strategy to avoid the potentially poor endometrial receptivity or ovarian 
hyperstimulation syndrome in fresh cycles. 
A major limitation of this population-based study is the lack of information available on 
clinical- specific cryopreservation protocols and processes for slow freezing-thaw and 
vitrification-warm of blastocysts and the potential impact on outcomes. The protocols for slow 
freezing-thaw and vitrification-warm of blastocysts may vary between clinics. The majority of 
blastocyst vitrification in Australia and New Zealand utilizes methodology involving high 
concentrations of both dimethyl sulphoxide (DMSO) and ethylene glycol (EG) together with a 
non-permeating cryoprotectant (sucrose or trehalose), while some clinics use a method in 
which the DMSO is replaced by propanediol (PROH) at a similar concentration. Currently, 
there is no consensus over which methods of vitrification and warming are optimal (Brison et 
al., 2012). In addition, the quality of embryo transferred may differ across clinics where some 
clinics would only cryopreserve the top-quality embryos to maintain the implantation rate 
while other clinics might wish to keep the reproductive potential of relatively poorer quality 
embryos (Edgar & Gook, 2012). The lack of consistent cryopreservation protocols and 
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comparison of embryo qualities might over-estimate the successful rate of vitrification and 
under-estimate the successful rate of slow freezing of blastocysts. That is, the higher clinical 
pregnancy rate and live delivery rate with vitrified blastocysts might be due to the possibility 
that the clinics with the higher fresh blastocyst implantation rates use vitrification while those 
with lower implantation rates use slow freezing, rather than the superiority of vitrification 
methodology. However, the successful rate of vitrified blastocyst transfer was consistently 
higher than those of slow frozen blastocysts across the study period, even though the use of 
vitrification increased significantly during this period. Vitrification was reported for 73.6% of 
autologous thaw cycles where a blastocyst was transferred in 2011, compared with 33.3% in 
2009. The proportion of slow freezing decreased from 66.7% in 2009 to 26.4% in 2011, while 
the clinical pregnancy rate was relatively stable for vitrification (29.9% in 2009 and 33.3% in 
2011) and slow freezing (24.9% in 2009 and 26.1% in 2011) during the study period 
(Macaldowie et al., 2013; Wang et al., 2011). Another limitation of this study is that although 
this is the largest population-based study reported in this field, the data are observational and 
hence conclusions concerning the biological effects of vitrification and slow freezing cannot 
be drawn from our study. 
5.6 CONCLUSION  
This study presents population-based evidence on clinical efficacy and perinatal 
outcomes after transfer of fresh, slow freezing and vitrification of blastocysts. Compared with 
slow freezing of blastocysts, vitrification of blastocysts resulted in significantly higher clinical 
pregnancy and live delivery rates with comparable perinatal outcomes at population level. At 
a policy level, the comparatively better perinatal outcomes associated with vitrified rather than 
fresh blastocysts demonstrated in this retrospective study provides further evidence for the use 
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of vitrification-warm cycles as one of the strategies to optimize perinatal outcomes following 
ART treatment.  
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Table 5-1 Demographic and obstetric characteristics in women following transfer of fresh, slow frozen and vitrified blastocysts, Australia and 
New Zealand, 2009-2011 
  
Fresh  
(n = 46890) 
Slow freezing  
(n = 11644) 
Vitrification  
(n = 19978) 
Test between groups, P-value 
Vitrification  
versus Fresh 
Vitrification  
versus Slow freezing 
Maternal age, mean(SD) 35.2 (4.7) 33.6 (4.4) 34.2 (4.4) <0.001 <0.001 
Maternal age, n (%) 
   
  
<25 566(1.2) 254(2.2) 329(1.6) 
<0.001 <0.001 
25-29 5215(11.1) 1851(15.9) 2804(14.0) 
30-34 14084(30.0) 4339(37.3) 7060(35.3) 
35-39 17743(37.8) 3970(34.1) 7492(37.5) 
40-44 8936(19.1) 927(8.0) 2244(11.2) 
45+ 346(0.7) 58(0.5) 47(0.2) 
Primiparas, n (%) 28661(61.1) 6057(52.0) 11479(57.5) <0.001 <0.001 
Reason for infertility, n (%) 
   
  
 Male factors 10593(22.6) 2435(20.9) 4577(22.9) 
<0.001 <0.001 
Female factors 14534(31.0) 3897(33.5) 5909(29.6) 
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Combined male/female factors 7833(16.7) 1573(13.5) 3232(16.2) 
Unexplained 13305(28.4) 3456(29.7) 6059(30.3) 
SD, standard deviation. 
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Table 5-2 Clinical parameters among fresh, slow frozen and vitrified blastocysts transfer, Australia and New Zealand, 2009-2011 
 Fresh Slow freezing Vitrification 
Test between groups, P-value 
Vitrification  
versus Fresh 
Vitrification  
versus Slow freezing 
Initiated cycles, n n.a 12852 20887 .. .. 
Embryo transfer cycles, n 46890 11644 19978 .. .. 
Thaw cycles result in transfer, % n.a 90.6 95.6 .. <0.001 
Duration of embryo storage days, mean(SD) n.a 438.2(469.7) 287.8(330.0) .. <0.001 
Total embryos thawed, n n.a 18971 26351 .. .. 
Total embryos transferred, n 58761 13548 22265 .. .. 
Thawed embryos result in transfer, % n.a 71.4 84.5 .. <0.001 
Embryos transferred/cycle, mean(SD) 1.3(0.4) 1.2(0.4) 1.1(0.3) <0.001 <0.001 
No. of embryo transferred, n (%) 
   
  
SET 35173(75.0) 9756(83.8) 17701(88.6) 
<0.001 <0.001 DET 11565(24.7) 1873(16.1) 2267(11.3) 
Three+ 152(0.3) 15(0.1) 10(0.1) 
SD, standard deviation; SET, single embryo transfer; DET, double embryo transfer.
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Table 5-3 Pregnancy outcomes following transfer of fresh, slow frozen and vitrified 
blastocysts, Australia and New Zealand, 2009-2011 
  
Fresh  
(n = 46890) 
Slow freezing  
(n = 11644) 
Vitrification  
(n = 19978) 
Clinical pregnancies 16845 2766 6537 
Miscarriage 3022 589 1314 
Reduction or termination 113 21 47 
Ectopic or heterotopic pregnancy 213 17 60 
Live deliveries 13049 2065 4955 
 
% per thaw cycle 
Clinical pregnancies n.a. 21.5 31.3 
Miscarriage n.a. 4.6 6.3 
Reduction or termination n.a. 0.2 0.2 
Ectopic or heterotopic pregnancy n.a. 0.1 0.3 
Live deliveries n.a. 16.1 23.7 
 
% per embryo transfer cycle 
Clinical pregnancies 35.9 23.8 32.7 
Miscarriage 6.4 5.1 6.6 
Reduction or termination 0.2 0.2 0.2 
Ectopic or heterotopic pregnancy 0.5 0.1 0.3 
Live deliveries 27.8 17.7 24.8 
 
% per clinical pregnancy 
Miscarriage 17.9 21.3 20.1 
Reduction or termination 0.7 0.8 0.7 
Ectopic or heterotopic pregnancy 1.3 0.6 0.9 
Live deliveries 77.5 74.7 75.8 
 
  
  
Chapter 5: Study 3 Clinical outcomes following cryopreservation of blastocysts by vitrification or slow freezing 161 
Table 5-4 Adjusted relative risk for pregnancy outcomes following transfer of slow frozen 
and vitrified blastocysts, Australia and New Zealand, 2009-2011 
  
Slow freezing 
Vitrification 
ARR(95% CI) 
Thawed cycles result in transfera Ref 1.05(1.03,1.08)* 
Pregnancy outcomesb 
  
Clinical pregnancies/thaw cyclea Ref 1.43(1.37,1.50)* 
Clinical pregnancies/embryo transfer Ref 1.38(1.32,1.45)* 
Live deliveries /thaw cyclea Ref 1.47(1.39,1.55)* 
Live deliveries /embryo transfer Ref 1.41(1.34,1.49)* 
Live deliveries /clinical pregnancy Ref 1.02(0.97,1.08) 
Miscarriage /clinical pregnancy Ref 0.91(0.82,1.01) 
Perinatal outcomesb 
  
Perinatal mortality Ref 1.10(0.64,1.89) 
Preterm delivery Ref 0.97(0.75,1.25) 
LBW births Ref 1.08(0.89,1.31) 
SGA birthsc Ref 0.88(0.70,1.10) 
LGA birthsc Ref 0.89 (0.78,1.02) 
a Maternal age, cause of infertility, parity, duration of embryo storage, and number of embryo thawed 
were adjusted in multivariable regression analysis. 
b Maternal age, cause of infertility, parity, duration of embryo storage, number of embryo transferred, 
and IVF/ICSI were adjusted in multivariable regression analysis. 
c 20-42 weeks gestation with known baby sex. 
ARR, Adjusted relative risk; CI, confidence interval; Ref, reference category; *, significant at the .05 
level. 
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Table 5-5 Perinatal outcomes of singletons following transfer of fresh, slow frozen and 
vitrified blastocysts, Australia and New Zealand, 2009-2011 
  
Fresh  
(n = 46890) 
Slow freezing  
(n = 11644) 
Vitrification  
(n = 19978) 
Births, n 12241 1987 4721 
Live births, n 12068 1965 4665 
Fetal deaths, n (rate per 1000 births) 125(10.2) 16(8.1) 42(8.9) 
Perinatal deaths, n (rate per 1000 births) 149(12.2) 20(10.1) 51(10.8) 
Sex, n (%) 
   
Male 6565(53.6) 1086(54.7) 2423(51.3) 
Female 5602(45.8) 894(45.0) 2276(48.2) 
Birthweight, mean (SD) 3276.2(611.6) 3449.7(620.4) 3421.6(590.5) 
Birthweight, n (%) 
   
 <1000 g 115(0.9) 13(0.7) 25(0.5) 
1000-1499 g 97(0.8) 16(0.8) 28(0.6) 
1500-2499 g 693(5.7) 67(3.4) 179(3.8) 
≥2500 g 11121(90.9) 1847(93.0) 4426(93.8) 
SGA, n (%)* 1277(10.5) 122(6.2) 291(6.2) 
LGA, n (%)* 1228(10.1) 372(18.8) 731(15.6) 
Gestational age, mean (SD) 38.4(2.6) 38.5(2.4) 38.5(2.3) 
Gestational age, n (%) 
   
< 28 weeks 174(1.4) 27(1.4) 47(1.0) 
28-31 weeks 143(1.2) 19(1.0) 46(1.0) 
32-36 weeks 937(7.7) 123(6.2) 318(6.7) 
37-41 weeks 10914(89.2) 1798(90.5) 4272(90.5) 
≥ 42 weeks 73(0.6) 20(1.0) 38(0.8) 
SD, standard deviation; SGA, small for gestational ageLGA, large for gestational age;
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Table 5-6 Adjusted relative risk for pregnancy outcomes and perinatal outcomes following 
transfer of fresh, slow frozen and vitrified blastocysts, Australia and New Zealand, 2009-
2011 
  
Fresh 
Slow freezing 
ARR(95% CI)  
Vitrification 
ARR(95% CI)  
Pregnancy outcomesa    
Clinical pregnancies/embryo transfer Ref 0.62(0.59,0.64)* 0.85(0.82,0.87)* 
Live deliveries /embryo transfer Ref 0.58(0.55,0.61)* 0.81(0.79,0.84)* 
Live deliveries /clinical pregnancy Ref 0.94(0.90,0.99)* 0.97(0.93,1.00)* 
Miscarriage /clinical pregnancy Ref 1.31(1.19,1.44)* 1.16(1.09,1.24)* 
Perinatal outcomesa    
Perinatal mortality Ref 0.87(0.53,1.42) 0.92(0.67,1.27) 
Preterm delivery Ref 0.80(0.68,0.96)* 0.86(0.77,0.96)* 
LBW births Ref 0.66(0.53,0.82)* 0.67(0.58,0.78)* 
SGA births(b) Ref 0.64(0.53,0.78)* 0.60(0.53,0.68)* 
LGA births(b) Ref 1.77(1.57,2.00)* 1.54(1.40,1.69)* 
a Maternal age, cause of infertility, parity, number of embryo transferred, IVF/ICSI were adjusted in 
multivariable regression analysis. 
b 20-42 weeks gestation with known baby sex . 
ARR, Adjusted relative risk; CI, confidence interval; LBW, low birthweight; SGA, small for 
gestational age; LGA, large for gestational age; Ref, reference category; *, significant at the .05 level. 
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6.1 ABSTRACT 
Study question: What is the cumulative live birth rate following a ‘freeze-all’ strategy 
compared with a ‘fresh transfer’ strategy? 
Summary answer: The ‘freeze-all’ strategy resulted in a similar cumulative live birth rate as 
the ‘fresh transfer’ strategy among high responders (>15 oocytes) but did not benefit normal 
(10-15 oocytes) and suboptimal responders (<10 oocytes). 
What is known and what this paper adds: Frozen-thawed embryo transfer is associated with 
decreased risk of adverse obstetric and perinatal outcomes compared with fresh embryo 
transfer. It is unclear whether the ‘freeze-all’ strategy should be offered to all women 
undergoing assisted reproductive technology (ART) treatment. Our study provides population-
based evidence of how the type of responder (suboptimal/normal/high) is associated with 
different clinical outcomes following a ‘freeze-all’ compared with a ‘fresh transfer’ strategy, 
and provides further insight into the current cycle-based discussion on whether a ‘freeze-all’ 
strategy is beneficial in women with less than 15 oocytes retrieved. 
Design: A population-based retrospective cohort study using data collected by the Victorian 
Assisted Reproductive Treatment Authority. This study included 14331 women undergoing 
their first stimulated ART cycle with at least one oocyte fertilized between 1 Jul 2009 and 30 
Jun 2014 in Victoria, Australia. Demographic characteristics, type of ART procedures and 
resulting pregnancy and birth outcomes were recorded for the stimulated cycle and associated 
thaw cycles until 30 June 2016, or until a live birth was achieved, or until all embryos from the 
stimulated cycle had been used.  
Participants and setting: Women were grouped by whether they had undergone the ‘freeze-
all’ strategy (n = 1028) where all embryos were cryopreserved for future transfer, or the ‘fresh 
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transfer’ strategy (n = 13303) where selected embryo(s) were transferred in the stimulated 
cycle, and remaining embryo(s) were cryopreserved for future use. A discrete-time survival 
model was used to evaluate the cumulative live birth rate following ‘freeze-all’ and ‘fresh 
transfer’ strategy.  
Main results and the role of chance: A total of 1028 women undergoing ‘freeze-all’ strategy 
and 13303 women undergoing ‘fresh transfer’ strategy had 1788 and 22334 embryo transfer 
cycles resulting in 452 and 5126 live births respectively. Most women (61.3%) in the ‘freeze-
all’ group had more than 15 oocytes retrieved in the stimulated cycle compared with 18.1% of 
women in the ‘fresh transfer’ group (p<0.001). For high responders (>15 oocytes), the 
cumulative live birth rate in the ‘freeze-all’ group was similar to the ‘fresh transfer’ group 
(56.8% vs. 56.2%, adjusted hazard ratio (AHR) 0.90, 95% confidence interval (CI) 0.77–1.04). 
However, the likelihood of a live birth was lower in the ‘freeze-all’ group compared with the 
‘fresh transfer’ group among normal responders (10-15 oocytes) (33.2% vs. 46.3%, AHR 0.62, 
95% CI 0.46–0.83) and suboptimal responders (<10 oocytes) (14.6% vs. 28.0%, AHR 0.67, 
95% CI 0.14–1.01). During the minimum follow-up time of two years, 34.1%, 24.4% and 8.4% 
of suboptimal, normal and high responders in the ‘freeze-all’ group did not return for any 
embryo transfer after the stimulated cycle, whereas all women in the ‘fresh transfer’ group had 
at least one embryo transferred in the stimulated cycle.  
Bias, confounding factors and other reasons for caution: A limitation of this population-
based study is the lack of information available on clinic-specific protocols for the ‘freeze-all’ 
strategy and the potential impact of these on outcomes. Data were not available on whether the 
‘freeze-all’ strategy was used to prevent ovarian hyperstimulation syndrome. 
Generalizability to other populations: This study presents population-based evidence on 
clinical efficacy associated with a ‘freeze-all’ and ‘fresh transfer’ strategy. The ‘freeze-all’ 
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strategy may benefit some subgroups of patients, including women who are high responders 
and those who are at risk of ovarian hyperstimulation syndrome, but should not be offered 
universally. Clinicians should consider the potential impact of electively deferring embryo 
transfer on treatment discontinuation in choosing the optimal embryo transfer strategy for 
couples undergoing ART treatment. 
Study funding/competing interest(s): No specific funding was received to undertake this 
study. There is no conflict of interest, except that M.B. is a shareholder in Genea Ltd. 
Keywords: assisted reproductive technology; freeze-only; cryopreservation; cumulative 
rates; live birth; embryo transfer 
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6.2 LAY SUMMARY 
A ‘fresh transfer’ strategy means that one or two embryos are transferred at the end of 
the stimulated cycle and any additional embryos are frozen for later use. A ‘freeze-all’ strategy 
means that all embryos available after a stimulated cycle are frozen and transferred in 
unstimulated cycles when it is thought that the environment in the uterus is more favorable. 
The ‘freeze-all’ strategy is increasingly being offered to couples going through assisted 
reproductive technology treatment. This study looks at whether the ‘freeze-all’ strategy makes 
a difference to the chances of a live birth compared with the ‘fresh transfer’ strategy. 
In this study we analyzed data from women who had their first stimulated cycle between 
1 Jul 2009 and 30 Jun 2014 in Victoria, Australia and recorded all births for cycles they had up 
until 30 June 2016. Women were classified into three groups: high responders who had more 
than 15 eggs retrieved, normal responders with 10-15 eggs and suboptimal responders with less 
than 10 eggs. The chance of a live birth was similar for the ‘fresh transfer’ and the ‘freeze-all’ 
strategy in high responders. However, the ‘freeze-all’ strategy resulted in a lower chance of a 
live birth than the ‘fresh transfer’ strategy in normal and suboptimal responders.  
Based on our findings we conclude that the ‘freeze-all’ strategy may be beneficial in high 
responders but should not be offered to women who have fewer than 15 eggs retrieved in the 
stimulated cycle. 
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6.3 INTRODUCTION 
The ‘fresh transfer’ strategy where the selected embryo(s) are transferred in the 
stimulated cycle (fresh embryo transfer), and any remaining embryos are cryopreserved for 
future use, is currently the most common strategy in assisted reproductive technology (ART) 
practice. However, in recent years the ‘freeze-all’ strategy where all embryos are cryopreserved 
for future transfer in subsequent cycles (frozen-thawed embryo transfer) is increasingly being 
favored (Blockeel et al., 2016; Coutifaris, 2017). In the United States, the proportion of cycles 
with embryo cryopreservation without fresh transfer has increased from 7.9% in 2004 to 40.7% 
in 2013 (Christianson et al., 2017). In Australia, the proportion of ‘freeze-all’ cycles increased 
from 4.1% of initiated fresh cycles in 2010 to 18.1% in 2015 (Fitzgerald et al., 2017; Harris et 
al., 2016).  The most common reasons for freezing all embryos are to avoid ovarian 
hyperstimulation syndrome (OHSS), the use of pre-implantation genetic diagnosis or 
screening, and to allow the embryos to be transferred in an unstimulated cycle when the 
intrauterine environment is presumed to be more favorable (Devroey et al., 2011; Evans et al., 
2014; Roque, 2015; Roque et al., 2017b).  
Cycle-based studies have found that frozen-thawed embryo transfer is associated with 
decreased risk of adverse obstetric and perinatal outcomes compared with fresh embryo 
transfer. Several large retrospective cohort studies and systematic reviews have shown 
significantly reduced risk of ectopic pregnancy,  preterm birth, low birthweight and small for 
gestational age in frozen-thawed embryo transfer compared with fresh embryo transfer 
(Ishihara et al., 2014; Li et al., 2015; Li et al., 2014a; Maheshwari et al., 2018; Sazonova et al., 
2012; Zhao et al., 2016).  
Despite the apparent obstetric and perinatal benefits of frozen-thawed embryo transfer, 
it is not known if adopting the ‘freeze-all’ strategy for all couples undergoing ART treatment 
outweigh the downsides of this strategy (Ata & Seli, 2017; Coutifaris, 2016, 2017; Isikoglu, 
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2016). They include the potential degeneration or loss of embryos during the freezing and 
thawing processes, the added financial costs, the emotional costs of deferring transfer, and the 
increased risks of having a large for gestational age baby and maternal hypertensive disorders 
(Coutifaris, 2016; Isikoglu, 2016; Li et al., 2014b; Maheshwari et al., 2018; Pinborg et al., 
2014). Most importantly, there is lack of consensus about whether a ‘freeze-all’ strategy can 
improve the clinical efficacy in terms of live birth rate (Ata & Seli, 2017; Blockeel et al., 2016; 
Roque et al., 2018; Roque et al., 2017b; Zhu et al., 2018).  
To date, there have been only a limited number of ‘freeze-all’ versus ‘fresh transfer’ 
RCTs and they have been restricted mostly to high responders (Wong et al., 2017). A recent 
systematic review and meta-analysis based on five randomized clinical trials reported that the 
‘freeze-all’ strategy could be favorable when high numbers of oocytes are retrieved in the 
stimulated cycle but did not appear to be advantageous when the mean number of oocytes 
retrieved was less than 15 (Dieamant et al., 2017). There are few existing studies on the clinical 
efficacy of a ‘freeze-all’ strategy among suboptimal (<10 oocytes) and normal responders (10 
– 15 oocytes). In Australia and New Zealand, most (60.0%) women undergoing oocyte retrieval 
in 2015 had less than 10 oocytes retrieved and only one in six (16.4%) had 15 or more oocytes 
retrieved (Fitzgerald et al., 2017). It is therefore critical to examine the clinical efficacy of a 
‘freeze-all’ strategy in women who have fewer than 15 oocytes retrieved. Moreover, there are 
currently no patient-based data on the cumulative live birth rate from the ‘freeze-all’ strategy 
compared with the ‘fresh transfer’ strategy to inform couples who have embryos available for 
transfer after a stimulated cycle. The aim of this population-based study was to investigate the 
cumulative live birth rate following a ‘freeze-all’ compared with a ‘fresh transfer’ strategy by 
the number of oocytes retrieved in the stimulated cycle.  
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6.4 MATERIALS AND METHODS 
6.4.1 Study design 
A retrospective population-based cohort study of women who had their first ever 
stimulated cycle with at least one oocyte fertilized between 1 July 2009 and 30 June 2014 in 
the state of Victoria, Australia was conducted using data collected by the Victorian Assisted 
Reproductive Treatment Authority (VARTA). VARTA is a statutory authority which records 
details of initiated ART treatments undertaken in all fertility clinics in Victoria, including 
demographic characteristics, type of ART treatment and resulting pregnancy and birth 
outcomes (VARTA, 2015). Approximately 30% of all ART treatment cycles undertaken in 
Australia are performed in Victoria (Harris et al., 2016). 
6.4.2 Study population and follow-up 
Between July 2009 and June 2014, 15403 women had their first ever stimulated cycle 
with at least one oocyte fertilized. Women who had preimplantation genetic diagnosis (3.3%), 
mixed fresh-frozen cycles where embryos from a subsequent stimulated cycles were added to 
the frozen embryo from the first stimulated cycle (1.2%) and women had no embryo transferred 
or cryopreserved (2.5%) were excluded (Figure 6-1). A total of 1028 women undergoing 
‘freeze-all’ strategy and 13303 women undergoing ‘fresh transfer’ strategy who had 2868 and 
22832 initiated cycles respectively (a stimulated cycle with embryos transferred or 
cryopreserved for future transfer, or a thaw cycle where frozen embryos were thawed with the 
intention to transfer), were included in the data analysis. 
Data were collated on treatment and clinical outcomes following the first oocyte retrieval 
(stimulated cycle and associated thaw cycles). The women were followed-up until 30 June 
2016, or until a live birth was achieved, or all embryos from the first oocyte retrieval had been 
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used. Cycles up to and including the first live birth were included, and cycles after the first live 
birth were excluded. 
6.4.3 Study variables and outcome measures 
Women were grouped by whether they had undergone the ‘freeze-all’ strategy where no 
fresh embryo(s) were transferred in the stimulated cycle and all resulting embryos were 
cryopreserved for transfer in subsequent cycles, or the ‘fresh transfer’ strategy where the 
selected embryo(s) were transferred in the stimulated cycle, and remaining embryos were 
cryopreserved for future use. The woman’s and partner’s age were recorded in completed years 
of age at the first stimulated cycle. Women were classified as high responders (>15 oocytes), 
normal responders (10-15 oocytes) and suboptimal responders (<10 oocytes) based on the 
number of oocytes retrieved in the stimulated cycle (Drakopoulos et al., 2016; Roque et al., 
2017a). 
The primary outcome was the cumulative live birth rate, defined as live deliveries (at 
least one live birth) per woman following the ‘freeze-all’ or ‘fresh transfer’ strategy. A live 
birth was deﬁned as a baby showing signs of life with gestational age ≥ 20 weeks or birthweight 
≥ 400 grams. The observed cumulative live birth rate was reported using the conservative 
assumption that women who did not return for treatment did not have a pregnancy resulting in 
a live birth. The optimal cumulative live birth rate was based on the assumption that eligible 
women who did not return for treatment would have had the same live birth rate as those who 
did return. 
6.4.4 Statistical analysis 
Chi-square test or Fisher's exact test for categorical variables and Mann-Whitney U-test 
for continuous variables were used to examine differences between the ‘freeze-all’ and ‘fresh 
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transfer’ groups regarding demographic, clinical and treatment characteristics, respectively. A 
discrete-time survival model was used to evaluate the number of cycles to live birth following 
‘freeze-all’ and ‘fresh transfer’ strategy (Mills, 2011). The adjusted hazard ratio (AHR) and 
95% confidence intervals (CI) were calculated by the number of oocytes retrieved in the 
stimulated cycle. Adjustment was made for year of the first stimulated cycle, the woman’s and 
the male partner’s age at first stimulated cycle, parity (nullipara/multipara), cause of infertility 
(male only/female only/combined male-female/unexplained), OHSS (yes/no), method of 
fertilization (IVF/ICSI/mixed IVF-ICSI), stage of transferred embryos (cleavage stage 
embryo/blastocyst) and the number of embryos transferred. A p-value <0.05 or a CI not 
including 1 were considered statistically significant. All statistical analysis was performed 
using SPSS 24.0 software (Armonk, NY, USA: IBM Corp.) and R version 3.4.1 (R Core Team, 
2013). 
6.4.5 Ethics 
Ethics approval for this study was granted by the Human Research Ethics Committee of 
the University of Technology Sydney, Australia (Reference NO. 2015000341). Access to the 
VARTA data was granted by VARTA. 
6.5 RESULTS 
The study population included 1028 women undergoing ‘freeze-all’ strategy and 13303 
women undergoing ‘fresh transfer’ strategy who had 1788 and 22334 embryo transfer cycles 
resulting in 452 and 5126 live births respectively. In the study period, the proportion of women 
undergoing the ‘freeze-all’ strategy increased from 4.1% in 2009 to 12.2% in 2014, while the 
proportion of women who developed OHSS remained relatively stable (1.3% in 2009 and 1.6% 
in 2014). 
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Table I presents the demographic and clinical characteristics of the study population by 
number of oocytes retrieved in the stimulated cycle. Among women with <10 oocytes, the 
proportions having OHSS were similar in the ‘freeze-all’ and ‘fresh transfer’ groups (0.5% vs. 
0.1%, p=0.273). However, among those with 10-15 oocytes and >15 oocytes, the proportion 
with OHSS was higher in the ‘freeze-all’ than in the ‘fresh transfer’ group (5.7% vs. 0.6%, 
p<0.001; 13.2% vs. 3.0%, p<0.001; respectively)   (Table 6-1). 
The majority (61.3%) of women in the ‘freeze-all’ group were classified as high 
responders with more than 15 oocytes retrieved in the stimulated cycle, while more than half 
(52.4%) of the women in the ‘fresh transfer’ group were classified as suboptimal responders 
with less than 10 oocytes retrieved (p<0.001). A higher proportion of blastocysts were 
transferred among suboptimal (<10 oocytes) and normal (10-15 oocytes) responders in the 
‘freeze-all’ group compared with the ‘fresh transfer’ group (31.7% vs. 24.2%, p=0.014; 57.4% 
vs. 44.0%, p<0.001; respectively) (Table 6-2). 
The cumulative live birth rates by number of oocytes retrieved in the stimulated cycle are 
shown in Table 6-3 and Figure 6-2. The ‘freeze-all’ group had a similar observed cumulative 
live birth rate compared with the ‘fresh transfer’ group among high responders (56.8% vs. 
56.2%) but a lower cumulative live birth rate among normal (33.2% vs. 46.3%) and suboptimal 
responders (14.6% vs. 28.0%). Among suboptimal and normal responders, the adjusted overall 
likelihood of a live birth was significantly lower for women undergoing the ‘freeze-all’ strategy 
than for those undergoing the ‘fresh transfer’ strategy (AHR 0.67, 95% CI 0.45–1.01 and AHR 
0.62, 95% CI 0.46–0.83, respectively). Among high responders the adjusted likelihood of a 
live birth in the ‘freeze-all’ group was not significantly different to women in the ‘fresh 
transfer’ group (AHR 0.90, 95% CI 0.77–1.04).  
The cycle-specific live birth rates by the number of oocytes retrieved in the stimulated 
cycle are reported in Supplementary Table 6-4 to Supplementary Table 6-7. Approximately 
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one in twelve (8.4%) high responders with at least one cryopreserved embryo in the ‘freeze-
all’ group did not return for any embryo transfer during the minimum follow-up time of two 
years. This proportion increased to 24.4% among normal responders and 34.1% among 
suboptimal responders, whereas all women in the ‘fresh transfer’ group had at least one embryo 
transferred in the stimulated cycle.   
6.6 DISCUSSION 
To our knowledge, this is the first population-based cohort study to investigate the 
cumulative live birth rates following ‘freeze-all’ strategy and ‘fresh transfer’ strategy. 
Moreover, this is the first population-based study to evaluate the clinical efficacy of the ‘freeze-
all’ strategy based on the number of oocytes retrieved in the stimulated cycle. Our study showed 
that, compared with a ‘fresh transfer’ strategy, the ‘freeze-all’ strategy resulted in a similar 
cumulative live birth rate among high responders but significantly lower cumulative live birth 
rates among normal and suboptimal responders. This suggests that a universal ‘freeze-all’ 
strategy is not warranted.  
The finding that the ‘freeze-all’ strategy resulted in a similar cumulative live birth rate 
among high responders compared with the ‘fresh transfer’ strategy, which is consistent with 
previous RCTs. The nine RCTs that have evaluated the live birth rate following a ‘freeze-all’ 
strategy compared with a ‘fresh transfer’ strategy were all performed in normal or high 
responders where the minimum average number of oocytes retrieved was 12 in both groups 
(Aflatoonian et al., 2018; Aghahosseini et al., 2017; Chen et al., 2016; Coates et al., 2017; 
Ferraretti et al., 1999; Shapiro et al., 2011a, 2011b; Shi et al., 2018; Vuong et al., 2018). A 
recent systematic review and meta-analysis based on five of these RCTs reported cumulative 
live birth rate (Chen et al., 2016; Ferraretti et al., 1999; Shapiro et al., 2011a, 2011b; Vuong et 
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al., 2018) showed no differences in cumulative live birth rates between the ‘freeze-all’ and 
‘fresh transfer’ strategies (risk ratio 1.04, 95% CI 0.97-1.11) (Roque et al., 2019).   
The results of our study demonstrate that a ‘freeze-all’ strategy is associated with reduced 
likelihood of a live birth in suboptimal and normal responders compared with a ‘fresh transfer’ 
strategy. There are few existing studies on the clinical efficacy of a ‘freeze-all’ strategy among 
suboptimal and normal responders. The findings from our study are consistent with the recent 
cycle-based U.S. study of 82,935 cycles from the Society for Assisted Reproductive 
Technology (SART) registry. Acharya et al. examined the live birth rate following the first 
embryo transfer cycle and found that it was higher with the ‘freeze-all’ strategy than the ‘fresh 
transfer’ strategy in women with 15 or more oocytes retrieved (52.0% vs. 48.9%) but not in 
those with 1-5 (11.5% vs. 25.9%) or 6-14 oocytes (35.3% vs. 41.2%) retrieved (Acharya, et al., 
2018).  Neither VARTA nor SART data could differentiate between women who had an 
elective ‘freeze-all’ strategy and women who had a ‘freeze-all’ strategy due to elevated risk of 
OHSS or premature rise in progesterone which is associated with a poorer prognosis. 
Therefore, the inclusion of women who had a ‘freeze-all’ strategy due to premature rise in 
progesterone could partially explain the reduced likelihood of a live birth observed among 
suboptimal and normal responders in our study and the U.S. SART registry study (Acharya et 
al., 2018). In contrast, a recent meta-analysis (Bosdou et al., 2018) based on two RCTs reported 
comparable live birth rates (relative risk: 0.99, 95% CI: 0.91 – 1.07) in the ‘freeze-all’ and 
‘fresh transfer’ strategy in ovulatory women (Shi et al., 2018) and women without PCOS 
(Vuong et al., 2018). A cohort study of 938 IVF cycles performed in a private IVF center found 
that the ‘freeze-all’ group had a higher ongoing pregnancy rate after the first embryo transfer 
than the ‘fresh transfer’ group in women with 10-15 oocytes retrieved (47% vs 34%, p=0.021) 
and a similar ongoing pregnancy rate in women with 4-9 oocytes retrieved in the stimulated 
cycle (33% vs. 31%, p=0.577) (Roque et al., 2017a). The differences between the findings in 
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Roque et al.’s study and the findings in our study are likely attributable to the different outcome 
measurements used.  While Roque et al. performed cycle-based analysis of women who 
returned for their first embryo transfer cycle, our study took into account couples who 
underwent multiple embryo transfer cycles and those who did not return for embryo transfer. 
In our population-based study, a proportion of women in the ‘freeze-all’ group who did not 
return for thaw cycles whereas all women in the ‘fresh transfer’ group had at least one embryo 
transferred in the stimulated cycle.  
The findings from our large population-based cohort study add to the body of evidence 
about the efficacy of a ‘freeze-all’ versus a ‘fresh transfer’ strategy. Although several large 
RCTs of high responders have shown comparable live birth rates following ‘freeze-all’ strategy 
and ‘fresh transfer’ strategy, this is the first population-based study to compare the efficacy of 
the ‘freeze-all’ strategy with the ‘fresh transfer’ strategy in suboptimal and normal responders. 
In addition, the primary outcome of our study was cumulative live birth rate which provides 
more meaningful information than cycle-based data for couples undergoing multiple cycles 
following one oocyte retrieval. Three of the five RCTs included in the Roque et al.’s systematic 
review and meta-analysis  reported significantly higher pregnancy or live birth rates per first 
transfer for women in the ‘freeze-all’ group compared with those in the ‘fresh transfer’ group 
(Chen et al., 2016; Shapiro et al., 2011a, 2011b)  but no group difference in cumulative live 
birth rate per women randomized (Roque et al., 2019). One of the largest RCT to date had over 
1500 women with PCOS randomized and included in the analysis (Chen et al., 2016). In this 
study Chen and colleagues reported that women in the ‘freeze-all’ group had a significantly 
higher live birth rate after the first transfer compared with those in the ‘fresh transfer’ group 
(49.3% (n=368 out of 746) vs. 42.0% (n=320 out of 762), rate ratio 1.17, 95% CI: 1.05 – 1.31) 
(Chen et al., 2016). However, the calculated cumulative live birth rate per women randomized 
included in the systematic review and meta-analysis showed no differences between the two 
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groups (62.3% (n=465 out of 746) vs. 59.7% (n=455 out of 762), rate ratio 1.04, 95% CI: 0.96 
– 1.13)(Roque et al., 2019).  
Last but not least, our population-based study provides real-world evidence on the 
clinical efficacy of a ‘freeze-all’ strategy. Couples who do not return for treatment would be 
minimized in a highly controlled RCT and therefore the non-technical factors associated with 
discontinuing treatment (i.e. emotional stress due to poor prognosis and delay in transfer, 
increased financial cost, etc.) would have minimal impact on the outcome measurements of the 
well-designed RCTs. However, these non-technical factors play a critical role in real-world 
clinical practice and the potential benefits of a ‘freeze-all’ strategy could be offset by these 
operational challenges (Zuidgeest et al., 2017). The high rates of discontinuing treatment 
among normal and suboptimal responders (24.4% and 34.1% respectively) in the ‘freeze-all’ 
group largely explained why women with lower number of oocytes retrieved in the stimulated 
cycle did not benefit from the ‘freeze-all’ strategy. A review of 22 studies on reasons for 
patients discontinue fertility treatment reported that the leading causes for discontinuation were 
postponement of treatment (39.2%), physical and psychological burden (19.1%), and relational 
and personal problems (16.7%) (Gameiro et al., 2012). In addition, our study observed a strong 
negative correlation between the number of oocytes retrieved in the stimulated cycle and the 
proportion of women in the ‘freeze-all’ group who did not return for embryo transfer, which 
suggested that poor prognosis may have influenced couples’ decision to not return for 
treatment.  Clinicians should take into consideration the risk of couples discontinuing treatment 
when electively deferring embryo transfer in the ‘freeze-all’ strategy. 
A limitation of our study is the lack of information available on clinic-specific protocols 
for the ‘freeze-all’ strategy (for example intention-to-treat, embryo quality, and 
cryopreservation techniques) and the potential impact of these on the outcomes. Protocols for 
the ‘freeze-all’ strategy may vary between clinics. In addition, there is no information about 
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whether the ‘freeze-all’ strategy was used to prevent OHSS or whether the embryos were 
electively cryopreserved for other reasons.  Further data from RCTs adjusting for intention-to-
treat and clinical-specific protocols are required to evaluate the effectiveness of ‘freeze-all’ 
compared with ‘fresh transfer’ strategy. Nevertheless, the OHSS rate in our study population 
was relatively stable during the study period which suggests that the increase in the use of the 
‘freeze-all’ strategy was for reasons other than preventing OHSS. Furthermore, approximately 
2.5% of the women with at least one oocyte fertilized had no embryo transferred or frozen in 
the stimulated cycle and were excluded from the analysis. It is not known if the plan was for 
these women to have the ‘fresh transfer’ or ‘freeze-all’ strategy, which may over or under-
estimate the efficacy of the ‘freeze-all’ strategy. In addition, compared with the women in the 
‘fresh transfer’ group, a significantly higher proportion of the women in the ‘freeze-all’ group 
had not used all the embryos from the stimulated cycle by the end of the minimum 2-year 
follow-up period. Maheshwari et al. proposed a three-step approach to report short, medium 
and long-term cumulative live birth rates, which allowed a 2-year, 5-year and 10 years follow-
up period, respectively (Maheshwari et al., 2015). Further studies are required to examine the 
medium and long-term efficacy of ‘freeze-all’ compared with ‘fresh transfer’ strategy.   
This population-based study found the cumulative live birth rate following the ‘freeze-
all’ was similar to ‘fresh transfer’ strategy among high responders but was consistently lower 
than the ‘fresh transfer’ strategy among suboptimal and normal responders.  Clinicians should 
consider the potential impact of electively deferring embryo transfer on treatment 
discontinuation when choosing the optimal embryo transfer strategy for couples undergoing 
ART treatment. The ‘freeze-all’ strategy may benefit some subgroups of patients, including 
women who are high responders and those who are at risk of OHSS, but should not be offered 
universally. 
  
Chapter 6: Study 4 Cumulative live birth rate following freeze-only versus conventional fresh transfer cycles 180 
6.7 AUTHOR’S ROLES 
All the authors were involved in the design of the study and interpretation of data. Z.L 
drafted the manuscript. Z.L and A.Y.W conducted the data analysis. M.B, K.H, C.F, L.J, N.S 
and E.A.S have revised the manuscript critically for important intellectual content. All authors 
approved the final version of the article. 
6.8 ACKNOWLEDGEMENTS  
The authors acknowledge the contribution of Victorian fertility clinics in the provision 
of data to VARTA. 
6.9 FUNDING 
No specific funding was received to undertake this study. 
6.10 CONFLICT OF INTEREST  
There is no conflict of interest, except that M.B. is a shareholder in Genea Ltd, a company 
that provides assisted conception services.   
  
Chapter 6: Study 4 Cumulative live birth rate following freeze-only versus conventional fresh transfer cycles 181 
6.11 REFERENCES 
Acharya, K. S., Acharya, C. R., Bishop, K., Harris, B., Raburn, D., & Muasher, S. J. (2018). 
Freezing of all embryos in in vitro fertilization is beneficial in high responders, but 
not intermediate and low responders: an analysis of 82,935 cycles from the Society 
for Assisted Reproductive Technology registry. Fertility and Sterility, 110(5), 880-
887. doi:10.1016/j.fertnstert.2018.05.024 
Aflatoonian, A., Mansoori-Torshizi, M., Farid Mojtahedi, M., Aflatoonian, B., Khalili, M. A., 
Amir-Arjmand, M. H., . . . Humaidan, P. (2018). Fresh versus frozen embryo transfer 
after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing 
hormone antagonist cycles among high responder women: A randomized, multi-
center study. International Journal of Reproductive Biomedicine (Yazd, Iran), 16(1), 
9-18.  
Aghahosseini, M., Aleyasin, A., Sarfjoo, F. S., Mahdavi, A., Yaraghi, M., & Saeedabadi, H. 
(2017). In vitro fertilization outcome in frozen versus fresh embryo transfer in women 
with elevated progesterone level on the day of HCG injection: An RCT. International 
Journal of Reproductive Biomedicine (Yazd, Iran), 15(12), 757-762.  
Ata, B., & Seli, E. (2017). A universal freeze all strategy: why it is not warranted. Current 
Opinion in Obstetrics and Gynecology, 29(3), 136-145. 
doi:10.1097/GCO.0000000000000362 
Blockeel, C., Drakopoulos, P., Santos-Ribeiro, S., Polyzos, N. P., & Tournaye, H. (2016). A 
fresh look at the freeze-all protocol: a SWOT analysis. Human Reproduction, 31(3), 
491-497. doi:10.1093/humrep/dev339 
Bosdou, J., Venetis, C., Tarlatzis, B., Grimbizis, G., & Kolibianakis, E. (2018). Higher 
probability of pregnancy after frozen-embryo transfer using a freeze-all policy 
  
Chapter 6: Study 4 Cumulative live birth rate following freeze-only versus conventional fresh transfer cycles 182 
compared to fresh-embryo transfer in high, but not in normal responder patients: a 
meta-analysis. Human Reproduction, 33(suppl_1), i132.  
Chen, Z. J., Shi, Y., Sun, Y., Zhang, B., Liang, X., Cao, Y., . . . Legro, R. S. (2016). Fresh 
versus frozen embryos for infertility in the polycystic ovary syndrome. New England 
Journal of Medicine, 375(6), 523-533. doi:10.1056/NEJMoa1513873 
Christianson, M. S., Sun, F., Zhang, H., Stern, J. E., & Polotsky, A. J. (2017). Trends in 
utilization of cryopreserved embryos in the United States from 2004-2013: an analysis 
of 411,811 cycles. Human Reproduction, 32(suppl_1), i496-i497.  
Coates, A., Kung, A., Mounts, E., Hesla, J., Bankowski, B., Barbieri, E., . . . Munne, S. 
(2017). Optimal euploid embryo transfer strategy, fresh versus frozen, after 
preimplantation genetic screening with next generation sequencing: a randomized 
controlled trial. Fertility and Sterility, 107(3), 723-730 e723. 
doi:10.1016/j.fertnstert.2016.12.022 
Coutifaris, C. (2016). "Freeze Only"--An Evolving Standard in Clinical In Vitro Fertilization. 
New England Journal of Medicine, 375(6), 577-579. doi:10.1056/NEJMe1606213 
Coutifaris, C. (2017). Freeze-only in vitro fertilization cycles for all? Fertility and Sterility, 
108(2), 233-234. doi:10.1016/j.fertnstert.2017.06.028 
Devroey, P., Polyzos, N. P., & Blockeel, C. (2011). An OHSS-Free Clinic by segmentation of 
IVF treatment. Human Reproduction, 26(10), 2593-2597. doi:10.1093/humrep/der251 
Dieamant, F. C., Petersen, C. G., Mauri, A. L., Comar, V., Mattila, M., Vagnini, L. D., . . . 
Franco, J. G., Jr. (2017). Fresh embryos versus freeze-all embryos - transfer 
strategies: Nuances of a meta-analysis. JBRA Assisted Reproduction, 21(3), 260-272. 
doi:10.5935/1518-0557.20170048 
Drakopoulos, P., Blockeel, C., Stoop, D., Camus, M., de Vos, M., Tournaye, H., & Polyzos, 
N. P. (2016). Conventional ovarian stimulation and single embryo transfer for 
  
Chapter 6: Study 4 Cumulative live birth rate following freeze-only versus conventional fresh transfer cycles 183 
IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates 
after utilization of all fresh and frozen embryos? Human Reproduction, 31(2), 370-
376. doi:10.1093/humrep/dev316 
Evans, J., Hannan, N. J., Edgell, T. A., Vollenhoven, B. J., Lutjen, P. J., Osianlis, T., . . . 
Rombauts, L. J. (2014). Fresh versus frozen embryo transfer: backing clinical 
decisions with scientific and clinical evidence. Human Reproduction Update, 20(6), 
808-821. doi:10.1093/humupd/dmu027 
Ferraretti, A. P., Gianaroli, L., Magli, C., Fortini, D., Selman, H. A., & Feliciani, E. (1999). 
Elective cryopreservation of all pronucleate embryos in women at risk of ovarian 
hyperstimulation syndrome: efficiency and safety. Human Reproduction, 14(6), 1457-
1460. doi:10.1093/humrep/14.6.1457 
Fitzgerald, O., Harris, K., Paul, R., & Chambers, G. (2017). Assisted reproductive technology 
in Australia and New Zealand 2015. Sydney: National Perinatal Epidemiology and 
Statistics Unit, the University of New South Wales. 
Gameiro, S., Boivin, J., Peronace, L., & Verhaak, C. M. (2012). Why do patients discontinue 
fertility treatment? A systematic review of reasons and predictors of discontinuation 
in fertility treatment. Human Reproduction Update, 18(6), 652-669. 
doi:10.1093/humupd/dms031 
Harris, K., Fitzgerald, O., Paul, R., Macaldowie, A., Lee, E., & Chambers, G. (2016). 
Assisted reproductive technology in Australia and New Zealand 2014. Retrieved from 
Sydney:  
Ishihara, O., Araki, R., Kuwahara, A., Itakura, A., Saito, H., & Adamson, G. D. (2014). 
Impact of frozen-thawed single-blastocyst transfer on maternal and neonatal outcome: 
an analysis of 277,042 single-embryo transfer cycles from 2008 to 2010 in Japan. 
Fertility and Sterility, 101(1), 128-133. doi:10.1016/j.fertnstert.2013.09.025 
  
Chapter 6: Study 4 Cumulative live birth rate following freeze-only versus conventional fresh transfer cycles 184 
Isikoglu, M. (2016). Is it too early for a major change? A critical objection to the freeze all 
policy. Archives of Gynecology and Obstetrics, 293(6), 1359-1360. 
doi:10.1007/s00404-016-4039-4 
Li, Z., Sullivan, E. A., Chapman, M., Farquhar, C., & Wang, Y. A. (2015). Risk of ectopic 
pregnancy lowest with transfer of single frozen blastocyst. Human Reproduction, 
30(9), 2048-2054. doi:10.1093/humrep/dev168 
Li, Z., Wang, Y. A., Ledger, W., Edgar, D. H., & Sullivan, E. A. (2014a). Clinical outcomes 
following cryopreservation of blastocysts by vitrification or slow freezing: a 
population-based cohort study. Human Reproduction, 29(12), 2794-2801. 
doi:10.1093/humrep/deu246 
Li, Z., Wang, Y. A., Ledger, W., & Sullivan, E. A. (2014b). Birthweight percentiles by 
gestational age for births following assisted reproductive technology in Australia and 
New Zealand, 2002-2010. Human Reproduction, 29(8), 1787-1800. 
doi:10.1093/humrep/deu120 
Maheshwari, A., McLernon, D., & Bhattacharya, S. (2015). Cumulative live birth rate: time 
for a consensus? Human Reproduction, 30(12), 2703-2707. 
doi:10.1093/humrep/dev263 
Maheshwari, A., Pandey, S., Amalraj Raja, E., Shetty, A., Hamilton, M., & Bhattacharya, S. 
(2018). Is frozen embryo transfer better for mothers and babies? Can cumulative 
meta-analysis provide a definitive answer? Human Reproduction Update, 24(1), 35-
58. doi:10.1093/humupd/dmx031 
Mills, M. (2011). Introducing survival and event history analysis. In (pp. 1 online resource 
(xx, 279 p.)). Retrieved from 
https://www.lib.uts.edu.au/goto?url=http://methods.sagepub.com/book/introducing-
survival-and-event-history-analysis  
  
Chapter 6: Study 4 Cumulative live birth rate following freeze-only versus conventional fresh transfer cycles 185 
Pinborg, A., Henningsen, A. A., Loft, A., Malchau, S. S., Forman, J., & Andersen, A. N. 
(2014). Large baby syndrome in singletons born after frozen embryo transfer (FET): 
is it due to maternal factors or the cryotechnique? Human Reproduction, 29(3), 618-
627. doi:10.1093/humrep/det440 
R Core Team. (2013). R: A language and environment for statistical computing. In: R 
Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-
project.org/. 
Roque, M. (2015). Freeze-all policy: is it time for that? Journal of Assisted Reproduction and 
Genetics, 32(2), 171-176. doi:10.1007/s10815-014-0391-0 
Roque, M., Haahr, T., Esteves, S. C., & Humaidan, P. (2018). The ‘Big Freeze’: freeze-all 
should not be used for everyone. Human Reproduction, 33(8), 1577-1578. 
doi:10.1093/humrep/dey218 
Roque, M., Haahr, T., Geber, S., Esteves, S. C., & Humaidan, P. (2019). Fresh versus 
elective frozen embryo transfer in IVF/ICSI cycles: a systematic review and meta-
analysis of reproductive outcomes. Human Reproduction Update, 25(1), 2-14. 
doi:10.1093/humupd/dmy033 
Roque, M., Valle, M., Guimaraes, F., Sampaio, M., & Geber, S. (2017a). Freeze-all cycle for 
all normal responders? Journal of Assisted Reproduction and Genetics, 34(2), 179-
185. doi:10.1007/s10815-016-0834-x 
Roque, M., Valle, M., Kostolias, A., Sampaio, M., & Geber, S. (2017b). Freeze-all cycle in 
reproductive medicine: current perspectives. JBRA Assisted Reproduction, 21(1), 49-
53. doi:10.5935/1518-0557.20170012 
Sazonova, A., Kallen, K., Thurin-Kjellberg, A., Wennerholm, U. B., & Bergh, C. (2012). 
Obstetric outcome in singletons after in vitro fertilization with cryopreserved/thawed 
embryos. Human Reproduction, 27(5), 1343-1350. doi:10.1093/humrep/des036 
  
Chapter 6: Study 4 Cumulative live birth rate following freeze-only versus conventional fresh transfer cycles 186 
Shapiro, B. S., Daneshmand, S. T., Garner, F. C., Aguirre, M., Hudson, C., & Thomas, S. 
(2011a). Evidence of impaired endometrial receptivity after ovarian stimulation for in 
vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed 
embryo transfer in normal responders. Fertility and Sterility, 96(2), 344-348. 
doi:10.1016/j.fertnstert.2011.05.050 
Shapiro, B. S., Daneshmand, S. T., Garner, F. C., Aguirre, M., Hudson, C., & Thomas, S. 
(2011b). Evidence of impaired endometrial receptivity after ovarian stimulation for in 
vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed 
embryo transfers in high responders. Fertility and Sterility, 96(2), 516-518. 
doi:10.1016/j.fertnstert.2011.02.059 
Shi, Y., Sun, Y., Hao, C., Zhang, H., Wei, D., Zhang, Y., . . . Chen, Z.-J. (2018). Transfer of 
fresh versus frozen embryos in ovulatory women. New England Journal of Medicine, 
378(2), 126-136. doi:10.1056/NEJMoa1705334 
VARTA. (2015). Victorian Assisted Reproductive Treatment Authority Annual Report 2015. 
Melbourne: Victorian Assisted Reproductive Treatment Authority  
Vuong, L. N., Dang, V. Q., Ho, T. M., Huynh, B. G., Ha, D. T., Pham, T. D., . . . Mol, B. W. 
(2018). IVF transfer of fresh or frozen embryos in women without polycystic ovaries. 
New England Journal of Medicine, 378(2), 137-147. doi:10.1056/NEJMoa1703768 
Wong, K. M., van Wely, M., Mol, F., Repping, S., & Mastenbroek, S. (2017). Fresh versus 
frozen embryo transfers in assisted reproduction. Cochrane Database of Systematic 
Reviews, 3, CD011184. doi:10.1002/14651858.CD011184.pub2 
Zhao, J., Xu, B., Zhang, Q., & Li, Y. P. (2016). Which one has a better obstetric and perinatal 
outcome in singleton pregnancy, IVF/ICSI or FET?: a systematic review and meta-
analysis. Reproductive Biology and Endocrinology, 14(1), 51. doi:10.1186/s12958-
016-0188-3 
  
Chapter 6: Study 4 Cumulative live birth rate following freeze-only versus conventional fresh transfer cycles 187 
Zhu, Q., Chen, Q., Wang, L., Lu, X., Lyu, Q., Wang, Y., & Kuang, Y. (2018). Live birth 
rates in the first complete IVF cycle among 20 687 women using a freeze-all strategy. 
Human Reproduction, 33(5), 924-929. doi:10.1093/humrep/dey044 
Zuidgeest, M. G. P., Goetz, I., Groenwold, R. H. H., Irving, E., van Thiel, G., Grobbee, D. E., 
& GetReal Work, P. (2017). Series: Pragmatic trials and real world evidence: Paper 1. 
Introduction. J Clin Epidemiol, 88, 7-13. doi:10.1016/j.jclinepi.2016.12.023 
  
Chapter 6: Study 4 Cumulative live birth rate following freeze-only versus conventional fresh transfer cycles 188 
Table 6-1 Demographic and clinical characteristics of study population, by type of treatment and number of oocytes retrieved in the stimulated 
cycle 
 
<10 oocytes retrieved 10-15 oocytes retrieved >15 oocytes retrieved 
Fresh transfer  Freeze-all 
p-value 
Fresh transfer  Freeze-all 
p-value 
Fresh transfer  Freeze-all 
p-value 
N(%) N(%) N(%) N(%) N(%) N(%) 
Women  6970(100.0)   205(100.0)    3923(100.0)  193(100.0)    2410(100.0)  630(100.0)   
Women’s age          
<30  677(9.7)   30(14.6)  
0.033 
 649(9.3)   46(22.4)  
0.114 
 506(7.3)   155(24.6)  
0.063 
30-34  1963(28.2)   48(23.4)   1472(21.1)   69(33.7)   972(13.9)   258(41.0)  
35-39  2563(36.8)   77(37.6)   1331(19.1)   57(27.8)   722(10.4)   180(28.6)  
40-44  1672(24.0)   44(21.5)   465(6.7)   21(10.2)   208(3.0)   36(5.7)  
45+  95(1.4)   6(2.9)   6(0.1)   0(0.0)   2(0.0)   1(0.2)  
Male partner's age          
<30  403(5.8)   18(8.8)  
0.239 
 321(4.6)   28(13.7)  
0.011 
 260(3.7)   79(12.5)  
0.299 
30-34  1669(23.9)   57(27.8)   1194(17.1)   65(31.7)   804(11.5)   223(35.4)  
35-39  2082(29.9)   62(30.2)   1193(17.1)   45(22.0)   700(10.0)   161(25.6)  
40-44  1401(20.1)   36(17.6)   606(8.7)   25(12.2)   360(5.2)   103(16.3)  
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45+  873(12.5)   21(10.2)   357(5.1)   18(8.8)   158(2.3)   38(6.0)  
Not stated  542(7.8)   11(5.4)    252(3.6)   12(5.9)    128(1.8)   26(4.1)   
Nulliparous  6211(89.1)   188(91.7)  0.238  3552(90.5)   174(90.2)  0.858  2154(89.4)   589(93.5)  0.002 
Reason for infertility          
Male factors  1160(16.6)   24(11.7)  
0.908 
 729(18.6)   41(21.2)  
0.135 
 438(18.2)   85(13.5)  
0.001 
Female factors  945(13.6)   21(10.2)   551(14.0)   31(16.1)   318(13.2)   75(11.9)  
Combined male 
/female factors 
 685(9.8)   16(7.8)   373(9.5)   25(13.0)   247(10.2)   75(11.9)  
Unexplained  981(14.1)   25(12.2)   545(13.9)   18(9.3)   378(15.7)   55(8.7)  
Not stated  3199(45.9)   119(58.0)    1725(44.0)   78(40.4)    1029(42.7)   340(54.0)   
OHSS  10(0.1)   1(0.5)  0.273  25(0.6)   11(5.7)  <0.001  73(3.0)   83(13.2)  <0.001 
 OHSS, Ovarian hyperstimulation syndrome 
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Table 6-2 Treatment characteristics, by type of treatment and number of oocytes retrieved in the stimulated cycle 
 
<10 oocytes retrieved 10-15 oocytes retrieved >15 oocytes retrieved 
Fresh transfer  Freeze-all p-value Fresh transfer  Freeze-all p-value Fresh transfer  Freeze-all p-value 
 Oocyte retrieval and fertilization 
No. of oocytes retrieved, median(IQR) 6(4-8) 5(4-8) 0.972 12(11-14) 12(11-14) 0.553 19(17-22) 25(20-31) <0.001 
Method of fertilization, n (%)          
IVF 2320(33.3) 45(22.0) 
0.002 
1270(32.4) 42(21.8) 
0.001 
774(32.1) 195(31.0) 
0.757 ICSI 4480(64.3) 156(76.1) 2445(62.3) 133(68.9) 1500(62.2) 402(63.8) 
Mixed 170(2.4) 4(2.0) 208(5.3) 18(9.3) 136(5.6) 33(5.2) 
No. of oocytes fertilized, median(IQR) 3(2-5) 3(2-5) 0.457 7(5-9) 7(5-9) 0.324 12(9-14) 15(12-20) <0.001 
No. of embryo cryopreserved, median(IQR) 1(0-2) 2(1-3) <0.001 2(1-4) 4(2-5) <0.001 4(2-7) 8(5-12) <0.001 
Method of cryopreservationa, n (%)          
Slow freezing 2180(59.7) 126(61.5) 
0.609 
1623(52.8) 79(40.9) 
0.001 
979(46.2) 318(50.5) 
0.057 
Vitrification 1474(40.3) 79(38.5) 1449(47.2) 114(59.1) 1142(53.8) 312(49.5) 
 Embryo transfer 
Initiated cycles, n 10423 421  7388 505  5021 1942  
Embryo transfer cycles, n 10154 202  7246 305  4934 1281  
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No. of embryos transferred per cycle, n (%)          
1 8856(87.2) 187(92.6) 
0.023 
6259(86.4) 275(90.2) 
0.058 
4218(85.5) 1060(82.7) 
0.015 
≥2 1298(12.8) 15(7.4) 987(13.6) 30(9.8) 716(14.5) 221(17.3) 
Stage of transferred embryo, n (%)          
Cleavage stage embryo 7698(75.8) 138(68.3) 
0.014 
4056(56.0) 130(42.6) 
<0.001 
2215(44.9) 539(42.1) 
0.071 
Blastocyst 2456(24.2) 64(31.7) 3190(44.0) 175(57.4) 2719(55.1) 742(57.9) 
 IQR, interquartile range; IVF, in vitro fertilization; ICSI, Intracytoplasmic sperm injection; 
a) Include only women with at least one embryo cryopreserved 
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Table 6-3 Cumulative live delivery rate by number of oocytes retrieved in stimulated cycle and type of treatment 
No. of oocytes retrieved 
in the stimulated cycle 
Fresh transfer Freeze-all 
Crude HRa (95% CI) AHRa (95% CI) No. of 
women 
No. of 
live births 
Cumulative LBR 
(%) 
No. of 
women 
No. of 
live births 
Cumulative LBR 
(%) 
<10b 6970 1955 28.0 205 30 14.6 0.61(0.42, 0.88) 0.67(0.45, 1.01) 
10-15b 3923 1816 46.3 193 64 33.2 0.76(0.58, 0.99) 0.62(0.46, 0.83) 
>15b 2410 1355 56.2 630 358 56.8 1.01(0.89, 1.15) 0.90(0.77, 1.04) 
Totalc 13303 5126 38.5 1028 452 44.0 1.13(1.02, 1.26) 0.76(0.67, 0.86) 
LBR, live birth rate; HR, hazard ratio; CI, confidence interval; AHR, adjusted hazard ratio;  
a) Reference group: ‘Fresh transfer’ group 
b) Adjusted for year of treatment at first stimulated cycle, woman’s and the male partner’s age at first stimulated cycle, parity, cause of infertility, OHSS, 
method of fertilization, number of embryo transferred, and stage of embryo transferred 
c) Adjusted for year of treatment at first stimulated cycle, woman’s and the male partner’s age at first stimulated cycle, parity, the number of oocytes 
retrieved in first stimulated cycle, cause of infertility, OHSS, method of fertilization, number of embryo transferred, and stage of embryo transferred 
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Supplementary Table 6-4 Cumulative live birth rate, by type of treatment 
Treatment cycle 
Treated  
patients 
Patients who did not return 
for treatment 
Embryo  
transfer cycles 
Pregnancies Live births 
Observed  
cumulative LBR 
Optimal 
cumulative LBR 
N N/Total(%)a N(%)b N(%)b N(%)b %  
 
Fresh transfer  
0 13303 n.a. n.a. n.a. n.a. n.a. n.a. 
1 13303 n.a. 13303(100.0) 4281(32.2) 3347(25.2) 25.2 25.2 
2 5730 456/6186(7.4) 5464(95.4) 1473(25.7) 1139(19.9) 33.7 34.4 
3 2373 278/2651(10.5) 2240(94.4) 552(23.3) 399(16.8) 36.7 37.8 
4 965 115/1080(10.6) 903(93.6) 207(21.5) 157(16.3) 37.9 39.1 
5 330 50/380(13.2) 303(91.8) 76(23.0) 59(17.9) 38.3 39.6 
6 97 20/117(17.1) 90(92.8) 18(18.6) 16(16.5) 38.5c 39.7 
 
Freeze-all  
0 1028 n.a. n.a. n.a. n.a. n.a. n.a. 
1 858 170/1028(16.5) 838(97.7) 300(35.0) 247(28.8) 24.0 28.8 
2 476 37/513(7.2) 463(97.3) 137(28.8) 103(21.6) 34.0 39.6 
3 255 27/282(9.6) 246(96.5) 66(25.9) 46(18.0) 38.5 44.5 
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4 147 14/161(8.7) 144(98.0) 47(32.0) 38(25.9) 42.2 48.6 
5 64 7/71(9.9) 60(93.8) 13(20.3) 11(17.2) 43.3 49.8 
6 27 3/30(10.0) 25(92.6) 6(22.2) 5(18.5) 44.0d 50.3 
LBR, live birth rate; n.a, not applicable 
a) The denominator is the number of women eligible to return for that ART cycle, calculated as the number of women in the previous cycle minus the number 
of women with a live delivery, and minus the number of women without remaining embryos 
b) The denominator is the number of women treated in the cycle cohort 
c) Including nine live births after the six cycles 
d) Including two live births after the six cycles 
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Supplementary Table 6-5 Cumulative live birth rate for women with <10 oocytes retrieved in stimulated cycles, by type of treatment  
Treatment cycle 
Treated  
patients 
Patients who did not return 
for treatment 
Embryo  
transfer cycles 
Pregnancies Live births 
Observed  
cumulative LBR 
Optimal 
cumulative LBR 
N N/Total(%)a N(%)b N(%)b N(%)b %  
 
Fresh transfer  
0 6970 n.a. n.a. n.a. n.a. n.a. n.a. 
1 6970 n.a. 6970(100.0) 1933(27.7) 1454(20.9) 20.9 20.9 
2 2461 232/2693(8.6) 2280(92.6) 489(19.9) 368(15.0) 26.1 26.6 
3 751 102/853(12.0) 682(90.8) 125(16.6) 92(12.3) 27.5 28.1 
4 212 19/231(8.2) 196(92.5) 42(19.8) 35(16.5) 28.0 28.7 
5 26 15/41(36.6) 23(88.5) 6(23.1) 5(19.2) 28.0 28.8 
6 3 0/3(0.0) 3(100.0) 1(33.3) 1(33.3) 28.0 28.8 
 
Freeze-all  
0 205 n.a. n.a. n.a. n.a. n.a. n.a. 
1 135 70/205(34.1) 126(93.3) 27(20.0) 22(16.3) 10.7 16.3 
2 55 5/60(8.3) 52(94.5) 10(18.2) 6(10.9) 13.7 19.5 
3 15 3/18(16.7) 14(93.3) 2(13.3) 1(6.7) 14.1 20.1 
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4 9 0/9(0.0) 9(100.0) 2(22.2) 1(11.1) 14.6 20.6 
5 2 1/3(33.3) 1(50.0) 0(0.0) 0(0.0) 14.6 20.6 
6 0 0/0 0 0 0 14.6 20.6 
 LBR, live birth rate; n.a, not applicable 
a) The denominator is the number of women eligible to return for that ART cycle, calculated as the number of women in the previous cycle minus the number 
of women with a live delivery, and minus the number of women without remaining embryos 
b) The denominator is the number of women treated in the cycle cohort 
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Supplementary Table 6-6 Cumulative live birth rate for women with 10-15 oocytes retrieved in stimulated cycles, by type of treatment  
Treatment cycle 
Treated  
patients 
Patients who did not return 
for treatment 
Embryo  
transfer cycles 
Pregnancies Live births 
Observed  
cumulative LBR 
Optimal 
cumulative LBR 
N N/Total(%)a N(%)b N(%)b N(%)b %  
 
Fresh transfer  
0 3923 n.a. n.a. n.a. n.a. n.a. n.a. 
1 3923 n.a. 3923(100.0) 1377(35.1) 1113(28.4) 28.4 28.4 
2 1961 139/2100(6.6) 1905(97.1) 550(28.0) 439(22.4) 39.6 40.4 
3 918 101/1019(9.9) 876(95.4) 242(26.4) 176(19.2) 44.0 45.3 
4 386 56/442(12.7) 359(93.0) 74(19.2) 54(14.0) 45.4 46.9 
5 145 16/161(9.9) 134(92.4) 32(22.1) 24(16.6) 46.0 47.6 
6 45 9/54(16.7) 40(88.9) 10(22.2) 8(17.8) 46.2c 47.8 
 
Freeze-all  
0 193 n.a. n.a. n.a. n.a. n.a. n.a. 
1 146 47/193(24.4) 144(98.6) 48(32.9) 38(26.0) 19.7 26.0 
2 81 9/90(10.0) 79(97.5) 22(27.2) 12(14.8) 25.9 32.9 
3 45 3/48(6.3) 44(97.8) 9(20.0) 9(20.0) 30.6 37.9 
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4 24 2/26(7.7) 22(91.7) 5(20.8) 4(16.7) 32.6 40.2 
5 10 0/10(0.0) 10(100.0) 1(10.0) 1(10.0) 33.2 40.7 
6 4 0/4(0.0) 4(100.0) 0(0.0) 0(0.0) 33.2 40.7 
LBR, live birth rate; n.a, not applicable 
a) The denominator is the number of women eligible to return for that ART cycle, calculated as the number of women in the previous cycle minus the number 
of women with a live delivery, and minus the number of women without remaining embryos 
b) The denominator is the number of women treated in the cycle cohort 
c) Including two live births after the six cycles 
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Supplementary Table 6-7 Cumulative live birth rate for women with >15 oocytes retrieved in stimulated cycles, by type of treatment  
Treatment cycle 
Treated  
patients 
Patients who did not return 
for treatment 
Embryo  
transfer cycles 
Pregnancies Live births 
Observed  
cumulative LBR 
Optimal 
cumulative LBR 
N N/Total(%)a N(%)b N(%)b N(%)b %  
 
Fresh transfer  
0 2410 n.a. n.a. n.a. n.a. n.a. n.a. 
1 2410 n.a. 2410(100.0) 971(40.3) 780(32.4) 32.4 32.4 
2 1308 85/1393(6.1) 1279(97.8) 434(33.2) 332(25.4) 46.1 47.0 
3 704 75/779(9.6) 682(96.9) 185(26.3) 131(18.6) 51.6 53.1 
4 367 40/407(9.8) 348(94.8) 91(24.8) 68(18.5) 54.4 56.2 
5 159 19/178(10.7) 146(91.8) 38(23.9) 30(18.9) 55.6 57.6 
6 49 11/60(18.3) 47(95.9) 7(14.3) 7(14.3) 55.9 c 57.9 
 
Freeze-all  
0 630 n.a. n.a. n.a. n.a. n.a. n.a. 
1 577 53/630(8.4) 568(98.4) 225(39.0) 187(32.4) 29.7 32.4 
2 340 23/363(6.3) 332(97.6) 105(30.9) 85(25.0) 43.2 46.8 
3 195 21/216(9.7) 188(96.4) 55(28.2) 36(18.5) 48.9 53.1 
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4 114 12/126(9.5) 113(99.1) 40(35.1) 33(28.9) 54.1 58.9 
5 52 6/58(10.3) 49(94.2) 12(23.1) 10(19.2) 55.7 60.7 
6 23 3/26(11.5) 21(91.3) 6(26.1) 5(21.7) 56.5 d 61.6 
LBR, live birth rate; n.a, not applicable 
a) The denominator is the number of women eligible to return for that ART cycle, calculated as the number of women in the previous cycle minus the number 
of women with a live delivery, and minus the number of women without remaining embryos 
b) The denominator is the number of women treated in the cycle cohort 
c) Including seven live births after the six cycles 
d) Including two live births after the six cycles 
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Excluded n= 1072 (6.9%) 
 Women had mixed fresh-thaw cycles n= 180 (1.2%) 
 Women had PGD cycles n= 511 (3.3%) 
Women had no embryo transferred or cryopreserved n= 381 
(2.5%) 
24122 embryo transfer cycles 
among 14331 women 
Freeze-all 
n= 1028 women 
Achieved live birth 
n= 452 (44.0%) 
Did not achieve live birth and 
used all embryos from the 
stimulated cycle 
n= 314 (30.5%) 
Did not achieve live birth and 
have remaining embryo(s) from 
stimulated cycle 
n= 262 (25.5%) 
Fresh transfer  
n= 13303 women 
Achieved live birth 
n= 5126 (38.5%) 
Did not achieve live birth and 
used all embryos from the 
stimulated cycle 
n= 7254 (54.5%) 
Did not achieve live birth and 
have remaining embryo(s) from 
stimulated cycle 
n= 923 (6.9%) 
Women had first stimulated cycle and had at 
least one embryo formed 
n= 15403 
Figure 6-1 Diagram of inclusion and exclusion of the study population 
PGD, pre-implantation genetic diagnosis; 
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Figure 6-2 Observed cumulative live birth rate by type of treatment and number of oocytes 
retrieved in stimulated cycle 
LBR, live birth rate;  
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Chapter 7: Discussion and conclusions 
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7.1 MAIN FINDINGS 
This program of research has contributed to the evidence base, providing population-
based information on the fertility and pregnancy outcomes following fresh versus frozen-
thawed embryo transfer for use by technicians, policymakers, practitioners and patients. This 
PhD thesis examined the birthweight for gestational age, ectopic pregnancy rate, and cycle-
based and cumulative live birth rate following transfer of fresh and frozen embryos (Table 7-1). 
It developed the first birthweight for gestational age percentile charts for singleton births 
following fresh and frozen-thawed embryo transfer cycles using population-based data. It 
provided population-based evidence that frozen-thawed embryo transfer was associated with 
decreased risk of SGA birth but increased risk of LGA birth. It presented evidence on a lower 
ectopic pregnancy rate following frozen-thawed embryo transfer compared with fresh embryo 
transfer. It proposed that vitrification was the preferred cryopreservation method for 
blastocysts, where vitrified blastocyst transfer resulted in a significantly higher live birth rate 
with comparable perinatal outcomes compared with slow frozen blastocyst transfer. This PhD 
thesis investigated the cumulative live birth rate following a ‘fresh transfer’ and ‘freeze-all’ 
strategy by number of oocytes retrieved. It provided the first patient-based evidence of how the 
type of responder (<10 oocytes/10–15 oocytes/>15 oocytes retrieved) was associated with 
different clinical outcomes, with the significantly lower cumulative live birth rates among 
normal (10–15 oocytes) and suboptimal responders (<10 oocytes) following a ‘freeze-all’ 
compared with a ‘fresh transfer’ strategy. A universal ‘freeze-all’ strategy is not warranted. 
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Table 7-1 Summary of PhD thesis findings 
Outcome measurements Favors fresh 
embryo transfer 
Comparable 
outcomes 
Favors frozen-thawed 
embryo transfer 
SGA birth   Study 1 and Study 3 
LGA birth Study 1 and Study 3   
Ectopic pregnancy   Study 2 
Cycle-based live birth rate Study 3   
Cumulative live birth rate    
<10 oocytes retrieved  Study 4   
10–15 oocytes retrieved Study 4   
>15 oocytes retrieved  Study 4  
SGA, small for gestational age; LGA, large for gestational age 
There is no evidence for a universal ‘freeze-all’ strategy 
This PhD thesis showed that the ‘freeze-all’ strategy resulted in a similar cumulative live 
birth rate among high responders, but reduced likelihood of a live birth in suboptimal and 
normal responders compared with a ‘fresh transfer’ strategy. It determined, for the first time 
internationally, the cumulative live birth rates following a first oocyte retrieval for normal and 
suboptimal responders, which provided further insight into the current cycle-based discussion 
on whether a ‘freeze-all’ strategy was beneficial in women with less than 15 oocytes retrieved. 
In recent years, there has been considerable debate about whether a ‘freeze-all’ strategy 
should be offered universally (Acharya et al., 2018; Ata & Seli, 2017; Basile & Garcia-Velasco, 
2016; Coutifaris, 2017; Dieamant et al., 2017; Isikoglu, 2016; Maheshwari et al., 2018; Roque 
et al., 2018; Roque et al., 2017b; Shi et al., 2018; Vuong et al., 2018; Zhu et al., 2018). The 
increasing use of PGD and PGS, the development of a safer stimulation protocol to prevent 
OHSS, the introduction of vitrification, and literature on the obstetric and perinatal outcomes 
following frozen-thawed embryo transfer, have led to a shift in clinical practice towards 
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‘freeze-all’. The pathophysiologic rationale behind the elective ‘freeze-all’ strategy is to 
‘improve the soil’ where embryos are placed into a more physiologically natural intrauterine 
environment. However, concerns have been raised whether ‘improving the soil’ could balance 
against ‘harming the seed’ associated with the potential unnatural changes during the 
cryopreservation and thawing process (Basile & Garcia-Velasco, 2016; Roque et al., 2017b). 
Several RCTs have been conducted to investigate these concerns. 
In 2018, the New England Journal of Medicine published two large RCTs which 
examined the fertility and pregnancy outcomes following the ‘fresh transfer’ versus ‘freeze-
only’ strategy in women without polycystic ovary syndrome (Vuong et al., 2018) and ovulatory 
women with infertility (Shi et al., 2018). Both studies showed that the live birth rate did not 
differ significantly between the ‘fresh transfer’ and ‘freeze-all’ groups. It is interesting to note 
that the ‘freeze-all’ strategy may not be beneficial to women who are not at risk of OHSS. Shi 
et al. (2018) found a significantly lower risk of moderate or severe OHSS among the ‘freeze-
all’ group than the ‘fresh transfer’ group in ovulatory women (rate ratio: 0.32, 95% CI: 0.14 – 
0.74), while Vuong et al. (2018) reported a similar risk of moderate or severe OHSS (risk ratio: 
0.75, 95% CI: 0.17 – 3.33) among women without polycystic ovary syndrome. The risks of 
other adverse obstetrical and neonatal complications did not differ significantly between the 
two groups in both studies, except that Vuong et al. (2018) observed an increased risk of low 
birthweight birth and SGA birth in the ‘fresh transfer’ group and the median time to conception 
was 1.4 months shorter in the ‘fresh transfer’ group. Vuong et al. (2018) argued that although 
the difference in median time to conception was relatively small, it might have an impact on 
the direct and indirect cost of treatment and the overall treatment duration. 
There are few existing studies on the fertility and pregnancy outcomes of a ‘freeze-all’ 
strategy among suboptimal and normal responders. To date, all the RCTs were performed in 
normal to high responders where the minimum average number of oocytes retrieved was 12 in 
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both ‘fresh transfer’ and ‘freeze-all’ groups (Chen et al., 2016; Coates et al., 2017; Ferraretti et 
al., 1999; Shapiro et al., 2011a, 2011b; Shi et al., 2018; Vuong et al., 2018). Only two 
retrospective cohort studies assessed the live birth rate per embryo transfer cycle following a 
‘freeze-only’ strategy in women with less than 15 oocytes retrieved in the stimulated cycle 
(Acharya et al., 2018; Roque et al., 2017a). The findings of this PhD thesis were consistent 
with the United States Society for Assisted Reproductive Technology (SART) Registry study, 
where Acharya et al. (2018) concluded that a ‘freeze-all’ strategy was not beneficial in women 
with less than 15 oocytes retrieved. As endometrial receptivity is most likely to be affected in 
women with an exaggerated response to ovarian stimulation (Weinerman & Mainigi, 2014), it 
is plausible that women with a high ovarian response can benefit from the improved embryo-
endometrium synchrony and endometrial receptivity offered by the ‘freeze-only’ strategy. 
However, findings from this PhD thesis and the United States SART Registry study suggest 
that the benefit of the ‘freeze-only’ strategy may not apply to all patterns of ovarian response. 
Findings on frozen-thawed embryo transfer associated with altered birthweight 
profiles and decreased risk of ectopic pregnancy are consistent with other literature, 
but yet no clear pathophysiological explanation  
The finding that frozen-thawed embryo transfer is associated with significantly decreased 
likelihood of SGA birth and significantly increased risk of LGA birth compared with fresh 
embryo transfer, is consistent with other published studies. A cumulative meta-analysis of 10 
studies on SGA (n = 53418 vs 89044 pregnancies following frozen-thawed vs fresh embryo 
transfer cycles) (Aflatoonian et al., 2016; Imudia et al., 2013; Ishihara et al., 2014; Kato et al., 
2012; Li et al., 2014; Liu et al., 2013; Pelkonen et al., 2010; Pinborg et al., 2014; Wennerholm 
et al., 2013; Wikland et al., 2010) and six studies on LGA (n = 51719 vs 86544 pregnancies 
following frozen-thawed vs fresh embryo transfer cycles) (Ishihara et al., 2014; Kato et al., 
2012; Li et al., 2014; Pinborg et al., 2014; Wennerholm et al., 2013; Wikland et al., 2010) 
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showed a significantly lower SGA rate (RR: 0.61, 95% CI: 0.56 – 0.67) and higher LGA rate 
(RR: 1.54, 95% CI: 1.48 – 1.61) following frozen-thawed embryo transfer compared with fresh 
embryo transfer (Maheshwari et al., 2018). The cumulative meta-analysis confirmed that the 
decreased risk of SGA birth and increased risk of LGA birth associated with frozen-thawed 
embryo transfer have been consistent in terms of direction and magnitude of effect, and 
minimal heterogeneity were observed among the studies (I2= 33.8% for SGA and I2= 11% for 
LGA respectively) (Maheshwari et al., 2018). Similar findings were reported by another recent 
meta-analysis (Sha et al., 2018). 
This PhD thesis suggests that frozen-thawed embryo transfer is associated with a lower 
risk of ectopic pregnancy compared with fresh embryo transfer. An earlier systematic review 
and meta-analysis summarized the conflicting results of seven studies conducted between 1994 
and 2007 (five original articles and two abstracts), and reported a non-statistically significant 
higher ectopic pregnancy rate following frozen-thawed embryo transfer compared with fresh 
embryo transfer (2.3% vs 1.5%, OR: 1.66, 95% CI: 0.62 – 4.41, I2= 86.3%) (Jee et al., 2009). 
However, other recent studies have shown similar findings to this PhD thesis (Huang et al., 
2014; Londra et al., 2015; Perkins et al., 2015). Huang et al. examined the incidence of ectopic 
pregnancy of 31,925 women undergoing fresh and frozen-thawed IVF embryo transfer cycles 
between 2006 and 2013 (Huang et al., 2014). Compared with fresh embryo transfer cycles, 
frozen-thawed embryo transfer cycles were associated with a statistically significantly lower 
risk of ectopic pregnancy per embryo transfer (1.0% vs 2.0%, p<0.001) and per clinical 
pregnancy (2.2% vs 4.6%, p<0.001) (Huang et al., 2014). Similar findings were reported by 
two large US studies based respectively on the 2008–2011 registry data from the Society for 
Assisted Reproductive Technologies (Londra et al., 2015) and 2001–2011 data from the 
Centers for Disease Control and Prevention's National ART Surveillance System (Perkins et 
al., 2015). 
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To date, there is no clear hypothesis for the altered birthweight profiles following transfer 
of frozen-thawed embryos. It is possible that the intrinsic maternal characteristics of women 
undergoing ART treatment, the cryopreservation and thawing process, and other ART 
treatment factors contribute to the variations in fetal growth following frozen-thawed embryo 
transfer compared with fresh embryo transfer. Study 1 showed that the proportion of SGA 
births following ART treatment were comparable to the general population for fresh embryo 
transfer cycles and significantly lower for frozen-thawed embryo transfer cycles. In addition, 
a Danish register-based controlled cohort study reported a significantly increased risk of LGA 
birth in singletons born following frozen-thawed embryo transfer compared with their 
consecutive sibling born after fresh embryo transfer (AOR: 3.5, 95% CI: 1.33 – 8.33) between 
1994 and 2008 (Pinborg et al., 2014). Hence, the decreased risk of SGA birth and increased 
risk of LGA birth following frozen-thawed embryo transfer cannot solely be explained by the 
underlying maternal characteristics or ART treatment factors other than the embryo 
cryopreservation and thawing process, but are partially related to the cryopreservation and 
thawing procedures per se.  
It has been hypothesized that the epigenetic alterations during the cryopreservation and 
thawing process influence the growth potential of the fetus (Grace & Sinclair, 2009; Pinborg 
et al., 2014; Pinborg et al., 2016). Animal studies have reported large offspring syndrome 
(LOS) in ruminant offspring conceived with the use of ART technology (Chen et al., 2015; 
Duranthon & Chavatte-Palmer, 2018; Farin et al., 2006; Grace & Sinclair, 2009; Young et al., 
1998). Epigenetic change in the gene encoding the type 2 insulin-like growth factor receptor 
IGF2R and the maternally expressed ncRNA H19 were reported to be associated with fetal 
overgrowth after sheep embryo culture (van Montfoort et al., 2012; Young et al., 2001). A 
recent comprehensive genetic analysis shown that LOS was related to the misregulation of s 
set of imprinted genes and the number of misregulated imprinted genes correlates with the 
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magnitude of overgrowth in LOS fetuses (Chen et al., 2015). LOS may also be linked to 
placental compensation for decreased feto-maternal contact among embryos produced in vitro 
with increased density of the blood vessels within the placentomes (Duranthon & Chavatte-
Palmer, 2018; Miles et al., 2004). In addition, the embryo culture media may also alter the fetal 
growth trajectory and birthweight (Chronopoulou & Harper, 2015; Duranthon & Chavatte-
Palmer, 2018; Sunde et al., 2016). It has been hypothesised that the different culture media may 
cause different physiological response of the embryo, mediated through epigenetic changes, 
and subsequently influence the phenotype of the offspring (Nelissen et al., 2014; Sunde et al., 
2016). Market-Velker et al. (2012) evaluated the loss of genomic imprinting and expression of 
genes involved in embryo metabolism of mouse embryos cultured in five commercial media in 
comparison to those developed in vivo. Epigenetic alterations were reported in all media groups 
compared with the in vivo group, to different extents for the different media with fast rates of 
preimplantation development in culture associated with aberrant metabolic marker expression 
and loss of genomic imprinting (Market Velker et al., 2012). Similarly, a cohort study of live 
births following transfer of fresh and frozen-thawed embryos showed that the medium used for 
culturing IVF embryos significantly affected the birthweight of the resulting singletons and 
twins (Nelissen et al., 2012). Further studies are required to examine the underlying 
mechanisms and whether the epigenetic modifications in the intrauterine growth profile can 
lead to long-term complications such as diabetes and cardiovascular diseases later in adolescent 
and adult life. 
Furthermore, it has been theorized that the supraphysiologic hormonal milieu of 
controlled ovarian stimulation in the fresh cycle may lead to abnormal endometrial 
angiogenesis and abnormal placentation, which accounts for the higher risk of SGA birth 
following fresh embryo transfer (Maheshwari et al., 2018). A similar hypothesis has been 
raised to rationalize the findings on ectopic pregnancy. Supraphysiologic hormonal levels may 
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jeopardize the endometrial receptivity which leads to retrograde embryo movement into the 
fallopian tubes and subsequently results in increased risk of ectopic pregnancy (Barnhart, 2014; 
Brady & Ginsburg, 2017; Perkins et al., 2015; Roque et al., 2017b). Elevated serum 
progesterone (≥3.34 nmol/l; 1.05 ng/ml) and oestradiol (≥19124 pmol/l; 5210.9 pg/ml) 
concentrations on the day of hCG administration were associated with a higher ectopic 
pregnancy rate compared with women without elevated progesterone and/or oestradiol levels 
(Wu et al., 2012). This theory was also supported by the similar ectopic pregnancy rate 
following fresh versus frozen-thawed donor cycles where no preceding controlled ovarian 
stimulation was required in either group. The 2001–2011 Centers for Disease Control and 
Prevention's National ART Surveillance System data showed a similar ectopic pregnancy rate 
following fresh donor cycles (1.0%, 641 ectopic pregnancies out of 65316 pregnancies) and 
frozen-thawed donor cycles (1.2%, 266 ectopic pregnancies out of 23158 pregnancies) (Perkins 
et al., 2015). A retrospective cohort study of 4034 frozen-thawed embryo transfer cycles 
reported a significantly lower ectopic pregnancy rate in natural cycles than in hormone 
replacement cycles (1.5% vs 3.3%, p<0.05 (Zhang et al., 2013). This comparison between 
natural and hormone replacement frozen-thawed embryo transfer also supported the hypothesis 
that exogenous hormones had a negative impact on the ectopic pregnancy rate following ART 
treatment.  
Vitrification is the preferred cryopreservation method for blastocysts 
This PhD thesis provided the first country-level population-based evidence that 
vitrification of blastocysts can achieve a higher live birth rate with comparable perinatal 
outcomes to those following slow freezing methods. No RCT has reported the live birth rate 
following vitrification versus slow freezing of blastocysts (Rienzi et al., 2017). The majority 
of RCTs comparing vitrification with slow freezing methods have focused on the embryo 
cryosurvival rate (Balaban et al., 2008; Debrock et al., 2015; Fasano et al., 2014; Huang et al., 
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2005; Kim et al., 2000; Li et al., 2007; Rama Raju et al., 2005; Zheng et al., 2005); only a very 
limited number of RCTs examined the clinical and/or ongoing pregnancy rate (Debrock et al., 
2015; Kim et al., 2000; Li et al., 2007; Rama Raju et al., 2005; Wilding et al., 2010). The live 
birth rate was reported in only two RCTs with cryopreservation of embryos performed at the 
cleavage stage (Debrock et al., 2015; Wilding et al., 2010). Wilding et al. found that 
vitrification of day 3 embryos could achieve a comparable live birth rate per embryo 
thawed/warmed to the conventional slow freezing method (12.0% vs 10.5%, RR: 1.15, 95% 
CI: 0.62 – 2.12) (Wilding et al., 2010). In contrast, Debrock et al. reported a significantly higher 
live birth rate per embryo thawed/warmed after vitrification of day 3 cleavage stage embryos 
compared with after slow freezing (16.1% vs 5.0%, p<0.0022, RR: 3.23, 95% CI: 1.64 – 6.35, 
216 cycles) (Debrock et al., 2015).  
Only a few observational studies report the live birth rate following transfer of vitrified 
versus slow frozen blastocysts (Kuwayama et al., 2005; Liebermann & Tucker, 2006; Wong & 
Wong, 2011). Two studies have similar findings to those reported in Study 3 (Kuwayama et 
al., 2005; Wong & Wong, 2011). Kuwayama et al. reported a significantly higher live birth rate 
per embryo transfer following transfer of vitrified blastocysts compared with slow frozen 
blastocysts (45.1% vs. 40.8%, p<0.05) (Kuwayama et al., 2005). Similarly, a hospital-based 
ART center in Hong Kong found that vitrification of blastocysts had 11 times the odds of the 
live birth rate per embryo transferred compared with the slow freezing method (OR = 11.42). 
However, the high odds of the live birth rate per embryo transferred observed in the vitrification 
group was probably attributable to the very low live birth rate in the slow freezing group (26.9% 
vs 3.1% respectively) (Wong & Wong, 2011). The third study showed a comparable clinical 
pregnancy rate per transfer (46.1% vs 42.9%), but a lower live birth rate in the vitrification 
group than the slow freezing group at the time of publication (n = 54 out of 117 pregnancies vs 
n = 79 out of 109 pregnancies) (Liebermann & Tucker, 2006). The findings from this PhD 
  
Chapter 7: Discussion and conclusions 213 
thesis added significantly to the body of evidence comparing the efficacy of vitrification and 
slow freezing methods in Australian settings, but should be externally validated on data from 
other countries or clinical settings, especially RCTs. 
7.2 STRENGTHS AND LIMITATIONS 
7.2.1 Strengths 
One of the major strengths of this program of research is the source of population-based 
ANZARD and VARTA data. Reporting of ART treatment and associated clinical outcomes in 
Australia is a requirement for ART clinics to be accredited by the Reproductive Technology 
Accreditation Committee (RTAC) (Reproductive Technology Accreditation Committee, 
2017). Similarly, according to ART legislation in the state of Victoria (Assisted Reproductive 
Treatment Act 2008), all Victorian-registered ART providers must submit to VARTA the 
treatment procedures carried out under this Act during the preceding financial year and the 
nature and outcome of those procedures in compliance with section 114 of the Assisted 
Reproductive Treatment Act 2008. This population-based approach offers many advantages in 
terms of low levels of loss to follow-up in ANZARD and VARTA datasets; large sample size 
which allows investigation of rare outcomes including ectopic pregnancy; and minimizing 
effects of selection and reporting bias inherent in much of the hospital or clinic-based studies 
on fertility and pregnancy outcomes following ART treatment.  
Most importantly, ANZARD and VARTA data reflect real-world clinical practice. The 
additional financial cost and delay in transfer associated with a ‘freeze-all’ strategy would have 
minimum impact on patient discontinuation in a well-designed RCT. The three most recent 
RCTs, with over 700 women randomized in each trial, all reported less than 1% loss to follow-
up (Chen et al., 2016; Shi et al., 2018; Vuong et al., 2018). However, the high proportions of 
women discontinuing treatment among normal and suboptimal responders in the population-
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based VARTA data are in indication of the complexity of choosing the optimal embryo transfer 
strategy for women undergoing ART treatment in real-world clinical practice. The impact of 
electively deferring embryo transfer on discontinuing treatment may offset the potential 
benefits (i.e. lower SGA birth and ectopic pregnancy rate) of a ‘freeze-all’ strategy.  
Furthermore, the majority of studies that examined the cumulative live birth rate 
following a ‘fresh transfer’ versus ‘freeze-all’ strategy reported a cumulative live birth rate 
within 12 months after the initial transfer (Chen et al., 2016; Roque et al., 2019; Vuong et al., 
2018), whereas the cumulative live birth rate reported in this thesis had a minimum two-year 
and up to seven-year follow-up period. The longer follow-up period allows for more accurate 
estimates of the chance of a live birth after one oocyte retrieval, which provides a more 
meaningful indicator of the quality and success of ART treatment, as well as treatment efficacy 
and the cost of reimbursement for patients, clinicians and policymakers (Maheshwari et al., 
2015).  
7.2.2 Limitations 
Gaps in the available information on exposure 
This program of research is limited by its retrospective nature. One of the major 
limitations is the lack of information on clinic-specific fresh and frozen-thawed embryo 
transfer protocols. Information about detailed ovarian stimulation protocol (e.g. GnRH agonist 
long protocol, GnRH antagonist protocol, mild stimulation protocol etc.) (Alper & Fauser, 
2017; Pacchiarotti et al., 2016; Shrestha et al., 2015), type of culture media used and embryo 
culture conditions, embryo cooling and warming rates, and type of cryoprotectants used (e.g. 
Cell Banker series, DMSO, EG, Glycerol, Trehalose, and Propylene glycol, etc.) (Jang et al., 
2017) are not recorded in the ANZARD or VARTA datasets. This information may vary 
significantly across clinics, and currently there is no consensus over which protocol(s) is 
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optimal in maximizing the success rate in parallel with minimizing adverse outcomes. In 
addition, the choice of cryopreserved embryo(s) may vary between clinics where some clinics 
freeze all embryos, including those with relatively poorer quality to keep the reproductive 
potential, while other clinics would only cryopreserve top-quality embryo(s) (Edgar & Gook, 
2012). Furthermore, the VARTA data do not include information about the reasons for using 
the ‘freeze-all’ strategy. The expected fertility and pregnancy outcomes of women undergoing 
the ‘freeze-all’ strategy to prevent OHSS are very different to those who had a ‘freeze-all’ 
strategy due to a premature progesterone rise, which is associated with a poorer prognosis. 
Gaps in the available information on residual confounders 
The ANZARD and VARTA data may not contain all of the variables of interest in a study 
evaluating the fertility and pregnancy outcomes following transfer of fresh versus frozen-
thawed embryos. Demographic confounders, including BMI and cigarette smoking, medical 
complications and other residual confounders, which may impact the interpretation of the 
findings of this PhD thesis, are not available in the ANZARD or VARTA datasets. BMI is an 
important factor in both infertility and the clinical outcomes following ART treatment (Bellver 
et al., 2007; Dağ & Dilbaz, 2015; Pandey et al., 2010). It has been estimated that women with 
a high BMI (over 29 kg/m2) had a 4% lower pregnancy rate per unit of BMI (kg/m2) (van der 
Steeg et al., 2008). Compared with women of normal weight, obese women undergoing ART 
treatment may encounter more difficulties, including higher odds of cycle cancellation, lower 
response to controlled ovarian stimulation, less oocytes retrieved, higher miscarriage rate and 
lower pregnancy and live birth rate (Bellver et al., 2010; Bellver et al., 2007; Dağ & Dilbaz, 
2015; Luke et al., 2011; van der Steeg et al., 2008; Veleva et al., 2008). Similarly, literature 
has shown that smoking has an adverse impact on female fecundity (Practice Committee of the 
American Society for Reproductive Medicine, 2018). A systematic review and meta-analysis 
of 21 studies examined the clinical outcomes following ART treatment between women who 
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actively smoke at the time of treatment and those who do not (Waylen et al., 2009). The meta-
analysis demonstrated that smoking patients achieved significantly lower odds of pregnancy 
and live birth per cycle, and significantly higher odds of spontaneous miscarriage and ectopic 
pregnancy compared with non-smokers (Waylen et al., 2009). The impact of these missing 
residual cofounders on the findings of this PhD thesis should be evaluated in further studies.   
7.3 DIRECTIONS FOR FUTURE RESEARCH AND RECOMMENDATIONS 
Study 1 developed the birthweight for gestational age percentile charts for singleton 
births following fresh and frozen-thawed embryo transfer. These charts should be compared 
with charts derived from general population data in further studies to evaluate the effectiveness 
of ART-specific birthweight percentile charts in terms of detection of high-risk fetuses and 
babies during the fetal and neonatal period.  
The scope of Study 3 of this PhD thesis was restricted to transfer of fresh, slow frozen 
and vitrified blastocysts. This decision was made because of the relatively small number of 
cycles with vitrification of cleavage stage embryos in Australia and New Zealand at the time 
Study 3 was conducted. There was inconsistent evidence on the live birth rate following 
transfer of vitrified versus slow frozen cleavage stage embryos. To date, only one RCT has 
reported a higher live birth rate following vitrified cleavage stage embryo compared with the 
slow freezing method (Debrock et al., 2015). In contrast, a systematic review and meta-analysis 
based on observational studies reported that vitrification resulted in a similar live birth rate per 
cycle or per transfer compared with slow frozen cleavage stage embryo (Rienzi et al., 2017). 
The proportion of cleavage stage embryo transfer cycles involving vitrification has increased 
from 1.7% in 2009 to 51.9% in 2016 in Australia and New Zealand (Fitzgerald et al., 2018; 
Wang et al., 2011). It would be beneficial to evaluate the pregnancy and perinatal outcomes 
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following transfer of slow frozen versus vitrified cleavage stage embryos to determine the 
preferred cryopreservation method for cleavage stage embryos. 
Study 4 provided evidence from a population-based retrospective cohort study to suggest 
that a ‘freeze-all’ strategy was not beneficial to normal and suboptimal responders and should 
not be offered universally to all women undergoing ART treatment. However, the reasons for 
patients undergoing a ‘freeze-all’ strategy were not available in the VARTA database. 
Specifically, we were unable to differentiate between women undergoing an elective ‘freeze-
all’ cycle and women who had all embryos cryopreserved due to an elevated risk of OHSS or 
premature progesterone rise. Women who developed OHSS were expected to have a higher 
live birth rate than the average of women undergoing ART treatment, while women who had a 
premature progesterone rise were associated with a relatively poor prognosis. The mix of 
patients with good and poor prognoses may have led to over or underestimation of the 
cumulative live birth rate following a ‘freeze-all’ strategy. Further prospective cohort studies 
or RCTs should be restricted to women undergoing elective ‘freeze-all’ cycles to minimize the 
potential influence of patient profiles.  
Study 4 examined the cumulative live birth rate following the ‘fresh transfer’ versus 
‘freeze-all’ strategy by number of oocytes retrieved in the stimulated cycle. The number of 
oocytes retrieved represented the ovarian response to controlled ovarian stimulation and it can 
be considered as a proxy indicator of the supraphysiologic hormonal levels in the stimulated 
cycle. In Study 4, it was hypothesized that the high responders would have a higher hormone 
profile and therefore would be more likely to benefit from improved endometrial receptivity 
associated with the ‘freeze-all’ strategy compared with normal and suboptimal responders. This 
hypothesis should be tested by measuring the estrogen and progesterone levels on the day of 
hCG administration and evaluating endometrial receptivity in a ‘freeze-all’ cycle. Opinions are 
divided as to which parameter is best suited for measuring endometrial receptivity. Mixed 
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findings were reported on whether endometrial assessment parameters, including endometrial 
thickness, endometrial pattern, endometrial volume and subendometrial blood flow, were 
suitable for predicting treatment outcomes (Heger et al., 2012; Senturk & Erel, 2008). 
Endometrial biopsy, to examine the histological changes of endometrium, should be considered 
when evaluating the threshold of when a stimulated cycle becomes supraphysiologic and 
jeopardizes the endometrial receptivity.  
‘Freeze-all’ cycles now account for more than one-fifth of initiated stimulated cycles in 
Australia and New Zealand, and an elective ‘freeze-all’ strategy is increasingly favored in 
current ART practice (Fitzgerald et al., 2018). While Australia is an international leader in the 
provision of ART services, there are no policies or clinical guidelines relating to the use of a 
‘freeze-all’ strategy. A ‘Good Practice Criteria’ for a ‘freeze-all’ strategy needs to be included 
in the RTAC’s Code of Practice for Assisted Reproductive Technology Units to inform the 
clinicians and infertile patients on choosing the optimal embryo transfer strategy for couples 
undergoing ART treatment. 
7.4 CONCLUSIONS 
The research findings reported in this PhD thesis have broadened the knowledge about 
fertility and pregnancy outcomes following a fresh embryo transfer compared with frozen-
thawed embryo transfer. The frozen-thawed embryo transfer cycle leads to decreased risk of 
ectopic pregnancy and SGA birth. Vitrification should be considered as the preferred 
cryopreservation method for blastocysts compared with the slow freezing method to achieve 
better perinatal outcomes following ART treatment. The ‘freeze-all’ strategy is beneficial to 
high responders by achieving a comparable cumulative live birth rate in parallel with improved 
obstetric and perinatal outcomes. Important questions remain about the effectiveness of a 
‘freeze-all’ strategy among normal and suboptimal responders. The evidence from this large-
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scale population-based program of research suggests that the ‘freeze-all’ strategy should not 
be offered universally.   
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Appendices 
Appendix A 
Australian and New Zealand Assisted Reproduction Database data items 
DESCRIPTION  NOTES  
Unit identifier   This number will be supplied by PRERU.  
Site of the Unit  Where the cycle was initiated.   
The code number will be allocated by PRERU.  
Patient’s ID/Medical Record 
Number   
Unique ID for this patient. This can take whatever form the Unit 
wishes but RTAC need to be able to identify the case-file from 
this number for validation of the data collection  
First two letters of female patient 
first name  
First two letters of female patient’s first name. This field will 
be used to generate the statistical linkage key.  
First two letters of female patient 
surname  
First two letters of female patient’s surname. This field will 
be used to generate the statistical linkage key.  
Female patient’s date of birth  This field needs to be completed for all female patients included 
oocyte/embryo donors. This field will be used to generate the 
statistical linkage key.  
Husband / male partner’s date 
of birth   
Leave blank if the female patient does not have husband or male 
partner.  
Age of oocyte/embryo donor   Completed years at time of OPU.  
This item MUST be completed for oocyte donation, oocyte 
recipient, embryo donation and embryo recipient, and surrogacy 
carrier cycles, otherwise MUST be left blank.  
Cause of Infertility: tubal disease  Answer yes if in the opinion of the treating clinician or clinic 
there is subfertility due to tubal disease.  
Otherwise answer no.  
Cause of Infertility: endometriosis  Answer yes if in the opinion of the treating clinician or clinic 
there is subfertility due to endometriosis.  
Otherwise answer no.  
Cause of infertility: Other female 
factors  
Answer yes if in the opinion of the treating clinician or clinic 
there is subfertility due to other female factors apart from tubal 
disease and endometriosis. Possible examples could include 
fibroids, ovulation disorders or premature ovarian failure. If there 
is no clinical female factor subfertility, answer no.  
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Cause of infertility: male factor  Answer yes if in the opinion of the treating clinician or clinic 
there is subfertility due to male factor problem. Otherwise 
answer no.  
Cause of infertility: Unexplained  Answer yes if in the opinion of the treating clinician or clinic 
there is clinical subfertility without any apparent explanation. If 
answered yes to any of the previous four fields CI_TUBE, 
CI_ENDO, CI_OTH and CI_MALE, answer no to CI_UNEX.  
Any pregnancies of  ≥ 20 weeks   Whether the female patient had a pregnancy of 20 complete 
weeks or more. Include all known pregnancies of ≥ 20 complete 
weeks regardless of whether by ART or by a different partner.   
Unique identification of each cycle  THIS FIELD MUST BE COMPLETED FOR ALL CYCLES – 
NO EXCEPTIONS!  
This field must be unique to each cycle and will be used to 
facilitate queries about the data.  
The date the cycle started  THIS FIELD MUST BE COMPLETED FOR ALL CYCLES – 
NO EXCEPTIONS!  
Coding CYC_DATE by the following rules:  
1. the first date where FSH/stimulation drug is administrated,  
2. the date of LMP for unstimulated cycles (including natural 
fresh cycles and thaw cycles),  
3. the date of embryos disposed for embryo disposal cycles,  
4. the date of oocytes/embryos imported or exported for 
oocyte/embryo import/export cycles,  
5. the date of embryos donated for frozen embryos donation 
cycles, or  
6. the date of embryos received for non-transfer embryo 
recipient cycles.  
This date defines the year in which a cycle is reported by 
UNSW/PRERU.   
Surrogacy arrangement  Whether surrogacy arrangement is involved in this cycle.    
Recode for all parties of the arrangement including commission 
patients (with or without OPU), surrogacy carrier, and oocyte 
donor if donated oocytes were used.   
Whether FSH stimulation was 
given  
Does not include clomiphene or hCG alone unless FSH was also 
given.  
First ever FSH stimulated cycle 
for OPU  
Whether the current fresh cycle is the first ever FSH stimulated 
cycle with the intension of OPU (include all treatments she had 
in other unit or country). This field must be completed for all 
fresh cycles (include cancelled fresh cycles before OPU). FSH 
stimulated artificial insemination cycle is not counted.   
If known the female patient had FSH stimulated cycle for OPU 
before, answer “n” to this field; if the current fresh cycle is her 
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first FSH stimulated cycle for OPU, answer “y” to this field. If 
unknown whether she had FSH stimulated cycle for OPU before, 
answer “u” to this field.  
Date of intrauterine insemination   Date of intra-uterine insemination using donated sperm.   
Only included cycles with intrauterine insemination using 
donated sperm. Exclude cycles such as intravirginal insemination 
using donated sperm.  
Date of cancellation for 
cancelled cycle before OPU  
Date of last day FSH is administrated in a cancelled cycle.   
Leave it blank if not a cancelled cycle.  
OPU date   The date of oocyte pickup.   
Number of eggs retrieved  Number of eggs retrieved at OPU. Include any immature oocytes 
that are identified.  
Number of eggs donated  Number of eggs donated to someone else (oocyte donation cycle,  
DON_AGE field must be coded).  
Number of eggs received  Number of eggs received from someone else (oocyte recipient 
cycle, DON_AGE field must be coded).  
Number of eggs imported  Records number of oocytes imported into the current unit from 
another unit.  
Movement between different sites of the same unit (three 
ANZARD Unit code) is not required.   
Number of eggs exported  Records number of oocytes exported from the current unit to 
another unit.  
Movement between different sites of the same unit (three 
ANZARD Unit code) is not required.  
Number of oocytes slow frozen  Number of oocytes frozen by slow freezing method in this cycle.  
Number of oocytes vitrified  Number of oocytes frozen by vitrification in this cycle.  
Number of slow frozen oocytes 
thawed   
Number of slow frozen oocytes thawed in this cycle.  
Number of vitrified oocytes 
warmed   
Number of vitrified oocytes warmed in this cycle.  
Freezing date of thawed/warmed 
oocytes  
If two batches of thawed/warmed oocytes with different 
freezing date, record the earlier freezing date.  
Number of eggs GIFT  Number of eggs replaced in a GIFT procedure.  
Number of eggs IVF  Number of eggs treated (inseminated) with IVF.   
Number of eggs ICSI  Number of eggs treated with ICSI.  
Site of sperm used   Site of sperm extraction: ejaculated, epididymal (whether by 
open biopsy or by PESA), testicular, other or unknown.   
  
Appendices 236 
DESCRIPTION  NOTES  
The person who provided sperm   Sperm provided by husband/partner, known donor, anonymous 
donor or unknown of the sperm provider.   
Number of eggs fertilised 
normally  
Number of eggs fertilised normally. The critical issue is the 
opinion of the treating embryologist. Thus even if two pronuclei 
are not seen but cleavage occurs, provided the embryologist 
considers this to be normal fertilisation then it should be 
included.   
Preimplantation genetic diagnosis  Answer yes where preimplantation genetic diagnosis in any form 
(including aneuploidy screening or sex selection) has been 
performed on any of the embryos (transferred or not). Otherwise 
answer no.  
This field needs to be coded for both fresh and thaw cycles.  
Assisted hatching  Answer yes where assisted hatching in any form has been 
performed on any of the embryos (transferred or not). Otherwise 
answer no. This filed needs to be coded for both fresh and thaw 
cycles.  
Number of embryos imported 
from another clinic  
Records number of embryos imported into the current unit from 
another unit.  
Movement between different sites of the same unit (three 
ANZARD Unit code) is not required.  
Number of embryos received 
from another patient/couple  
Records the number of embryos that a patient/couple received 
from another patient/couple (embryo recipient cycle, DON_AGE 
field must be coded).  
Number of slow frozen 
cleavage embryos thawed   
Number of slow frozen cleavage embryos thawed with 
intention of performing an embryo transfer.  
For the ANZARD collection, cleavage embryo is simply defined 
as an embryo one to four days after fertilization.   
Number of vitrified cleavage 
embryos warmed   
Number of vitrified cleavage embryos warmed with intention of 
performing an embryo transfer.  
Number of slow frozen blastocysts 
thawed   
Number of slow frozen blastocysts thawed with intention of 
performing an embryo transfer.   
For the ANZARD collection, blastocyst is simply defined as an 
embryo five or six days after fertilization.  
Number of vitrified blastocysts 
warmed   
Number of vitrified blastocysts warmed with intention of 
performing an embryo transfer.  
Freezing date of thawed/warmed 
embryos  
  
If two batches of thawed/warmed embryos with different 
freezing date, record the earlier freezing date.  
Thawed/warmed  
embryo originally from oocyte 
donor or embryo donor  
If thawed/warmed embryos were originally from donated 
oocytes, record this field as “o”.  
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If thawed/warmed embryos were donated embryos, record this 
field as “e”. (DON_AGE field must be coded).  
Embryo transfer date  If it is known that an embryo transfer has taken place but the 
exact date is unknown, make comments in COMMENT field.  
Number of cleavage embryos 
transferred  
Number of cleavage stage embryos transferred.  
Number of blastocysts transferred  Number of blastocyst stage embryos transferred.  
Any transferred embryos 
fertilised by ICSI?  
Answer YES if any of the transferred embryos fertilised by ICSI.  
Number of cleavage embryos 
slow frozen  
Number of cleavage embryos frozen by slow freezing method in 
this cycle.  
Number of cleavage embryos 
vitrified  
Number of cleavage embryos frozen by vitrification in this cycle.  
Number of blastocysts slow 
frozen  
Number of blastocysts frozen by slow freezing method in this 
cycle.  
Number of blastocysts vitrified  Number of blastocysts frozen by vitrification in this cycle.  
Number of and embryos 
exported to another clinic  
Records the number of embryos exported from the current 
unit to another unit.   
Movement between different sites of the same unit (three 
ANZARD Unit code) is not required.  
Number of embryos donated to 
another patient  
Records the number of embryos donated to someone else 
(embryo donation cycle) (DON_AGE field must be coded).  
Number of potentially usable 
frozen embryos discarded   
Frozen embryos disposed in accordance with patient’s request or 
Govt. regulation.   
Clinical pregnancy   A clinical pregnancy must fulfil one of the following criteria:   
1.known to be ongoing at 20 weeks;   
2.evidence by ultrasound of an intrauterine sac and/or fetal heart;   
3.examination of products of conception reveal chorionic villi; or   
4.a definite ectopic pregnancy that has been diagnosed 
laparoscopically or by ultrasound.  
Date pregnancy ended  This is the date on which delivery, miscarriage or termination 
takes place. This date MUST eventually be completed if the 
answer to PR_CLIN field is "yes", If exact date is unknown, 
enter an approximate guess. Where multiple births occur over 
more than one date, enter the date of the first born baby.  
Number of fetal hearts  Number of fetal hearts seen on first ultrasound (intrauterine only)   
This field must be completed if PR_CLIN field is “yes”.  
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Ectopic pregnancy   If this pregnancy is an ectopic pregnancy, or a combined ectopic 
and uterine pregnancy (heterotopic).   
This field must be completed if PR_CLIN field is “yes”.  
Elective termination of pregnancy   Do NOT include pregnancies where a planned fetal reduction of 
a multiple pregnancy results in a subsequent unintended 
miscarriage, or a pregnancy where there has been an IUFD 
requiring induced delivery. Give reasons for TOP in ABN_LESS 
field.  
This field must be completed if PR_CLIN field is “yes”.  
Selective reduction performed   Where selective reduction was performed due to fetal 
abnormality/other reasons, give details in ABN_LESS field. 
This field must be completed if PR_CLIN field is “yes”.  
Fetal abnormality in a 
pregnancy ending <20 weeks or 
by selective reduction  
This field applies to elective terminations of pregnancy and fetal 
reductions due to fetal abnormality.  
Specify as much detail as possible.   
Maternal complications of 
pregnancy  
Insert as much detail as possible.   
Number of babies delivered.   Include all liveborn and stillborn babies after 20 weeks 
gestation or at least with birthweight   
≥ 400 grams.   
This field must be completed if PR_CLIN field is “yes”.  
Caesarean delivery  Doesn't matter whether the CS was planned or emergency. If any 
of a multiple birth is a caesarean section delivery, answer yes.  
Baby 1 Outcome  Outcome of the first born baby.  
Baby 1 sex   Sex of the first born baby.  
Baby 1 birthweight  Birthweight (grams) of the first born baby.  
Baby 1 abnormality  Put in as much detail as known about congenital malformation 
of the first born baby.   
Baby 1 date of neonatal death  Record the date of death of the first born baby if the death 
occurred within 28 days after birth.  
Baby 2 Outcome  Outcome of the second born baby.  
Baby 2 sex   Sex of the second born baby.  
Baby 2 birthweight  Birthweight (grams) of the second born baby.  
Baby 2 abnormality  Put in as much detail as known about congenital malformation 
of the second born baby.   
Baby 2 date of neonatal death  Record the date of death of the second born baby if the death 
occurred within 28 days after birth.  
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Baby 3 Outcome  Outcome of the third born baby.  
Baby 3 sex   Sex of the third born baby.  
Baby 3 weight  Birthweight (grams) of the third born baby.  
Baby 3 abnormality  Put in as much detail as known about congenital malformation 
of the third born baby.   
Baby 3 date of neonatal death  Record the date of death of the third born baby if the death 
occurred within 28 days after birth.  
Baby 4 Outcome  Outcome of fourth born baby.  
Baby 4 sex   Sex of the fourth born baby.  
Baby 4 weight  Birthweight (grams) of the fourth born baby.  
Baby 4 abnormality  Put in as much detail as known about congenital malformation 
of the fourth born baby.   
Baby 4 date of neonatal death  Record the date of death of the fourth born baby if the death 
occurred within 28 days after birth.  
Hospital admission  with ART 
related morbidity  
Answer yes where the female partner is admitted to hospital with 
any condition (excluding any pregnancy related issues, such as 
ectopic pregnancy) that could be in any way related to fertility 
treatment. e.g. OHSS, infection or bleeding after e.g. pickup.  
OHSS  Answer yes if OHSS occurred.  
Morbidity detail  Put in as much detail as known about cause of morbidity. This 
field must Not be blank if MORB_ADM field and/or 
MRB_OHSS field is “yes”.  
Postcode of patient residential 
area  
Postcode of patient current residential area 
New Zealand units put “NZ”.  
Any comments of this cycle  Explanations/comments where cannot code any fields properly 
according to the data dictionary.  
  
